topic,summary of points,"what facts, if any?","what anecdotes, if any?",anecdote quote,original transcript
The topic is reading a list of names.,They want people to read the list of names.,N/A,N/A,N/A,And then you wanna just go ahead and read the list of names.
The topic is not clear.,They do not state any clear points.,N/A,N/A,N/A,"I tell you what, just go ahead. Let's just say our name. We'll pick it up."
The topic is the proposed changes to the state's education budget.,The person's points are that the proposed changes are bad for Kentucky's education budget.,The facts are that the proposed changes would cut funding for education in Kentucky.,There are no anecdotes.,N/A,"Tyler Thompson on behalf of the state of Kentucky,"
The topic is unknown.,They cannot summarize their points.,N/A,N/A,N/A,You state your name please.
The topic they are talking about is the case against Purdue.,They are testifying in a case against Purdue.,The facts are that they are testifying in a case against Purdue.,They do not support their points with anecdotes.,N/A,"And, um, you are here today, um, uh, to give testimony, uh, in a case, um, pending against Purdue, various entities, um, uh, by the state of Kentucky. You're aware of that."
They are talking about the idea.,They think it is a good idea and it will work well.,The facts are that it will work and it is a good idea.,They do not support their point with anecdotes.,N/A,And you've given
The topic is unknown.,They are asking for confirmation from Mitchell.,N/A,N/A,N/A,"Um, is that correct? Mitchell? Yeah,"
The topic is unknown.,They have no points.,N/A,N/A,N/A,Sure. Okay. And
N/A,They are not making any points.,N/A,N/A,N/A,"Yeah, we won't disseminate until y'all designate and respond there's period"
The topic is the person's current role at Purdue.,They are asking about the person's role at Purdue.,The facts are that the person is from Kentucky and is currently employed at Purdue.,There are no anecdotes.,N/A,"Order and, and, uh, just so you know, I know you're not from Kentucky, is that correct? That's correct. Um, um, all, uh, objections other than to the form of the question are preserved in Kentucky. Thank you. On video. Um, what is your current role at Purdue?"
The topic they are talking about is the number of Purdue entities.,They want to know how many Purdue entities there are.,N/A,N/A,N/A,"Talking about? Well, let's, uh, let's talk about the number of Purdue entities. There are, uh, how many Purdue entities are"
The Sackler family owning 69 different corporations.,The person has seen 69 different corporations that the Sackler family owns and questions if that is correct.,The fact is that the person has seen 69 different corporations that the Sackler family owns.,N/A,N/A,"I've seen upwards of 69 different corporations perhaps that, uh, the Sackler family owns. Is that correct?"
The topic is the Purdue Frederick company.,The person's points are that there are a number of Purdue entities and that they are unsure of the existence of the Purdue Frederick company.,The facts are that there are a number of Purdue entities.,There are no anecdotes.,There are no quotes.,"Um, there are a number of Purdue entities. Um, the Purdue Frederick company, Inc. Does it still exist?"
The topic is companies that involve Purdue.,They want to know what companies the person has a role with that involve Purdue.,N/A,N/A,N/A,"Okay. Um, tell me what companies that you currently, uh, have a role with that, uh, involve Purdue."
The person is talking about whether or not they will sit on the board of any other Purdue companies.,The person's points are that they are not sure if they want to sit on the board of any other Purdue companies and that they need more information before making a decision.,The facts are that the person is not sure if they want to sit on the board of any other Purdue companies and that they need more information before making a decision.,There are no anecdotes.,There are no quotes.,Okay. Do you sit on the board of any other Purdue companies?
They are talking about the idea of Monday Pharma.,They think it is a good idea and it will help the company.,The facts are that it will help the company and it is a good idea.,They do not support their point with anecdotes.,N/A,Okay. What about Monday Pharma?
The topic is the Sackler family and their ownership of different pharma companies.,They are asking if the Sackler family owns MUN Pharma and what Mundi Pharma is.,N/A,N/A,N/A,"Okay. Does the Sackler family own MUN Pharma? Yes. Uh, what about, uh, what is Mundi Pharma?"
The topic is the company's location.,They are asking if the company is in Germany.,N/A,N/A,N/A,Okay. Is that company over in Germany?
The topic is whether or not Purdue owns Roxanne.,They are asking a question about whether or not Purdue owns Roxanne.,N/A,N/A,N/A,"Uh, what about Roxanne? Does Purdue own Roxanne?"
Ownership of Roxanne,They are asking if someone owned Roxanne in the past.,N/A,N/A,N/A,"Have, did they own Roxanne in the past?"
The topic the person is talking about is how many companies are owned by the Sackler family.,The person's points are that they are unsure of how many companies are owned by the Sackler family and they would like to know.,N/A,N/A,N/A,"All. Um, do you know how many current companies, uh, are owned by the Sackler family?"
The topic they are talking about is OxyContin.,"They want to know how many companies were involved in the production, manufacturing, or distribution of OxyContin.","The facts are that they want to know how many companies were involved in the production, manufacturing, or distribution of OxyContin.",They do not support their point with anecdotes.,N/A,"Right. In, in discussing OxyContin, how many companies were involved in the production, manufacturing or distribution of OxyContin?"
The topic they are talking about is the world.,They think that it is a good thing because it brings people together and helps people learn about different cultures.,The facts are that it is a good thing because it brings people together and helps people learn about different cultures.,They do not support their point with anecdotes.,N/A,In the world?
The topic the person is talking about is Purdue's ownership of the companies that sell Oxycontin.,The person's points are that Purdue owns parts of the companies that sell Oxycontin and that these companies make money off of the drug.,The facts are that Purdue owns parts of the companies that sell Oxycontin and that these companies make money off of the drug.,There are no anecdotes given.,There is no quote given.,"Um, just Purdue do licensing agreements with other companies to sell Oxycon it does. Do they own parts of those companies?"
The topic they are talking about is how many companies Purdue owns that distribute or dispense OxyContin.,They are asking how many companies Purdue owns that distribute or dispense OxyContin.,N/A,N/A,N/A,"How many companies does Purdue own that? Uh, distributes or dispenses OxyContin?"
The topic is the names of the things.,The person wants to know the names of the things.,N/A,N/A,N/A,Can you tell me the names of them?
The topic is the opioid crisis.,They are accusing the person of being the director of a company that is responsible for the opioid crisis.,N/A,N/A,N/A,"Are you still the director of Purdue Pharma, Inc?"
The topic they are talking about is whether the person is still a general partner of Purdue Pharma LP.,They do not mention any points.,N/A,N/A,N/A,Are you still a general partner of Purdue Pharma LP?
"They are talking about the person's involvement with Purdue Pharma, Inc.","They are claiming that the person was a director of Purdue Pharma, Inc.","The fact is that the person was a director of Purdue Pharma, Inc.",They do not support their point with an anecdote.,N/A,"In July 30th, 2014. Were you a director of Purdue Pharma, Inc?"
The topic they are talking about is the affidavit.,They are questioning whether or not the person's name appears on the affidavit.,The facts are that the person's name appears on the affidavit.,They do not support their point with anecdotes.,N/A,"This is a affidavit filed in the Southern district of West Virginia. Um, and does that appear to be your name"
"The person is talking about the document dated July 30th, 2014.",The person's points are that the document is dated and that it is a declaration from Dr. Richard S. Sackler.,"The facts are that the document is dated July 30th, 2014 and that it is a declaration from Dr. Richard S. Sackler.",There are no anecdotes.,There are no quotes.,"And it's dated, uh, July 30th, 2014. It says declaration of Dr. Richard Richard S Sackler. I am a director of Purdue Pharma, Inc. The general partner of Purdue Pharma LP. I've held disposition since 1990."
"The topic they are talking about is the production, marketing, and promotion of Purdue sales representatives for OxyContin.","They want to know how involved the person was in the production, marketing, and promotion of Purdue sales representatives for OxyContin.",N/A,N/A,N/A,"How involved were you in the production and, um, marketing and promotion in the training and management of Purdue sales representatives for OxyContin."
The topic is not stated.,They are questioning the person's reasoning.,N/A,N/A,N/A,"Okay. And when you say it depends on the time, why do you say that?"
The topic they are talking about is OxyContin.,They think that OxyContin is a problem and that it is not being dealt with effectively.,The facts are that OxyContin is a problem and that it is not being dealt with effectively.,They do not support their point with anecdotes.,N/A,"When you were involved on the supervisory level, but not the active level. How much of your day to day activity was devoted to OxyContin?"
The topic the person is talking about is their involvement in the marketing of OxyContin.,The person's points are that they were not directly involved with the day-to-day marketing or promotion of OxyContin and that those responsibilities fell principally to senior management.,The facts are that the person was not directly involved with the day-to-day marketing or promotion of OxyContin and that those responsibilities fell principally to senior management.,There are no anecdotes.,There are no quotes.,"In this declaration. Uh, it says, uh, during the time period set forth in the amended complaint, 1996 to 2009, I was not directly involved with the day-to-day marketing or promotion of OxyContin, the training or management of Purdue sales representative, or the scientific research into the conversion ratio from MS. Contin to OxyContin. Um, those responsibilities fell principally fail to produce senior management in research and development, regulatory fair sales, affairs, sales, training, and marketing among others. Uh, is that accurate?"
The topic is emailing Dr. Sackler.,They think it is a good idea and they want to show support for it.,The facts are that it is a good idea and that it has been shown to be effective.,They do not support their point with anecdotes.,N/A,"I want to show you email Dr. Sackler dated Monday, May 31st, 1999. Uh, do you know who Cornelia Dr. Cornelia Hinch is?"
The topic they are talking about is the idea.,They think that it is a good idea and that it will work.,The facts are that it is a good idea and that it will work.,They do not support their point with anecdotes.,N/A,Do. And who is that?
They are talking about the drug Ms. Cotton.,They think that it is a good drug.,The facts are that it is a morphine sulfate and it is an immediate release narcotic opioid.,They do not support their point with anecdotes.,N/A,"Okay. And to give this a little bit of context, you all had a drug called Ms. Cotton, a morphine sulfate, uh, that was an immediate release narcotic opioid or narcotic, is that correct?"
The topic is controlled release.,The person's points are that controlled release is primarily used for cancer patients or malignant pain patients.,The facts are that controlled release is primarily used for cancer patients or malignant pain patients.,There are no anecdotes.,There are no quotes.,Controlled release. I'm sorry. And that was used primarily for cancer patients or malignant pain patients. Is that correct?
The topic is not stated.,They think it is good because majority of people use it.,The facts are that majority of people use it.,They do not support their point with anecdotes.,N/A,Okay. Majority of use
The topic is Purdue Pharma's opinion on the stigma attached to morphine.,"The person's points are that Purdue Pharma felt that morphine had a stigma attached to it, and that this stigma kept doctors from prescribing it.","The facts are that Purdue Pharma felt that morphine had a stigma attached to it, and that this stigma kept doctors from prescribing it.",There are no anecdotes.,There are no quotes.,"And it was sort of felt by Purdue Pharma that, that morphine had a stigma attached to it that kept doctors from prescribing it, uh, um, across the board. Is that accurate?"
The topic is unknown.,They do not state any points.,N/A,N/A,N/A,"And you all had a, uh,"
The topic is support for a topic.,The person's points are that the topic is good and that they support it.,The facts are that the topic is good and that they support it.,The anecdote is that the person supports the topic.,"Yes, the person supports the topic.",Yes.
The topic the person is talking about is addiction.,"The person's points are that addiction has played out differently in different centuries, and that they want to know more about the topic.",The facts are that addiction has played out differently in different centuries.,The person does not support their points with anecdotes.,N/A,"Okay. Have you ever gone back and studied the history of addiction and, and how it has played out in the 19th and 20th century?"
The topic the person is talking about is why doctors do not want to prescribe morphine and if there is a stigma around it.,The person's points are that they want to understand why doctors do not want to prescribe morphine and if there is a stigma around it.,The facts are that the person wants to understand why doctors do not want to prescribe morphine and if there is a stigma around it.,The anecdote is that the person wants to understand why doctors do not want to prescribe morphine and if there is a stigma around it.,"The person quotes the anecdote by saying ""Right. Um, what was your understanding of why doctors did not want to prescribe morphine for anything, uh, or had a stigma about prescribing it for anything other than cancer and malignant pain?""","Right. Um, what was your understanding of why doctors did not want to prescribe morphine for anything, uh, or had a stigma about prescribing it for anything other than cancer and malignant pain?"
The topic is the existence of stigma.,"The person's points are that stigma may exist, but they are not sure why.",N/A,N/A,N/A,Why do you think that stigma existed?
The topic is addiction and dependence with respect to morphine.,The person's points are that there are concerns about addiction and dependence with respect to morphine.,The facts are that there are concerns about addiction and dependence with respect to morphine.,There are no anecdotes.,N/A,"Okay. Um, were there concerns about addiction, uh, and, um, dependence with respect to morphine?"
The topic they are talking about is MS. Contin.,They are asking if the company had the exclusive right to sell MS. Contin.,The facts are that the company had the exclusive right to sell MS. Contin.,They do not support their point with anecdotes.,N/A,"So going back to building our context here, you all had a drug called MS. Contin that, um, you had the exclusive right to sell. Is that correct?"
The topic is the expiration of exclusivity.,The person's points are that they do not know when the exclusivity expires and they are curious about it.,The facts are that the person does not know when the exclusivity expires.,There are no anecdotes.,There are no quotes.,Do you know when that exclusivity was set to expire?
"The topic they are talking about is their concern that when they say Purdue, they are referring to Purdue companies involved.","They are concerned that when they say Purdue, they are referring to Purdue companies involved.","The facts are that they are concerned that when they say Purdue, they are referring to Purdue companies involved.",They do not support their point with anecdotes.,N/A,"Do you recall that? One of the concerns that Purdue, uh, senior management had, I'm using Purdue in relation to Purdue companies that are involved with OxyContin, and rather than just sit here and name 'em all out. Can we agree that when I say Purdue, I'm referring to Purdue companies involved"
The topic is Purdue companies and their involvement in the cell and distribution of OxyContin.,The person's points are that they want to know which Purdue companies were involved in the cell and distribution of OxyContin.,The facts are that the person wants to know which Purdue companies were involved in the cell and distribution of OxyContin.,There are no anecdotes.,There is no quote.,"Well, let's, let's talk about it then. Which Purdue companies were involved in the cell and distribution of OxyContin,"
The topic is Purdue companies selling a product.,They are asking if there were any other Purdue companies involved in the selling of the product.,N/A,N/A,N/A,Okay. Were there any other Purdue companies involved in the selling of the product?
,They support their point with facts.,The premises they rely on are that Ms. Cotton had the exclusive right to sell.,The topic they are talking about is Ms. Cotton's exclusive right to sell.,,"Um, who had the exclusive right to sell Ms. Cotton"
The topic they are talking about is the distinction between Purdue Frederick and Purdue Pharma.,They summarize their points by saying that they are unsure of the distinction and asking for clarification.,N/A,N/A,N/A,What is the distinction between Purdue Frederick and Purdue Pharma?
Purdue Pharma,They are asking if there were any actions taken with respect to Purdue Pharma or OxyContin.,N/A,N/A,N/A,"Were there any actions taken with respect to Purdue, um, or, or with respect to OxyContin that would not fall under the Purdue Pharma umbrella?"
The topic is OxyContin.,They are saying that everything done with OxyContin falls under the Purdue Pharma umbrella.,The facts are that everything done with OxyContin falls under the Purdue Pharma umbrella.,They do not support their point with anecdotes.,N/A,"Question? Yeah. Are, are you, are you maintaining that there are any actions done with respect to OxyContin it's it's creation, production, marketing sales that do not fall under the Purdue Pharma umbrella?"
N/A,They do not make any points.,N/A,N/A,N/A,Okay.
The topic is whether Purdue Frederick continued to exist.,They are asking if Purdue Frederick continued to exist.,N/A,N/A,N/A,"Okay. And then Purdue Frederick continued to exist though, correct?"
The topic the person is talking about is Purdue Frederick's involvement in OxyContin.,The person's points are that they are not sure if Purdue Frederick was involved in OxyContin and they want to know if they were.,N/A,N/A,N/A,"Okay. And was Purdue Frederick also a company involved with marketing, promoting, um, uh, sales and production of OxyContin?"
,They summarize their points by saying that the manufacturer did play a role in the opioid crisis.,The facts they mention are that Purdue Pharma and Purdue Frederick both played a role in the opioid crisis.,They do not mention any anecdotes.,They make the claim that Purdue Pharma and Purdue Frederick both played a role in the opioid crisis.,"Okay. Other than the manufacturer did, did Purdue Frederick and Purdue Pharma both play a role in the,"
"The topic they are talking about is the difference between the employees of Purdue, Frederick and Purdue Pharma.",They are asking if there is a difference between the employees of the two companies.,N/A,N/A,N/A,"Okay. Is there, or all of it? Is there any difference between the employees of Purdue, Frederick and Purdue Pharma?"
The topic is the difference in the board of directors.,They do not mention any points.,N/A,N/A,N/A,Okay. Any difference in the board of directors
The topic they are talking about is OxyContin.,They want to talk about OxyContin and the difference between Purdue and Purdue Pharma.,The facts are that OxyContin is a painkiller and Purdue is the company that makes it.,They do not support their point with anecdotes.,N/A,"Right. Well, let me go back to, let's talk about, um, OxyContin and I'm gonna use the term Purdue for both Purdue, Frederick and Purdue Pharma. Um, if at some point you, you feel like there's a distinction to be made you let me know. Okay. Um, but, um, at a time when"
The topic is unknown.,They want to know the other person's reasoning for objecting to the combination.,N/A,N/A,N/A,Combination. What is your reason for the objection?
They are talking about the difference between Purdue Pharma LP and Purdue Frederick LP.,They want to make sure they are only referring to Purdue Pharma LP and not Purdue Frederick LP.,N/A,N/A,N/A,"Okay, let's do this. I'm gonna refer to Purdue as, as Purdue Pharma LP. Um, and also Purdue Frederick LP, if at some point, uh, you feel like it's only Purdue Frederick or only Purdue Pharma, you let me know. Okay."
The topic is unknown.,They have no points.,N/A,N/A,N/A,"Um, so let's"
The topic is whether sales reps were employed by Purdue Frederick or Purdue Pharma.,"The person's points are that they are unsure whether sales reps were employed by Purdue Frederick or Purdue Pharma, and they would like to know.",N/A,N/A,N/A,"For instance, let me ask you this sales reps, uh, were sales reps employed by Purdue Frederick or Purdue Pharma"
The topic is employment.,They are asking a question.,N/A,N/A,N/A,Do you know which sales reps were employed by? Purdue? Frederick
The topic they are talking about is police training.,They are asking if the police officers received different training.,N/A,N/A,N/A,Do you know if they received different training?
The topic the person is talking about is the expiration of the license to sell Ms. Cotton.,They are asking if the company was aware that the license to sell Ms. Cotton was going to expire and if there was going to be competition from generic companies.,The facts are that the license to sell Ms. Cotton was going to expire and there was going to be competition from generic companies.,The person does not support their point with anecdotes.,N/A,"Okay. Um, well, I'll tell you what I, I'm gonna refer to when I say Purdue as Purdue Frederick, if you feel like it's Purdue Pharma, you let me know. Okay. Okay. All right. So back in 19 early nineties, when you're developing Ms. Cotton, um, um, this exclusive license that you had to sell, Ms. Con Ms. Cotton was going to expire and there was gonna be competition from generic companies, correct?"
The topic they are talking about is that it is a good idea to have a later time when its license is about to expire.,They think that it is a good idea to have a later time when its license is about to expire.,The facts are that it is a good idea to have a later time when its license is about to expire.,They do not support their point with anecdotes.,They do not quote any anecdotes.,The later time when its license is about to expire?
The topic they are talking about is the development of oxycodone and how to position it in the market.,They are discussing the concerns around developing oxycodone and how to position it in the market.,The facts are around the development of oxycodone and how to position it in the market.,They do not support their point with anecdotes.,N/A,"And one of the things that in developing oxycodone, um, uh, controlled release, one of the, one of the concerns was how to position it in the market. Uh, and whether you were gonna position it, uh, an obsolete Ms. Cotton, or try to position it alongside Ms. Cotton was, do you recall that issue?"
The topic they are talking about is the market share for OxyContin.,They are discussing the market share for OxyContin.,The facts are the market share for OxyContin.,They do not support their point with anecdotes.,They do not quote any anecdote.,"One of the concerns when, when you were developing oxycodone, uh, or I'm sorry, OxyContin controlled release was how you were gonna position it for market share, and whether you were gonna position it and make Ms. Cotton obsolete, uh, and take that market, share that Ms. Cotton had, or whether you were gonna position it alongside Ms. Cotton and, uh, sell them both together. Do you recall that concern?"
The topic they are talking about is a waste of time and money.,They think it is a waste of time and money.,The facts are that it is a waste of time and money.,They do not support their points with anecdotes.,N/A,No. That's
The topic they are talking about is the memo.,They think it is a good idea and that it will help the company.,The facts are that it is a good idea and it will help the company.,They do not support their point with anecdotes.,N/A,"Here's a memo dated, um, uh, to Richard Sackler, um, from Robert Keiko. Do you know Dr. Keiko? I do. He's a PhD. What he is, what was his role?"
The topic the person is talking about is the release of another controlled release opioid analgesic.,The person's points are that other firms are developing controlled release opioid analgesics and that Ms. Cotton may eventually face serious generic competition.,The facts are that other firms are developing controlled release opioid analgesics and that Ms. Cotton may eventually face serious generic competition.,There are no anecdotes.,There are no quotes.,"Okay. And under here, it says rationale for another controlled release opioid analgesic. This is Bates number. It's actually got two Bates stamps. So, um, it's PDD 9 5 2 0 8 0 5 2 92, but it says rationale for another controlled release opioid analgesic, Ms. Cotton may eventually face such serious generic competition that other controlled release opioids must be considered. Other pharmaceutical firms are thought to also be developing other controlled release opioid analgesics."
The topic is a good idea.,They think it is a good idea and are happy with it.,The facts are that it is a good idea and they are happy with it.,They do not support their point with anecdotes.,N/A,Sure. That's why I was holding it over here in front. It's
They are talking about distance.,They think distance is good because it allows for extra copy.,The facts are that distance allows for extra copy.,They do not support their point with anecdotes.,N/A,Distance. Extra copy.
,They think it is a great idea to always hand in your work on time.,The anecdote is that they always hand in their work on time.,They claim that this is a good idea.,They rely on the premise that handing in your work on time is a good thing.,Great. Just always hand
The topic they are talking about is the second highlighted portion.,They are summarizing their points.,"The facts are that it says ""right"" down there.",They are not supporting their point with anecdotes.,They are not quoting an anecdote.,"So do you see down there, the second highlighted portion that says right?"
It is unclear what the person is talking about.,They do not state any clear points.,N/A,N/A,N/A,"Yeah, I'll, I'll, I'll tell you where it goes."
They are talking about a new controlled release opioid analgesic.,They think it is a good idea because it will help with pain relief.,The facts are that it will help with pain relief.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Okay. So the second highlighted portion rationale for another controlled release opioid analgesic. And do you see the first sentence below that?
The topic is support for a topic.,The person's points are that the topic is good and that they support it.,The facts are that the topic is good and that they support it.,The anecdote is that the person supports the topic.,"Yes, the person supports the topic.",Yes.
The topic they are talking about is controlled release opioid analgesics.,They are summarizing the points.,The facts are that other pharmaceutical firms are also developing other controlled release opioid analgesics.,They are not supporting their point with anecdotes.,They are not quoting an anecdote.,"And the text below that says, Ms. Cotton may eventually face such serious generic competition that other controlled release opioids must be considered. Other pharmaceutical firms are thought to be, to also be developing other controlled release opioid analgesics. Did I read that correctly?"
The topic the person is talking about is their concern and wanting to know more about the topic.,The person's points are that they are concerned and that they want to know more about the topic.,The facts are that the person is concerned and wants to know more about the topic.,The anecdote is that the person is concerned and wants to know more about the topic.,"The person quotes the anecdote by saying ""And was that a concern at that time?""",And was that a concern at that time?
The topic they are talking about is the decision to come out with oxycodone or OxyContin.,They are asking if the decision to come out with oxycodone or OxyContin was because it is less likely to have generic competition.,"The facts are that other pharmaceutical firms are formulating controlled release morphine and controlled release hydromorphone, but there is no evidence to date that this is being done with oxycodone.",They do not support their point with anecdotes.,N/A,"And then if you'll turn to the next page and look at the second paragraph and I'll read that it says while we have reason to believe that other pharmaceutical firms are formulating controlled release morphine and controlled release hydromorphone, there is no evidence to date that this is being done with oxycodone, a controlled release. Oxycodone is thus less likely to initially have generic competition. And was that a, a, uh, consideration when deciding to come out with oxycodone or OxyContin?"
The topic is their role in the company.,They discuss their limited role in the company.,The facts are that they had a limited role in the company.,They do not support their point with anecdotes.,N/A,"All right. Now we read your paragraph 11, where you discussed that you had limited role in the,"
The topic is unknown.,They want to see the exhibit.,N/A,N/A,N/A,"Paragraph 11, let's make this, um, exhibit one to the deposition. I need to see that back please. Um,"
They are talking about the OxyContin scandal.,They are questioning whether or not she was involved in the promotion of OxyContin.,"The facts are that she was not involved in the promotion of OxyContin, the training or management of the Purdue sales representatives or the scientific research into the conversion ratio of, of MS. Contin to OxyContin.",They do not support their point with anecdotes.,N/A,"Yeah. Um, and this declaration said that you were not, uh, directly involved with the day to day marketing or promotion of OxyContin, the training or management of the Purdue sales representatives or the scientific research into the conversion ratio of, of MS. Contin to OxyContin. Um, is that correct?"
The topic the person is talking about is an email.,The person's points are that they want to show an email and that it should be marked as exhibit two in the deposition.,The facts are that the person wants to show an email and that it should be marked as exhibit two in the deposition.,There are no anecdotes.,There is no quote.,"I want to show you a, an email let's mark this exhibit two to the deposition."
The topic they are talking about is the email from the person to Cornelia Hinch.,"They summarize their points by saying that the email is from the person to Cornelia Hinch and it is dated May 29th, 1999.","The facts are that the email is from the person to Cornelia Hinch and it is dated May 29th, 1999.",They do not support their point with anecdotes.,N/A,"Okay. And then this, um, email that was just handed to you, um, a few moments ago says, uh, again, it's Cornelia Hinch. Um, it's dated May 29th, 1999. Um, it says, uh, if you'll read the highlighted portion, it says, this is an email from you to her, correct?"
The topic is whether the person should commit their life to OxyContin.,They are questioning whether they read the statement correctly.,N/A,N/A,N/A,"It says you won't believe how committed I am to make OxyContin a huge success. It is almost that I dedicated my life to it. After the initial launch phase, I will have to catch up with my private life again. Did I read that correctly? You"
The topic is OxyContin.,They support their point with facts.,They do not support their point with anecdotes.,N/A,N/A,"When you say you dedicated your life to it, uh, and that you have no time for your private life. What were your day to day activities with respect to OxyContin?"
They are talking about the endo litigation.,They want to know if the person has read their deposition.,N/A,N/A,N/A,Have you read your deposition in the endo litigation?
The topic is unknown.,They want to know more about how many physicians were selling it.,N/A,N/A,N/A,"Okay. When you say you were encouraged by the number of physicians that were selling it, um,"
The topic is the company's illegal marketing and branding of the drug.,"The person's points are that the company is committing a felony, and that they are marketing and branding the drug in an illegal way.","The facts are that the company is committing a felony, and that they are marketing and branding the drug in an illegal way.",There are no anecdotes.,There are no quotes.,"It, prescribing it, you were not aware at this time, were you, or were you aware that your, um, uh, company was committing a felony and how they were marketing and branding the drug?"
no topic,summarizes points,the facts are that the exhibit is three,no anecdotes,no quote,Let's mark this exhibit three.
The topic is Purdue.,The points are that Purdue pled guilty to a felony charge of misbranding a drug and that they were intending to defraud or mislead people.,The facts are that Purdue pled guilty to a felony charge of misbranding a drug and that they were intending to defraud or mislead people.,There are no anecdotes.,There are no quotes.,"And we'll get into this a little more later on, but you're aware that Purdue pled guilty to a felony charge of misbranding a drug, which was OxyContin with the intent to defraud or mislead. You, you are aware of that, correct."
The topic is the company.,They think the company is doing a good job.,The facts are that the company is doing a good job.,They do not support their point with anecdotes.,N/A,Purdue Frederick company. E
The topic is Purdue Pharma.,"They are saying that the fraud occurred with Purdue Frederick company and not with Purdue Pharma, LLP.","The facts are that the fraud occurred with Purdue Frederick company and not with Purdue Pharma, LLP.",There are no anecdotes.,There are no quotes.,"Yeah. Did you, is it your understanding that the fraud, um, uh, only occurred with respect to the Purdue Frederick company and not with respect to Purdue Pharma, LLP?"
The topic the person is talking about is Purdue Pharma.,"The person's points are that they want to know if anyone did any investigation to see if Purdue Pharma sales reps were exceeding what they were allowed to do, and if the reps were making false claims when marketing the product.",N/A,N/A,N/A,"Did you do any investigation to find out whether were, uh, sales reps employed by Purdue Pharma, uh, were, um, exceeding, uh, what they were allowed to do? Uh, and when they were marketing that they were making claims that were untrue."
what topic are they talking about?,can you summarize their points?,"if they support their point with facts, what are the facts?","if they support their point with anecdotes, what are the anecdotes?",can you quote the anecdote?,"Uh, I'm referring to you personally."
The topic is the investigation.,The person's points are that the investigation is a waste of time and resources.,The facts are that the investigation is a waste of time and resources.,There are no anecdotes.,There are no quotes.,"And, and did you all launch this investigation as soon as you learned there was a problem?"
Michael,N/A,N/A,N/A,N/A,"Do you re uh, who's Michael"
The presentation at Purdue.,They have not seen the presentation and want to know more about it.,N/A,N/A,N/A,"Uh, have you seen his presentation at Purdue that he, uh, uh, do you know what at Purdue is the Bureau's internal newsletter that goes out to all the employees?"
topic,summarizes points,claims,,,"Um, alright. We'll get to that later. Um, copies of this is a memorandum dated, um,"
The topic they are talking about is the meeting that was held on July 15th.,They are discussing a meeting that was held and the distribution list for it.,The facts are the date and time of the meeting and who was in attendance.,They do not support their points with anecdotes.,N/A,"July 15th, 1992 meeting with chk held Wednesday, July 24th, 1992 from Dr. JW Watkins. Uh, and there's a distribution list and I assume you are Dr. RS Sackler. Is that correct?"
The company's context.,They are trying to understand the company and its context.,N/A,N/A,N/A,"And if you would turn to page six of this document, that is P D D 1 7 0 1 5 4 6 2 2 6. And to give it a little context, Sheia Nogi, uh, is that a Japanese company?"
The topic is the business venture.,The person's points are that the venture is uncertain and that it involves OxyContin.,The facts are that the business venture is uncertain and that it involves OxyContin.,There are no anecdotes.,There is no quote.,"And at one time, were you all talking about doing some sort of business with them involving potentially, uh, OxyContin controlled release?"
The topic is business dealings with a company.,The person's points are that they are not sure if they have done business with the company and that they want to know more information.,N/A,N/A,N/A,"Uh, and did you do business with them involving OxyContin controlled release?"
The topic is the positioning of oxycodone.,They are looking at options presented by Dr. Keiko.,The facts are that there are two options for positioning oxycodone.,There are no anecdotes.,N/A,"Let's look at page six, if you would the, um, looks like maybe the third paragraph down that begins with Dr. Keiko. Yes. Do you see that Dr. Keiko presented two options identified for positioning of oxycodone aro Contin. Now, is that the controlled release?"
The topic they are talking about is a study on MST cotton tablets.,"They point out that the first study was relevant to the US, and the second study was relevant to PF.","The facts are that the first study was relevant to the US, and the second study was relevant to PF.",They do not support their points with anecdotes.,N/A,"Versus MST cotton tablets in the us. The first was relevant if PF, who is PF"
The topic they are talking about is oxycodone Aqua Contin tablets.,They think that oxycodone Aqua Contin tablets are better than Ms. Cotton tablets and that they should be used for the entire spectrum of pain.,The facts are that oxycodone Aqua Contin tablets are better than Ms. Cotton tablets and that they should be used for the entire spectrum of pain.,They do not support their point with anecdotes.,They do not quote any anecdote.,"Did not suffer substantial erosion of its MS Contin market by generic competition. This envision using oxycodone Aqua Contin tablets over the entire spectrum of pain in patients whose treatment had been initiated with this product whilst Ms. Cotton tablets would be used as therapy for chronic severe pain in patients who were changed from other medication, including oxycodone, Aqua Contin tablets, an alternative scenario would apply if Ms. Cotton tablets were subject to erosion by generic competitors. In this case, oxycodone, Aqua Contin tablets would be promoted for the use across the entire pain spectrum, including those patients who might otherwise receive controlled release morphine. Did I read that correctly?"
The topic is OxyContin.,The person's points are that they are unsure of the intent and that OxyContin is a controlled release.,The facts are that OxyContin is a controlled release.,N/A,N/A,"Okay. And was it your intent, uh, to promote OxyContin, um, controlled release across the entire pain spectrum"
The topic is whether or not the intent was to promote the topic across the entire pain spectrum.,The person's points are that they are not sure if the intent was to promote the topic across the entire pain spectrum.,N/A,N/A,N/A,Was it also your intent in the us to promote it across the entire pain spectrum?
no topic,summarizes points,the facts are that the person is talking about,no anecdotes,no quote,Okay. Let's mark this as exhibit
They are talking about the OxyContin launch team memo.,They are summarizing their points.,The facts are that OxyContin was launched in January of 96.,They are not supporting their point with anecdotes.,N/A,"Okay. And here is, um, P D D 9 5 2 4 7 0 6 4 2 6 OxyContin launch team memo dated 3 31 95. And OxyContin was actually launched in January of 96. Is that correct?"
The topic the person is talking about is whether or not the person had any significant problems with OxyContin CR.,The person's points are that they are not sure if the person had any significant problems and that they experienced problems with OxyContin CR.,The facts are that the person is not sure if the person had any significant problems and that they experienced problems with OxyContin CR.,The person does not support their point with anecdotes.,N/A,"And what this says, if you will turn to page three, first of all, let me ask you this. Do you recall having any significant problem with Ms. Cotton, uh, with respect to a addiction abuse, diversion, or any of the problems that you experienced with OxyContin CR"
They are talking about the importance of establishing OxyContin.,They think that AB rated generics will arrive eventually and that it is important to establish OxyContin now.,They do not quote any facts specifically.,They do not support their point with anecdotes.,They do not quote any anecdotes specifically.,"All right. So let's look at, uh, page two, the last paragraph, it says our meeting ended with a question and comment period. Michael Friedman emphasized the threat that AB rated generics posed to Ms. Cotton. We're not sure when AB rated generics will be launched, but we don't think it will be until 1996, inevitably AB rated generics will arrive. And this is why it is of extreme, timely importance that we must establish OxyContin. OxyContin can cure the vulnerability of the AB rated generic threat. And that is why it is so crucial that we devote our fullest efforts now to a successful launch of OxyContin. Um, did I read that correctly?"
Lydia Johnson,They do not mention any points.,N/A,N/A,N/A,And who is Lydia Johnson?
The topic is the marketing department.,They are confused about which department this is.,N/A,N/A,N/A,"Uh, this department, it looks like it's the marketing department. Is that right?"
The topic is the person's belief.,They think that the person's belief is not important and that the person is wrong.,N/A,N/A,N/A,"Was it your belief that it was of extreme, timely importance that OxyContin be established because AB generics were going to arrive and compete with Ms. Cotton?"
N/A,summarizes points made in previous exhibits,previous exhibits are being referenced,N/A,N/A,Let's mark this as exhibit four.
no,cannot summarize points,no,no,no,I'm
The topic is counting out change.,They are summarizing their points.,The facts are that they are counting out the change.,They do not support their point with anecdotes.,N/A,"Then this would be, be five,"
The topic is apologizing.,The person's points are that they are sorry.,The facts are that the person is sorry.,The person does not support their point with an anecdote.,The person does not quote an anecdote.,I'm sorry.
n/a,does not state a clear opinion,n/a,n/a,n/a,Yeah. Okay.
topic is not clear,points are that this has not been marked as an exhibit,N/A,N/A,N/A,I don't think this has been marked as an exhibit.
N/A,They do not mention any points.,N/A,N/A,N/A,Yeah. This has not been marked as an exhibit.
no,cannot summarize points,no,no,no,Five. I'll
,They think that the sale of OxyContin has generated a lot of money.,They do not support their point with anecdotes.,They do not quote any anecdotes.,They make the claim that the sale of OxyContin has generated a lot of money.,Sackler. Do you know how much money to date has been generated by the sale of OxyContin?
The topic is how much money Purdue Frederick or Purdue Pharma has made off the sale of OxyContin.,The person's points are that they are unsure how much money has been made and that they would like to know.,N/A,N/A,N/A,How much money has Purdue Frederick or Purdue Pharma made off the sale of OxyContin?
The topic is the OxyContin clan.,They are summarizing an article.,The facts are that the OxyContin clan is a new addition to the Forbes 2015 list of the richest US families.,They do not support their point with anecdotes.,N/A,"Okay. Um, there was a article, um, last month in Forbes, the OxyContin clan, the 14 billion newcomer to Forbes 2015 list of the richest us families. Have you seen that?"
The person is talking about Purdue Pharma sales.,The person's points are that they are not sure what percentage of Purdue Pharma sales are made up of OxyContin and they would like to know.,The facts are that the person does not know what percentage of Purdue Pharma sales are made up of OxyContin.,The person does not support their point with anecdotes.,N/A,"Um, do you know what percentage of Purdue Pharma sales, uh, is made up of OxyContin"
The topic is good.,The person's points are that the topic is good and that they support it.,The facts are that the topic is good and that they support it.,The anecdote is that the person supports the topic.,"Yes, the person supports the topic.",Yes.
The topic is not stated.,The person's points are that they have looked at the topic and they are undecided.,The facts are that the person has looked at the topic.,The person does not support their points with anecdotes.,N/A,"Um, okay. Um, I've, I've looked at the, the"
The topic is whether or not Purdue Frederick sells OxyContin.,The person's points are that they are unsure if Purdue Frederick sells OxyContin and that there are other entities that generate income from the sale of OxyContin.,The facts are that Purdue Frederick may or may not sell OxyContin and that there are other entities that generate income from the sale of OxyContin.,There are no anecdotes.,There are no quotes.,"Sales, Purdue Frederick does not sell, um, anymore, correct? No. You've got another, a number of other entities that generate income from the sale of OxyContin, correct"
They are talking about the company's profits.,They think that the company is doing well because of OxyContin.,The facts are that the company makes a lot of money from OxyContin.,They do not support their point with anecdotes.,N/A,Yes. And is it approximately 90% of the profits of the company come from OxyContin?
The topic is Purdue Pharma.,"The person's points are that Purdue Pharma is responsible for the opioid crisis, and that the company is unethical.","The facts are that Purdue Pharma is responsible for the opioid crisis, and that the company is unethical.",There are no anecdotes.,There are no quotes.,Purdue Pharma.
The topic they are talking about is OxyContin.,They think that OxyContin is harmful and that it is being sold irresponsibly.,The facts are that OxyContin is a harmful drug and that it is being sold irresponsibly.,They do not support their point with anecdotes.,N/A,"Um, do you currently make over a billion dollars a year selling OxyContin?"
The topic is not stated.,The teacher thinks it is a great idea and it is a positive way to get kids interested in learning.,N/A,N/A,N/A,"Yes,"
,"The person's points are that they are not sure if Purdue Pharma makes over a billion dollars a year, but they have heard that the company makes a lot of money.",The facts are that Purdue Pharma is a large company and that it makes a lot of money.,The person does not quote any anecdotes.,The claims made are that Purdue Pharma is a large company and that it makes a lot of money.,Right. Does Purdue Pharma make over a billion dollars a year?
The topic is gross sales.,They think gross sales are a good thing.,The facts are that gross sales are over $3 billion a year.,They do not support their point with anecdotes.,N/A,"Um, let's talk about gross sales are gross sales over $3 billion a year."
The topic they are talking about is the gross sales.,They point out that the gross sales are good.,The facts are that the gross sales are up.,They do not support their point with anecdotes.,They do not quote any anecdotes.,What are the gross sales?
The topic they are talking about is Purdue Pharma.,They think that Purdue Pharma is a good company.,The facts are that Purdue Pharma is a good company.,They do not support their point with anecdotes.,N/A,"Right? Purdue, Purdue Pharma."
The topic they are talking about is entities at Purdue University that make money.,They are asking if there are any other Purdue entities that make money.,N/A,N/A,N/A,Are there any other Purdue entities that make money that would not be included in that 1 billion sales
The Sackler family,The person is curious about how much money the Sackler family has made from OxyContin sales,No,No,No,Do you know how much the Sackler family has made off the sale of OxyContin? I don't
The topic they are talking about is investing in a company.,They think it is a good investment.,The facts are that it is over a billion dollars.,They do not support their point with anecdotes.,N/A,But fair to say it's over a billion dollars.
The topic is numbers.,They are asking if the number is over 10 billion.,N/A,N/A,N/A,Do you know if it's over 10 billion?
The topic they are talking about is overpopulation.,They think that it is a good thing because it means that there are more people on the planet.,The facts are that there are over 5 billion people on the planet.,They do not support their point with anecdotes.,N/A,"You know, if it's over 5 billion,"
The topic is the document and which entity it is for.,They are questioning what the document is and which entity it is for.,There are no facts given.,There are no anecdotes given.,There are no quotes given.,"This appears to me, uh, what's been marked as exhibit five. It's P K Y six six, I'm sorry. Six exhibit six, P K Y 1 7 3 8 1 0 2 0 0 6. Appears to be a profit calculation for, um, a Purdue entity. Can you tell me which entity that is?"
The topic is whether Purdue Frederick still existed in 2006.,The person does not mention any specific points.,N/A,N/A,N/A,Did Purdue Frederick still exist in 2006?
The topic they are talking about is profit calculation for OxyContin tablets.,They are summarizing their points.,The facts are that this is a profit calculation for OxyContin tablets only.,They do not support their point with anecdotes.,N/A,"This appears to be a, um, profit calculation for OxyContin tablets only. Do you see that?"
The topic they are talking about is profit contribution.,They are summarizing points.,"The facts are that by 2006, profit contribution was 4 million.",There are no anecdotes.,N/A,"And it appears that, um, at least by 2006 profit, uh, contribution was 4 million, uh, 4 billion, 718,767,000. Is that correct?"
The topic is a proposal.,They want to know what would be subtracted from the proposal.,N/A,N/A,N/A,And what would you subtract from that?
The topic they are talking about is gross profit.,They are summarizing their points.,"The facts are that gross profit is 7 billion, 500, 2 million, 367,000.",They do not support their point with anecdotes.,They do not quote the anecdote.,"Let's mark this well let's you're right. I think it is, uh, look up at the top where it says gross profit, 7 billion, 500, 2 million, 367,000."
The topic they are talking about is shipping warehousing.,They are summarizing their points.,The facts are that they have paid Abbott for co promotion commission.,They do not support their point with anecdotes.,N/A,"You. Yeah. So deducted from that is shipping warehousing. You have 530, 6 million paid to Abbott for co promotion commission."
The topic is an S and P expense.,They are asking a question.,N/A,N/A,N/A,Correct. You have an S and P expense. What's that?
The topic they are talking about is sales and promotion.,They are questioning the sales and promotion numbers.,The facts are the sales and promotion numbers.,They do not support their point with anecdotes.,N/A,"All right. That was, uh, 141 million, uh, on sales and promotion. Is that correct?"
The topic they are talking about is R and D expense.,They think that R and D expense is good because it is a lot of money.,The facts are that R and D expense is 308 million.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"R and D expense? Um, 308 million,"
The topic they are talking about is Salesforce.,They think that Salesforce is a great tool for sales and marketing teams and that it helps them work together more efficiently.,The facts are that Salesforce is a great tool for sales and marketing teams and that it helps them work together more efficiently.,They do not support their point with anecdotes.,N/A,Salesforce.
They are talking about Salesforce.,They are summarizing points.,"The facts are that Salesforce is 960 or 87 million, 222 that they've been paid.",They do not support their point with anecdotes.,N/A,"Right. And then Salesforce is 960 or, or 87 million, 222 that they've been paid."
N/A,The person is listing off expenses and does not seem to have a opinion on them,The person is listing off expenses and does not seem to have a opinion on them,N/A,N/A,"Um, and then it's got a GNA expense. What is"
The topic they are talking about is the 492 million.,They think that it is a good thing and that it will help a lot of people.,The facts are that it will help a lot of people.,They do not support their point with anecdotes.,N/A,Right? 492 million.
The topic is not clear.,They are not sure if the topic is helpful or not.,N/A,N/A,N/A,"Uh,"
They are talking about the OxyContin litigation expenses.,They are talking about the OxyContin litigation expenses.,The facts are that the profit after all the expenses are subtracted is 4 billion 718 million.,They do not support their point with anecdotes.,N/A,"You are, then there is product liability and patent litigation, uh, expense. Um, you had, uh, OxyContin litigation expenses. Uh, then you have profit after all those are subtracted on OxyContin of 4 billion, 718 million. Is that correct?"
the topic is the exhibit,summarizes points,the facts are that the exhibit is six,no anecdotes,no quote,Let's mark this as plaintiff's exhibit six.
The topic is taking a break.,They want to take a break if others need one.,N/A,N/A,N/A,"Um, I'm trying to go a little bit longer. I mean, if y'all need a break, we can take a break. I could take a break quick, take a break."
The topic they are talking about is oxycodone.,They are discussing the fact that oxycodone is controlled release OxyContin.,The facts are that oxycodone is controlled release OxyContin.,They do not support their point with anecdotes.,N/A,"All. Um, this exhibit, I out, one more thing in exhibit four. And if you look at the second paragraph, there's a comment that says when discussing oxycodone, Aqua Contin, um, which is controlled release OxyContin, oxycodone. I'm"
The topic is the economy.,They think it is a good idea and they support their points with facts.,The facts are that it is a good idea and it will help the economy.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"Uh, the first,"
Unknown,They have not stated any clear points.,N/A,N/A,N/A,"Uh, second paragraph."
The topic the person is talking about is a new molecule that lacks the stigma of morphine.,"The person's points are that the molecule lacks the stigma of morphine, and that it could be of particular advantage to patients who cannot be adequately treated with morphine.","The facts are that the molecule lacks the stigma of morphine, and that it could be of particular advantage to patients who cannot be adequately treated with morphine.",There are no anecdotes.,N/A,"It says the molecule lacks the stigma of morphine and maybe of particular advantage in the 5% approximately of patients who cannot be adequately treated with morphine. Um, was it your understanding that approximately 95% of the patients out there could be treated with Ms. Cotton?"
The topic is the statement itself.,The person's points are that they are undecided on the statement and they want to know if the other person disagrees with them.,N/A,N/A,N/A,"Um, do you disagree with that statement that I,"
The topic is Ms. Common.,The person's points are that Ms. Common is not effective and that patients deserve better treatment.,The facts are that Ms. Common is not effective.,There are no anecdotes.,There are no quotes.,Disagree. What percentage do you think of patients could be adequately treated with Ms. Common
The topic is not clear.,"The person's points are that they want to know what the other person's studies are based on, and they want to know if the other person has any studies to back up their claims.",There are no facts given.,There are no anecdotes given.,There are no quotes given.,And what studies are you basing that on?
The topic is whether or not MS can be treated with medication.,The person's points are that they are unsure if MS can be treated with medication and would like to know if there have been any studies done on the topic.,The facts are that the person would like to know if there have been any studies done on the topic of MS.,The person does not support their points with anecdotes.,N/A,"Did you ever do any studies to determine, uh, what percentage of patients could be adequately treated with MS."
The person is talking about the safety of OxyContin.,The person asks if any studies were done on the abuse liability for OxyContin before it was put on the market.,N/A,N/A,N/A,Did you ever do any studies on abuse liability for OxyContin before you all put it on the market?
,They are summarizing their points.,"The facts are that the person has been identified by Bates stamp, P D D 8 8 1 1 2 3 8 4 7.",They are quoting the anecdote.,"The claims they make are that the person has been identified by Bates stamp, P D D 8 8 1 1 2 3 8 4 7.","Let me show you, um, what's been, uh, identified by Bates stamp, P D D 8 8 1 1 2 3 8 4 7. Copies of mark that we'll mark this plaintiff's exhibit seven. And I'll ask you if you can identify this,"
The topic they are talking about is the document.,They are questioning whether or not the document is from Paul Goldenheim.,N/A,N/A,N/A,And does this appear to be a memo to you from Paul? Goldenheim
They are talking about Paul Goldenheim.,They cannot summarize their points.,N/A,N/A,N/A,And who is Paul? Goldenheim
The topic is the memo.,They are summarizing the points of the memo.,The facts are the date of the memo and the individuals it was sent to.,There are no anecdotes.,N/A,"Okay. And just to kind of walk through this memo from the bottom down there, it looks like you had sent a memo, um, on March 14th of 97 to a number of individuals at, uh,"
The B F a R M,They are asking what the B F a R M is.,N/A,N/A,N/A,And the paragraph at the bottom says the B F a R M. What is that?
The topic they are talking about is whether oxycodone should be less regulated in Germany.,They are summarizing a question about whether oxycodone could be classified as a controlled drug in Germany.,"The facts are that oxycodone is difficult to extract from the matrix, and it was unknown.",They do not support their point with anecdotes.,N/A,"Says we're asked whether OxyContin could be classified as a controlled drug or whether it would be possible to obtain a relaxed status because of the difficulty in extracting oxycodone from the matrix. And the fact it was less liable to abuse because it was unknown. Um, so just dialing down on that first sentence, you were wondering whether oxycodone could be less regulated in Germany. Is that correct?"
The topic they are talking about is the BFR.,They are summarizing the points.,The facts are that the BFR is the German regulatory authority.,There are no anecdotes.,,"I'll tell you, I'll read it to you. Uh, the next sentence says the BFR, uh, B F a R M, which I understand is the German regulatory authority."
They are talking about the classification of OxyContin.,They are questioning if they read something correctly.,N/A,N/A,N/A,"Answer that. Unfortunately, OxyContin would definitely be classified as a controlled drug for all strengths as is morphine. There could be no exception because of the controlled release protection, because there had been a few reports of abuse and there were limited data on long term use. Did I read that correctly?"
The topic is data.,The person's points are that there is a lot of data on the topic and that there are very few ads.,The facts are that there is a lot of data on the topic and that there are very few ads.,There are no anecdotes.,There are no quotes.,"Okay. And then you have here in caps, we have a lot of use data in the us with very, very, very few ad. What are AEs?"
The topic they are talking about is whether or not to unschedule the drug.,They want more data to be collected before making a decision.,The facts are that there is potential for abuse with the drug and they want to know if it is equal to or lower than other non-scheduled drugs.,They do not support their point with anecdotes.,N/A,"Okay. And then you have in caps, uh, continuing, we can run another long-term trial to get more data. And if the abuse potential is equal or lower than with other non-scheduled drugs would Bera, unschedule it? That's your question? Correct. That"
The topic they are talking about is Dr. Golden ham's opinion on the subject of descheduling the agent.,They are summarizing points.,"The facts are that Dr. Golden ham writes back on the subject of, is this an opening to descheduling the agent and descheduling means make it less restrictive, correct.",They do not support their point with anecdotes.,N/A,"Question. And then Dr. Golden ham writes back on the subject of, is this an opening to descheduling the agent and descheduling means make it less restrictive, correct."
The topic the person is talking about is less restrictions.,"The person's points are that if the topic is less restricted, then more people would buy it.","The facts are that if the topic is less restricted, then more people would buy it.",The person does not support their point with anecdotes.,The person does not quote any anecdotes.,"Um, and if it's less restricted, uh, would you think that you could sell it to more people?"
The topic is that it will increase sales.,They think it will increase sales.,The facts are that it will increase sales.,They do not support their point with anecdotes.,N/A,It's gonna increase sales
The topic they are talking about is the idea.,They think it is a good idea and they support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,And
,They are summarizing points made by someone else.,"The facts are that as of 1997, there were no abuse liability studies.",They do not quote any anecdotes.,"They make the claim that as of 1997, there were no abuse liability studies.","And his response is we do not have any abuse liability studies. And this is as of 1997, correct?"
The topic is abuse or liability studies.,They want to know if any abuse or liability studies have been done.,N/A,N/A,N/A,"Uh, to, to date, have you done abuse, liability studies?"
The topic is when something was done.,They want to know when the thing was done.,N/A,N/A,N/A,When were they done?
"The topic they are talking about is abuse, liability studies for OxyContin controlled release.","They want to know if the company has done abuse, liability studies for OxyContin controlled release.","The facts are that they want to know if the company has done abuse, liability studies for OxyContin controlled release.",They do not support their point with anecdotes.,N/A,"Have you done abuse, liability studies for OxyContin controlled release?"
The topic is unknown.,They are questioning the timing of when the events happened.,N/A,N/A,N/A,And when were those done?
The topic is the new formulation's effectiveness.,They are questioning the new formulation's effectiveness.,The facts are that the new formulation is no more effective than the old one.,They do not support their point with anecdotes.,N/A,"You're saying the new formulation,"
The topic is the new formulation.,They want to know when the new formulation was submitted.,The facts are when the new formulation was submitted.,They do not support their point with anecdotes.,N/A,Okay. When were the new formulation submitted?
,"The person's points are that it is a difficult project from a clinical perspective, and that they are investigating for hydrocodone.","The facts are that by 1997, two years after the product was on the market, they say that they do not have any abuse liability studies.","The claims made are that it is a difficult project from a clinical perspective, and that they are investigating for hydrocodone.","The premises relied on are that by 1997, two years after the product was on the market, they say that they do not have any abuse liability studies.","So, um, uh, by 19 97, 2 years after this product was on the market, uh, he says we do not have any abuse liability studies. I think this is a dead end. Adding Naloxone, I think is the only possibility, but this is a difficult project from the clinical spec, uh, perspective we are investigating for hydrocodone. Um, and was that his response?"
The topic is whether or not the schedule will be corrected.,They think that the schedule will not be corrected.,N/A,N/A,N/A,He's basically saying they're not gonna correct schedule this
The topic is Naloxone.,"The person's points are that Naloxone is an additive that decreases the risk of overdose and death, and that it is not a medication that someone would seek out to get high.",The facts are that Naloxone is an additive that decreases the risk of overdose and death.,The person does not support their points with anecdotes.,N/A,"And Naloxone is an additive,"
The topic they are talking about is Naloxone.,They think that Naloxone should be incorporated because it could save lives.,The facts are that Naloxone is a drug that can reverse the effects of an opioid overdose.,They do not support their point with anecdotes.,N/A,And you all did not incorporate Naloxone. Correct.
,They think it is a good idea and it helped them.,The anecdote is about how they were required to do it and it helped them.,They make the claim that it is a good idea.,They rely on the premise that it helped them.,Did they require you to do that?
The topic is the reason.,They are asking for the reason.,N/A,N/A,N/A,What was the reason
The topic they are talking about is the email chain.,They are saying that the email chain is wrong and that it should be taken down.,The facts are that the email chain is wrong and it should be taken down.,They do not support their point with anecdotes.,N/A,"Let me show you an email chain. That's been produced mark. This that's wrong. Pull that off or not for sticks. And it's P PDD 2 9 5 2 0 8 0 6 4 3 9. And um, if you start at the back, I believe this email chain, um, begins at the back. And this is an email from you dated, um,"
"They are talking about the last email being the first email and the dated 3, 2 97.",They think it is a good thing.,"The facts are that the last email is the first email and the dated 3, 2 97.",They do not support their point with anecdotes.,They do not quote any anecdote.,"Yeah, the last email is the first email and the dated 3, 2 97."
It is unclear what topic they are talking about.,They do not state any clear points.,N/A,N/A,N/A,"I'm sorry. Yeah, there is uh, my, my tore off, uh,"
"The topic they are talking about is that 3 12 97, 2 27 97 is the first.",They are summarizing their points.,"The facts are that 3 12 97, 2 27 97 is the first.",They do not support their point with anecdotes.,They do not quote any anecdotes.,"3 12 97, 2 27 97 is the first."
"The topic they are talking about is ""is.""",They think it is a good thing.,"The facts are that it is a verb meaning ""to exist"" and it can also be used as a noun meaning ""the existence of something.""",They do not support their point with anecdotes.,N/A,Is
The topic is email.,They are looking for a specific email.,N/A,N/A,N/A,"Here. So if you'll go to the 2 27 97 email,"
They are talking about the Sackler family.,They are summarizing a point made by Walter Wimmer about the Sackler family.,The fact is that Mundy Pharma is owned by the Sackler family.,There are no anecdotes.,There are no quotes.,"It says, um, this is from Walter Wimmer at Mundy Pharma Germany. And that's a company that's owned by the Sackler family,"
It is unclear what topic they are talking about.,They do not make any points.,N/A,N/A,N/A,Is. And who's Walter
The topic they are talking about is getting OxyContin off the narcotic drug status.,They are summarizing a conversation where the person said there is a 50% chance to get OxyContin off the narcotic drug status.,The facts are that there is a 50% chance to get OxyContin off the narcotic drug status.,They do not support their point with anecdotes.,N/A,"And he says, um, dear Bob, um, first paragraph in the course of this conversation, he explained to you that due to his discussions with B F a R M, he does see a 50% chance to get OxyContin off the narcotic drug status provided. You could give some information on the very low abuse potential of our CR formulation. Did I read that correctly?"
The topic is Dr. Robert Keiko.,They are summarizing Dr. Robert Keiko's points.,The facts are that Dr. Robert Keiko has an email dated 2/27/97.,There are no anecdotes.,There are no quotes.,"And then in response to that, if you go up to the top, Dr. Robert Keiko has an email dated 2 27 97."
,The person's points are that the risks are not appreciated and that the proposal should not proceed as proposed.,The facts are that the risks are not appreciated and that the proposal should not proceed as proposed.,The person does not support their point with anecdotes.,The claims the person makes are that the risks are not appreciated and that the proposal should not proceed as proposed.,"And he says, while my thinking is still development developing, frankly, I'm very concerned and I would have to recommend against the uncontrolled, but monitored proposal at this time, parentheses perhaps if only to make sure the risks are appreciated and accepted before we proceed as proposed. Um, do you know what, uh, risk he was discussing?"
The topic they are talking about is why he was recommending against going uncontrolled with respect to Oxy.,They want to know why he was recommending against going uncontrolled with respect to Oxy.,N/A,N/A,N/A,"Did you ever discuss with him why he was recommending against, uh, going uncontrolled, but monitored with respect to Oxy?"
The topic is the abuse of oxycodone products.,They are summarizing the points made by the person in the text.,"The facts are that oxycodone products were once less controlled than now, and that abuse resulted in greater controls.",There are no anecdotes.,N/A,"Well, let's read the rest of it. It might help. Um, he says under paragraph B, I don't believe we have a sufficiently strong case to argue that OxyContin has minimal or no abuse liability. And this is dated 1997, correct? Yes. He says in the us oxycodone containing products were once less controlled than now. Abuse resulted in greater controls. Um, is that accurate?"
The topic is not stated.,The person's points are that the topic was abused in the past and that there are controls in place now.,The facts are that the topic was abused in the past and that there are controls in place now.,There are no anecdotes.,There are no quotes.,"Um, and what he's saying, there is these weren't as controlled at, at one time and they got abused and that's why we have controls now. Correct."
The topic is oxycodone.,They are summarizing the points.,The facts are that oxycodone is still among the most abused opioids in the US.,There are no anecdotes.,There are no quotes.,He says oxycodone containing products are still among the most abused opioids in the us. This information is available to B F a R M the German regulators.
The topic they are talking about is OxyContin.,They think that OxyContin is a good way to get rid of pain and that it is not a drug that people abuse.,"The facts are that in New Zealand, MST is the most common source of temporarily abused morphine slash heroin.",They do not support their point with anecdotes.,N/A,"To them. And he says the local tissue necrosis that can result from injection of OxyContin fixed, uh, in quotations for such abuse is not likely to be a deterrent to abuse. Let us not forget that in New Zealand, MST is the most common sources of temporarily abused morphine slash heroin. And were you aware at that time that, uh, OxyContin, there was a concern that, that oxycodone opioids could be, uh, injected or abused?"
It is unclear.,They do not state any clear points.,N/A,N/A,N/A,And then he says
The topic is the documents.,They think it is good that he says our dossier acknowledge.,N/A,N/A,N/A,"Saw it. Then he says our dossier acknowledge. And by dossier, I assume he means the documents. Yes."
They are talking about the research program.,They are saying that a small number of patients in the research program is acknowledged in the dossier.,The facts are that a small number of patients in the research program is acknowledged in the dossier.,They do not support their point with anecdotes.,N/A,"Has. Yes. Our dossier acknowledges a small handful of patients in our research program. And that means studies you all were doing, is"
They are talking about how there were patients who were not accounted for in terms of their drug use.,They are talking about how there were patients who were not accounted for in terms of their drug use.,The facts are that there were patients who were not accounted for in terms of their drug use.,They do not support their point with anecdotes.,N/A,"To me who were suspect in terms of their drug accountability. Do you know if that was reported to anyone that, that U's dossier had a handful of patients who were suspect in terms of their drug accountability?"
They are talking about an issue with the Roth reprint.,They are mentioning an issue with the Roth reprint and how some patients had withdrawal symptoms that were not reported.,The facts are that there were patients with withdrawal symptoms that were not reported.,There are no anecdotes.,There are no quotes.,"Both, do you remember the issues with the Roth reprint, where there were patients who they determined, um, had withdrawal symptoms and that was not reported?"
The topic is the Roth reprint.,"The person's points are that they are not sure if the person they are talking to is familiar with the Roth reprint, and they apologize if the person is not familiar with it.",The facts are that the person is not sure if the person they are talking to is familiar with the Roth reprint.,There are no anecdotes.,There is no quote.,"I'm sorry. Are you, are you familiar with the Roth reprint?"
The topic is the plea agreement.,The person's points are that they are unsure if the plea agreement was part of the felony and they want to know if it was.,N/A,N/A,N/A,"You know, whether that was part of the plea agreement that Purdue Frederick had when they pled guilty to a felony?"
The topic is the company's lack of a system to monitor abuse or diversion of the drug.,They are saying that the company did not have a system to monitor abuse or diversion of the drug.,The facts are that the company did not have a system to monitor abuse or diversion of the drug.,There are no anecdotes.,There are no quotes.,"And it says under paragraph C, um, oh, continuing on. We do not, we do not have a postmarketing abuse monitoring system and database from which we could conclude that diversion abuse is not occurring. Were you aware that you all put this on the market and, uh, OxyContin CR and did not have a post marketing abuse monitoring system or database from which you could tell whether abuse or diversion was occurring?"
The topic is whether or not it would have been a good idea to have an abuse monitoring system and database before putting OxyContin controlled release on the market.,"The person's points are that they are unsure if having an abuse monitoring system and database would have been helpful, and that it may have been difficult to implement such a system.","The facts are that OxyContin controlled release was put on the market without an abuse monitoring system or database, and that such a system may have been difficult to implement.",There are no anecdotes.,There are no quotes.,Do you think it would've been a good idea before putting OxyContin controlled release on the market to have an abuse monitoring system and database from which to tell if it was being diverted or abused?
,They are questioning whether or not it is a good idea to make OxyContin uncontrolled in Germany because of the potential for abuse.,"The facts are that if OxyContin is uncontrolled in Germany, it is likely to be abused and eventually controlled, which could damage OxyContin's reputation internationally.",They do not quote any anecdotes.,They make the claim that it is unclear whether or not making OxyContin uncontrolled in Germany is a good idea.,"And then under paragraph C, it says if OxyContin is uncontrolled in Germany, it is highly likely that it will eventually be abused there and then controlled. This may be more damaging to OxyContin internationally than any temporarily higher cells that could be gleaned from an uncontrolled status. Let us not forget the experience with Bupenorphine, which was initially uncontrolled reports of abuse in Germany, in part eventually led to lots of bad press and controlled status. Worldwide sales suffered even where Bupenorphine had already been controlled. So given the above, what do others have to offer that should prompt us to pursue the proposal for uncontrolled status for OxyContin, anywhere question mark. And was that, uh, the response of Robert Keiko?"
Robert Keiko,N/A,N/A,N/A,N/A,And who was Robert Keiko?
The topic they are talking about is whether or not the person was the chief medical officer.,They are questioning whether or not the person was the chief medical officer.,N/A,N/A,N/A,Was he the chief medical officer?
They are talking about the email.,They think it is a good idea and are supportive of it.,The facts are that it is a good idea and that they are supportive of it.,They do not support their point with anecdotes.,N/A,"And then the next email, which comes from you is Dr. Richard, Richard Sackler at"
The topic is unclear.,They do not provide any points.,N/A,N/A,N/A,"Uh, it looks like it's 3, 2 19 97. Um, and there"
The topic is the date.,They are confused about the date.,N/A,N/A,N/A,"I'm looking at three, two, it says, oh, 2 0 3 97. But I think the way it's confused is really March 3rd."
It's unclear.,They don't mention any specific points.,N/A,N/A,N/A,It's page five. Maybe
The topic is whether or not to pursue an idea.,They want to know if the idea is feasible and how it would improve sales.,N/A,N/A,N/A,"You. And this is your response to Robert Keiko saying this is a bad idea for all these reasons. And you say, this is the first time I've heard of this idea. What makes us believe that we can accomplish it? Walter? How substantially would it improve your sales? And what you're talking about there is if we can get it uncontrolled in Germany, how substantially will it approve improve sales? Correct?"
The topic they are talking about is the European Union.,They think that the European Union is a good thing and that it will help the countries involved.,The facts they mention are that the European Union will help the countries involved.,They do not mention any anecdotes.,N/A,"Was. Please give a five year projection with control and without does each member of the EU, is that European union? Yes. Decide this for themselves. Or would one lead if one would lead then is Denmark or Germany more likely to agree. And then Harry Kutzko of mul Mundy Pharma Mo Monday, Pharma writes you back on March 7th and says, dear Dr. Richard"
They are talking about the same page.,They think it is a good idea and support their point with facts.,The facts are that it is the same page.,They do not support their point with anecdotes.,N/A,"That's the same page, the one right above."
The topic they are talking about is the harms of OxyContin.,"They think that OxyContin use will increase without controls, and that this increase will be harmful.","The facts are that OxyContin use will increase without controls, and that this increase will be harmful.",They do not support their points with anecdotes.,N/A,Please find stated below our five year projection of OxyContin without and with controls as requested mm-hmm
"The topic they are talking about is first year nonnarcotic, uh, narcotic drug with control, be 3.000 TDM.",They are summarizing their points.,"The facts are that with first year nonnarcotic, uh, narcotic drug with control, be 3.000 TDM.",They do not support their point with anecdotes.,N/A,"And it was projected that with first year nonnarcotic, uh, narcotic drug with control, be 3.000 TDM. Do you know what that is?"
The topic is that it would make 3 million.,They think it is a good idea because it would make 3 million.,The facts are that it would make 3 million.,They do not support their point with anecdotes.,N/A,Marks. And that would be 3 million.
They are talking about the turnover of nonnarcotic drugs.,They think that turnover over nonnarcotic drug and over non-narcotic drug without control is 10 million.,The facts are that turnover over nonnarcotic drug and over non-narcotic drug without control is 10 million.,They do not support their point with anecdotes.,N/A,And then turnover over nonnarcotic drug and over non-narcotic drug without control is 10 million
The topic they are talking about is gun control.,They are talking about how gun control is necessary to prevent mass shootings.,"The facts are that without gun control, there will be more mass shootings.",They do not support their point with anecdotes.,N/A,"Year. And on the fifth year, it was projected to be 18 million with control, but 30 million without control."
The topic they are talking about is whether or not the regulatory authorities said that it was a good idea.,They are summarizing their points.,The facts are that the regulatory authorities said that it was a good idea.,They are not supporting their point with anecdotes.,N/A,"And then you wrote back on 3, 8 97, right above that one. And it says, BK advised that the regulatory authorities did say,"
The topic they are talking about is getting OxyContin CR uncontrolled.,They want to know if there is some way to appeal the German decision objection.,The facts are that the regulatory authorities said that Oxy would be scheduled and under narcotic control.,There are no anecdotes.,N/A,"And, uh, advised the regulatory authorities said that Oxy would be scheduled. And so would be under narcotic control. Does this correspond to your info? If so, if so, is this matter now closed or is there some appeal or other procedure you would want to consider? So you still saw the advantage of getting OxyContin CR uh, uncontrolled. Um, and we're wondering if there was some way you might appeal the German decision objection,"
The topic is unclear.,The person's points are that they are unsure of the topic and would like clarification.,N/A,N/A,N/A,"Well, correct me if I'm wrong there. Why did you say, is there some appeal or other procedure you want to consider? Um,"
The topic is thought controls.,"The person's points are that they are undecided on whether or not thought controls are appropriate, and that if there was some appeal that could be taken, they would have done so already.","The facts are that the person is undecided on whether or not thought controls are appropriate, and that if there was some appeal that could be taken, they would have done so already.",There are no anecdotes.,There is no quote.,"Let me ask you, if you thought controls were appropriate, why were you asking here raising the issue? If there was some appeal that could be taken"
They are talking about the appeal process.,They think that the matter is closed and there is no way of appeal.,The facts are that they attended the meeting with the BGA and that the registration office said that the matter is now closed.,They do not support their point with anecdotes.,N/A,"Okay. Well, let me ask you this. Let's go to the next one, which is page four. He writes back. Yes. Richard, this does correspond to the information given by Mr. G our registration office. We also attended the meeting with the BGA. This matter is now closed. There is no way of appeal. Is that what he told you?"
The topic they are talking about is an idea that was raised and then failed to be realized.,"They think it is a good idea, but are unsure if it can be done.",N/A,N/A,N/A,"And then you wrote back and said, when we are next together, we should talk about how this idea was raised and why it failed to be realized. I thought that it was a good idea if it could be done. Was that your response to"
The topic they are talking about is getting the product off narcotic drug status.,They are summarizing a response from Walter Wimmer.,The facts are that it would be possible to combine oxycodone with Naloxone provided the development cost wasn't too high.,They do not support their point with anecdotes.,N/A,"Up at the top. There's a note. Uh, there's another response from Walter Wimmer, um, who says to get the product off narcotic drug status, it would be possible to combine oxycodone with Naloxone provided the development cost. Weren't too high that was sent on three"
The topic they are talking about is adding Naloxone to narcotics.,They are questioning whether or not it would be feasible to add Naloxone to narcotics in the United States.,N/A,N/A,N/A,"Okay. And then the top one is cut off. I'm sorry, but it says Paul, Michael, would this be a feasible approach here in the us? I don't know of any C2 narcotic. That is descheduled when Naloxone is added to you, that is that a question you were raising?"
The topic they are talking about is the addiction and physical dependency rates of oxycodone products.,They are claiming that Purdue Pharma never conducted or retained anyone to conduct studies regarding addiction and physical dependency rates of oxycodone products.,"The facts are that as of March 4th, 2002, Purdue Pharma never conducted or retained anyone to conduct studies regarding addiction and physical dependency rates of oxycodone products.",They do not support their point with anecdotes.,N/A,"Oh. Um, would I be correct that Purdue Pharma never conducted or retained anyone to conduct studies regarding addiction and physical dependency rates of oxycodone products? Um, <affirmative> at least as of March 4th, 2002,"
The topic they are talking about is addiction and physical dependency rates of Oxycon code on products.,They are saying that Purdue Pharma never conducted or retained anyone to conduct studies regarding addiction and physical dependency rates of Oxycon code on products.,The facts are that counsel for Purdue Pharma answered interrogatories that requested the names of all individuals retained by Purdue Pharma to do studies regarding addiction and physical dependency rates of OxyContin products and copies of all studies.,They do not support their point with anecdotes.,N/A,"Are you aware that counsel for Purdue Pharma, um, answered interrogatories that requested the names of all individuals retained by Purdue Pharma to do studies regarding addiction and physical dependency rates of OxyContin products and copies of all studies. And he answered, we never conducted or retained anyone to conduct studies regarding addiction and physical dependency rates of Oxycon code on products."
The topic they are talking about is moving the deposition along.,They are trying to move the deposition along.,The facts are that they are trying to move the deposition along.,They do not support their point with anecdotes.,N/A,"Uh, no. I'm just asking him if he's aware of it. Cause I'm trying to move the deposition along. So are you aware of that?"
The topic the person is talking about is addiction and physical dependency rates of oxycodone products.,"The person's points are that they are curious if any studies have been done on addiction and physical dependency rates of oxycodone products and if so, what the results were.",The facts are that the person wants to know if any studies have been done on addiction and physical dependency rates of oxycodone products and what the results were.,The person does not support their points with anecdotes.,N/A,Are you aware of any studies conducted or retained or anyone being retained to conduct studies regarding addiction and physical dependency rates of oxycodone products prior to 2002?
The papers,The person's points are that the papers are from the library and they are not good.,N/A,N/A,N/A,"You got these,"
It is unknown what topic they are talking about.,They have not stated any points.,N/A,N/A,N/A,"No, I still won't ask about this. Did this,"
They are talking about how great it was that it was eight.,They think it was great.,The facts are that it was eight.,They don't support their point with anecdotes.,They don't quote any anecdotes.,It was eight.
,They support their point with facts.,They make the claim that marketing OxyContin tablets will be effective.,"The premises they rely on are that marketing OxyContin tablets will be marketed against Percocet and Duragesic, and that the OxyContin line may replace our MS. Contin line if MSC generics are competing.",The topic they are talking about is marketing OxyContin tablets.,"It's OxyContin product two. All right. I'm gonna switch and ask you a little bit about the OxyContin project team. And this is a memo dated December 14th, 1993, PD D 95 25 0 9 3 5 6. And there's a few paragraphs I want to try to cover here. If you will look at the bulletin points on the front page, the second one from the bottom says marketing OxyContin tablets will be marketed against Percocet and Duragesic the OxyContin line may replace our MS. Contin line if MSC generics are competing. Is that correct?"
The topic is cancer patients.,They are questioning the cancer group of patients.,N/A,N/A,N/A,"Okay. And that's not the, uh, is that the malignant cancer group of patients or is that, uh, non-malignant cancer group of patients?"
The topic is unknown.,They want to know the answer.,N/A,N/A,N/A,All right. You may answer
The topic the person is talking about is Percocet and Duragesic.,"The person's points are that they are unsure of what Percocet and Duragesic was used mostly to treat, and they would like to know.",There are no facts given.,There are no anecdotes given.,There is no quote given.,Do you have a knowledge of what Percocet and Duragesic was used mostly to treat
The topic is toxicity.,They are summarizing points from a document.,The facts are the results of a study.,There are no anecdotes.,N/A,"And then if you'll turn over to, um, paragraph 2.3, and this is 1993, um, it says abuse, toxic benchtop study the results of a spoon."
The topic is the spoon and shoot study.,The person's points are that they do not know what the spoon and shoot study is and they want to know more about it.,N/A,N/A,N/A,The results of a spoon and shoot study have been sent to the FDA. What was the spoon and shoot study?
The topic they are talking about is the study done on oxycodone.,They are questioning the study and whether or not the drug can be abused.,The facts are that the study was done to determine if the drug could be abused.,They do not support their point with anecdotes.,N/A,"Um, was that a study done to determine if, uh, the drug could be abused by extracting oxycodone from the tablet?"
The topic they are talking about is a crush tablet study.,They are questioning if a study is needed and if one has been conducted in the past.,N/A,N/A,N/A,"And then under 3.2, the last sentence says a crush tablet study may be conducted if we decide such a study is needed. Do you know if you ever decided such a study was needed?"
They are talking about the topic of it being a good thing.,They think it is a good thing.,The facts are that it is a good thing.,They do not support their point with anecdotes.,They do not quote any anecdotes.,3.2 last
The topic they are talking about is Mike Innerato's role in the company.,They are questioning whether or not Mike Innerato was a guy in charge of marketing.,N/A,N/A,N/A,"And then on 5.4, the very last sentence says Mike Innerato. And was he a guy in charge of marketing?"
The topic is quality of life questions in research studies.,They are discussing the possibility of including quality of life questions in future studies.,N/A,N/A,N/A,"All right. It says, uh, Mike Innerato asked if we had any quality of life questions in our ongoing studies. Robert reader stated that we did not, but that we could include quality of life questions and future studies."
Quality of life questions.,They are asking if quality of life questions were included.,N/A,N/A,N/A,Do you know if quality of life questions were included?
The topic they are talking about is OxyContin and morphine.,They are asking whether OxyContin is more powerful or less powerful than morphine.,N/A,N/A,N/A,"Yeah. Let's mark that as zip been marked yet exhibit nine, with respect to oxycodone and morphine. Um, do you know, um, whether OxyContin is more powerful or less powerful a drug than morphine?"
The topic is Dr. Goldenheim.,"The person's points are that they are unsure if Dr. Goldenheim is good, and they question if he was an employee of the company.","The facts are that the person is unsure if Dr. Goldenheim is good, and they question if he was an employee of the company.",There are no anecdotes.,There are no quotes.,"Um, I think Dr. Is it good? Goldenheim yes. Was he an employee of,"
The topic is the strength of OxyContin.,They think that the person testifying is correct- that OxyContin is twice as strong as morphine.,The facts are that the person testifying said that OxyContin is twice as strong as morphine.,They do not support their point with anecdotes.,N/A,I think he testified that that OxyContin was twice as strong as morphine. Is that your understanding?
The topic the person is talking about is a drug that is equal to or less strong than morphine.,The person's points are that they are not sure how many doctors think the drug is equal to or less strong than morphine and they would like to know.,The facts are that the person does not know how many doctors think the drug is equal to or less strong than morphine.,The person does not support their point with anecdotes.,N/A,Do you know how many doctors or what percentage of doctors thought that it was equal to or less strong than morphine?
The topic they are talking about is the oxycodone project.,They think the oxycodone project is a good idea.,The facts are that the oxycodone project is a good idea.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"Let's mark this as plaintiff's exhibit 10. This is the, um, a memo dated 1992, August 10th, oxycodone project team meeting minutes."
It is impossible to determine what topic they are talking about.,They do not make any points.,N/A,N/A,N/A,And it is PDD 9 5 2 1 4 1 0 3 2 9 3 9.
They are talking about conducting a literature search on oxycodone and oxymorphone.,They are conducting a literature search on oxycodone and oxymorphone.,The facts are that they are conducting a literature search on oxycodone and oxymorphone.,They do not support their point with anecdotes.,N/A,"And if you'll look at this, it says a literature search, the second paragraph, a literature search on oxycodone and oxymorphone. Just a second is being conducted."
They are talking about being on the same page.,They think the other person is not on the same page.,N/A,N/A,N/A,"No, you're not. You're on page two. I'm on page one. Oh,"
They are talking about conducting a literature search on oxycodone and oxymorphone.,They are conducting a literature search on oxycodone and oxymorphone.,The facts are that they are conducting a literature search on oxycodone and oxymorphone.,They do not support their point with anecdotes.,N/A,"I'm sorry. Second paragraph. A literature search on oxycodone and oxymorphone is being conducted by one of the summer employees. Um, um, do you know who was doing the literature search initially?"
They are talking about the idea to develop different dosages of a tablet.,They are confused about the idea to develop different dosages of the tablet.,N/A,N/A,N/A,"Fifth paragraph down second sentence says the current consideration is to develop 20, 40, 80 and 160 milligram tablet. In addition to the 10 milligram tablet now in the clinic. And whose idea was it to develop? Uh, 20, 40, 80 and 160 milligram tablets. I'm sorry,"
They are talking about the idea.,They think it is a great idea and are very excited about it.,The facts are that it is a great idea and they are very excited about it.,They do not support their point with anecdotes.,N/A,First page. Just what I called out. Fourth paragraph. Second sentence.
The topic they are talking about is coordinating the package insert with advertising claims.,Their point is that the package insert should include comparative claims and be coordinated with the advertising claims.,The fact is that it is a working document.,They do not support their point with an anecdote.,They do not quote an anecdote.,"And then if you'll go to the second page, um, first paragraph, it says with regard to the package insert and the first year advertising claims, it was discussed with that. Mr. Cigar should meet with others and rework the quote draft package insert the purpose would be to idealize the insert and coordinate the contents with the advertising claims and clinical trials program. The package insert should include comparative claims. It must be kept in mind. This is a working document. Why did you want to, uh, coordinate the package, insert with your advertising? Claims"
The topic is OxyContin.,"The person's points are that physicians are aware of OxyContin being twice as strong as morphine, and that they think it is a good idea to have this information.",The facts are that physicians are aware of OxyContin being twice as strong as morphine.,There are no anecdotes.,There are no quotes.,"And this is a, you talked about physicians being aware of, uh, OxyContin being, uh, twice as strong as morphine a second ago. Let me hand you let's mark this as exhibit 11. This is an email. It says the author is doc. May"
The topic is the email.,The person's points are that they are unsure if they are familiar with the email and that the author is Dr. Richard Sackler.,The facts are that the email is dated 5/28/97 and that the author is Dr. Richard Sackler.,There are no anecdotes.,There are no quotes.,"Sorry. In front of you says the author is Dr. Richard Richard Sackler at Norwalk dated 5 28 97. Uh, are you familiar with this email to Michael Friedman? Yes, who's Michael Friedman."
The topic is sales.,The person's points are that the issue is complex and that they need clarification.,The facts are that the issue is complex and that they need clarification.,There are no anecdotes.,There are no quotes.,"Sales. Okay. And let's drop down and see what Michael Friedman has written. Uh, first paragraph, he says, my purpose in writing this memorandum is to clarify our position on the very complex issues raised by Mike CU during the phase four team meeting in which we're the subject of Dr. Richards inquiry. When they say Dr. Richards, who's that?"
The topic they are talking about is oxycodone.,"They are saying that many physicians think oxycodone is weaker than morphine, but this is because they associate it with less serious pain syndromes.",The facts are that the association arises from their extensive experience with and use of oxycodone combinations.,There are no anecdotes.,There are no quotes.,"Was me. All right. First paragraph, we are well aware of the view held by many physicians that oxycodone is weaker than morphine. We also that this is the result of their association of oxycodone with less serious pain syndromes. This Associa and drones, this association arises from their extensive experience with and use of oxycodone combinations"
,The person's points are that oxycodone is an effective pain treatment and that it is underutilized.,The facts are that oxycodone is an effective pain treatment and that it is underutilized.,The claims the person makes are that oxycodone is an effective pain treatment and that it is underutilized.,The premises the person relies on are that oxycodone is an effective pain treatment and that it is underutilized.,"To treat pain arising from a diverse set of causes, some serious, but most less serious. This quote personality of oxycodone is an integral part of the quote personality. Um, this personality of oxycodone is an integral part of the personality of OxyContin. When we launched OxyContin, we init intentionally avoided a probation promotional theme that would link OxyContin to cancer pain. We specifically linked OxyContin to the oxycodone combinations with our old way new way campaign. We made sure our initial detail piece provided reps with the opportunity to sell the product for a number of different pain states. With all of this, we were still concerned that the drug would be slotted for cancer pain, and we would encounter resistance in the non-malignant pain market and says our pricing of the product was geared toward the nonmalignant market. We knew if we priced low per milligram for the higher dose cancer patient, we would be priced way too low per milligram for the standard nonmalignant pain patient, where we really wanted to make a market. We feared that the cancer pain experts would object to the two to one ratio. And that two to one ratio is the ratio of oxycodone OxyContin to morphine. Is that correct?"
N/A,They do not make any points.,N/A,N/A,N/A,Okay.
They are talking about the cost of therapy.,They think it is a good idea because it is cheaper and they had no choice.,The facts are that it is cheaper and they had no choice.,They do not support their point with anecdotes.,N/A,"Yes. Yes. Uh, and resulting cost of therapy for high dose patients. However, we had no choice given our position for OxyContin in any case we're developing hydromorphone."
They are talking about how they are developing.,They are talking about how they are developing.,The facts are that they are developing.,They do not support their point with anecdotes.,N/A,We're developing
The topic they are talking about is the high dose patient.,They think the high dose patient is doing well.,The facts are that the high dose patient is doing well.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"For the high dose patient,"
The topic is the nonmalignant pain market.,The person's points are that the nonmalignant pain market is successful and that it helps patients with chronic pain.,The facts are that the nonmalignant pain market is successful.,There are no anecdotes.,N/A,"And then it says, despite our initial uncertainty we've been successful beyond our expectations in the nonmalignant pain market. Yes. And nonmalignant pain market is sort of the chronic, uh, arthritis back pain. Um, those types of patients."
They are talking about the idea.,They think it is a good idea and support it.,The facts are that it is a good idea.,They do not support their point with anecdotes.,N/A,"Mm-hmm <affirmative>. And then he says here,"
The topic is the use of OxyContin.,The person's points are that the drug is effective and that it is less threatening than alternatives.,The facts are that the drug is effective and less threatening than alternatives.,There are no anecdotes.,There are no quotes.,"Doctors use the drug in nonmalignant pain because it is effective. And the personality of OxyContin is less threatening to them and their patients than that, of the morphine alternatives. I apologize for this unspecific term, but I feel it captures the notion that there are image related attributes that influence drug acceptance. While we might wish to see more of this product sold for cancer pain, it would be extremely dangerous at this early stage in the life of the product to tamper with this quote personality to make physicians think the drug is stronger or equal to morphine. We are better off expanding use of OxyContin in the nonmalignant pain states and waiting for hydromorphone in 1999 to relaunch into cancer pain. Why was it felt that there would be a danger? Uh, it would be extremely dangerous at the early stage in the life of this product to tamper with this quote personality to make physicians think the drug is stronger or equal to morphine."
The topic is OxyContin.,"The person's points are that physicians think OxyContin is stronger than morphine, and that sales of OxyContin would go down if they did.","The facts are that physicians think OxyContin is stronger than morphine, and that sales of OxyContin would go down if they did.",There are no anecdotes.,There are no quotes.,"Did you think that if physicians thought it was stronger or equal to morphine, um, much less, twice as strong as morphine, that they would be less likely to write prescriptions and sales of OxyContin would go down?"
The topic the person is talking about is oxycodone.,"The person's points are that they are aware of the view held by many physicians that oxycodone is weaker than morphine, and they agree with the decision not to do anything about it.",The facts are that oxycodone has been on the market for two years and many physicians believe it is weaker than morphine.,There are no anecdotes.,N/A,"This is 19 97, 2 years after the launch of OxyContin controlled release, correct? Yes. So it's been on the market now, uh, over, uh, well, you launched of January 96, we're now in may of 97. And it says we are well aware of the view held by many physicians that oxycodone is weaker than morphine. And, and the conclusion of this was, um, I do not plan to do anything about that. And you wrote back and said, I agree with you. Is there a general agreement or are there some holdouts? And was that what you wrote up at the top"
The topic is non-malignant pain.,They are asking a question to clarify a point.,N/A,N/A,N/A,Okay. So you weren't doing this because the pain market for non-malignant pain was a much greater market share. Is that your
The topic is the email.,They want to look at the email.,The facts are that there is an email to Michael co at Norwalk.,They do not support their point with anecdotes.,N/A,"Let's let's let's look at the, the email you wrote to Michael co at Norwalk. Let's mark this as plaintiff's exhibit 12."
The topic the person is talking about is OxyContin.,"The person's points are that some physicians perceive OxyContin as not being as strong as MS. Contin, and that oncologists are cancer.","The facts are that some physicians perceive OxyContin as not being as strong as MS. Contin, and that oncologists are cancer.",There are no anecdotes.,There are no quotes.,"And Michael Colin writes, uh, on June 2nd of 97. And that was after the email we were just looking at and says in recent team meetings, we've discussed the issue that OxyContin is perceived by some physicians, particularly oncologists as not being as strong as MS. Contin now oncologists are cancer."
They are talking about the strength of OxyContin.,They think that OxyContin is not as strong as MS. Contin.,The facts are that cancer doctors don't think that OxyContin is as strong as MS. Contin.,They don't support their point with anecdotes.,N/A,"Doctors, correct? Yes. So even the cancer doctors don't think that OxyContin is, uh, as strong as MS. Contin object object, according to this, correct? Objection"
The topic is OxyContin.,They are saying that OxyContin is not as strong as MS. Contin.,The facts are that some physicians perceive OxyContin as not being as strong as MS. Contin.,There are no anecdotes.,There are no quotes.,"Says. Oh, well, let me rephrase it. Uh, you, you were aware or at least Michael CU was advising you that OxyContin is perceived by some physicians, particularly oncologists as not being as strong as MS. Contin, is that correct?"
The topic they are talking about is the positive effect of the drug on non-cancer pain patients.,"The person's points are that the drug is having a positive effect with physicians treating non-cancer pain, and that it is cells.",The facts are that the drug is having a positive effect with physicians treating non-cancer pain.,They do not support their point with anecdotes.,N/A,"Say. And he says, although this perception has had some effect with physicians switching to Ms. Cotton with more severe cancer pain patient, it has actually had a positive effect with physicians use in non-cancer pain. And there he's saying non-cancer physicians that don't think it's as strong as MS. Contin we're having a positive effect from that. And I'm assuming he's talking about cells, wouldn't you?"
The topic the person is talking about is oxycodone.,"The person's points are that oxycodone is perceived as being a weaker opioid than morphine, and that OxyContin is being used much earlier for non-cancer pain because of this.","The facts are that oxycodone is perceived as being a weaker opioid than morphine, and that OxyContin is being used much earlier for non-cancer pain because of this.",There are no anecdotes.,There are no quotes.,"He says, since oxycodone is perceived as being a weaker opioid than morphine, it has resulted in OxyContin being used much earlier for non-cancer pain. Physicians are positioning this product where Percocet, hydrocodone and Tylenol with coding have been traditionally used. So he's saying here, physicians are using it because they think it's weaker than morphine, correct?"
The topic is OxyContin.,They want to know if the person agrees that physicians saw OxyContin as less strong than morphine.,N/A,N/A,N/A,"We're we're not done reading it yet, but let me ask you this. You were advised by your senior, um, employees that physicians perceived OxyContin controlled release as less strong than morphine. Uh, many physicians perceived it that way. Uh, correct"
The topic is OxyContin controlled release.,They are questioning the research that has been done on the topic.,N/A,N/A,N/A,"Did you do any studies yourself or conduct any investigation to determine what percentage of physicians believe that OxyContin controlled release was less powerful than morphine? And we're, we're not aware it was twice as strong as"
The topic is support for a topic.,The person's points are that the topic is good and that they support it.,The facts are that the topic is good and that they support it.,The anecdote is that the person supports the topic.,"Yes, the person supports the topic.",Yes.
The topic the person is talking about is a drug that is being mis marketed as being stronger than it actually is.,"The person's points are that the sales force was telling physicians that the drug is stronger than it actually is, and that this needs to be corrected.",The facts are that the sales force was telling physicians that the drug is stronger than it actually is.,There are no anecdotes.,There is no quote.,"Sure. And it's your belief that your sales force was telling these physicians that, uh, it's actually twice as strong as morphine and correcting that misperception that they"
The topic is not stated.,"They think that promotional pieces, symposiums, review articles, and studies would all point out the benefits of the topic.","The facts are that promotional pieces, symposiums, review articles, and studies would all point out the benefits of the topic.",N/A,N/A,"So promotional pieces, your symposiums, your review articles, your studies would all point that out."
The topic of the email is positioning OxyContin in the market.,They are summarizing the points made in the email.,"The facts are that the non-cancer pain market is much greater than the cancer pain market, and that if OxyContin is positioned as more powerful than morphine, it may help in the cancer pain market but hurt in the non-cancer pain market.",There are no anecdotes.,N/A,"Materials. Well, well, let's read the rest of Michael Collins, um, email dated 6, 2 97. Well, after the launch of OxyContin, paragraph three says since the non-cancer pain market is much greater than the cancer pain market, it is important that we allow this product to be positioned where it currently is in the physician's mind. If we stress the power of OxyContin versus morphine, it may help us in the smaller cancer pain market, but hurt us in the larger, larger potential non-cancer pain market. Some physicians may start positioning this product where morphine is used and wait until the pain is severe before using it. Marketing has decided that, and by that they're talking about the marketing group, correct?"
The topic the person is talking about is the marketing department's decision to focus on expanding OxyContin use for non-cancer pain.,The person's points are that it is important to be careful when developing promotional pieces and that OxyContin is not as strong as in S Contin.,The facts are that the marketing department should focus on expanding OxyContin use for non-cancer pain and that it is important to be careful when developing promotional pieces.,The anecdote is that OxyContin is not as strong as in S Contin.,The person quotes the anecdote.,"Yes. Yeah. Marketing department. So it says marketing has decided that the effects of the phase four team should be predominantly focused on expanding OxyContin use for non-cancer pain. And then if you look at the last paragraph, it says it is important that we'd be careful not to change the perception of physicians toward oxycodone when developing promotional pieces, symposia, review articles, studies, et cetera. And what they're talking about there is let's not clear up this misconception that physicians have that OxyContin is, um, not as strong as in S Contin,"
The topic the person is talking about is the approach to cancer pain.,The person's points are that oncologists are the cancer pain doctors and that the sales force can teach the oncologist the proper dose and titrate OxyContin to ensure that they stay with it as the pain increases.,The facts are that oncologists are the cancer pain doctors and that the sales force can teach the oncologist the proper dose and titrate OxyContin to ensure that they stay with it as the pain increases.,The person does not support their points with anecdotes.,N/A,"Oh sure. Our approach to cancer pain will be to get physicians to use it earlier. Instead of products such as Percocet, Vicodin, or Tylenol three, the sales force can teach the oncologist the proper dose and titrate OxyContin to ensure that they stay with it as the pain increases. Now, oncologists are the cancer pain doctors, correct? That doesn't say anything about all the nonmalignant, uh, doctors, all the doctors that treat nonmalignant pain. Correct."
It is unclear what the person is talking about.,They do not have any points.,N/A,N/A,N/A,"And, uh, well,"
The topic is OxyContin.,"The person's points are that OxyContin is twice as strong as morphine, and that nonmalignant pain physicians' perception that it is not correct should not be changed.",The facts are that OxyContin is twice as strong as morphine.,N/A,N/A,"It, well, the whole purpose of this email is that you not teach the nonmalignant pain physicians. That OxyContin is, uh, twice as strong as morphine and let them continue with their perception that it's not correct."
The topic they are talking about is oxycodone.,They are summarizing the points.,The facts are that oxycodone should not be promoted as a pain reliever.,They are not supporting their point with anecdotes.,N/A,"Well, let's, let's continue reading the rest of it. Then. Um, last paragraph, it is important that we be careful not to change the perception of physicians toward oxycodone when developing promotional pieces, symposia, review articles, studies, etc. Now, et cetera. Now, am I correct? That what he's saying in here is let's not clear up the misperception in any of our promotional pieces, symposia review articles or studies"
The topic the person is talking about is the effect of OxyContin's perception on sales.,"The person's points are that some physicians think OxyContin is not as strong as MS. Contin, and that this perception has had some effect on sales.","The facts are that some physicians think OxyContin is not as strong as MS. Contin, and that this perception has had some effect on sales.",The person does not support their points with anecdotes.,N/A,"Yeah. Sure. Well, let's go back and talk about it a little bit more then. So in the first paragraph, he says, we've discussed the issue that OxyContin is perceived by some physicians, particularly oncologists as not being as strong as MS. Contin. Although this perception has had some effect with physicians, switching to MS. Contin with the more severe cancer pain, um, it has actually had a positive effect with physicians use and non-cancer pain. So what he's saying there, if I'm reading this correctly, is that because they think it is, uh, not as strong as Ms. Cotton, when they need a strong drug for cancer pain patients, some of the physicians aren't switching to it because they don't think it's as strong and that may hurt sales a little bit there, but with the non-cancer pain where you don't want as strong a drug as an end of life, malignant cancer pain patient might need, it's actually helping ourselves that they have this misperception because they are going ahead and prescribing it because they don't think it's as strong as Ms. Cotton, that it is that what that first paragraph is saying."
The topic the person is talking about is oxycodone.,The person's points are that more people are using oxycodone earlier for non-cancer pain because they think it is weaker.,The facts are that more people are using oxycodone earlier for non-cancer pain because they think it is weaker.,There are no anecdotes.,N/A,"So then he says, since oxycodone is perceived as being weaker, opioid than morphine, it has resulted in OxyContin being used much earlier for non-cancer pain. Correct. So he's saying more people are using it earlier for non-cancer pain. Cause they think it's weaker,"
The topic is that it is helping cells because they don't think it is as strong as something else.,They think that it is helping cells because they don't think it is as strong as something else.,The facts are that it is helping cells because they don't think it is as strong as something else.,They do not support their point with anecdotes.,N/A,"Sure. And what he's saying here is the non-cancer pain doctors, which is the much bigger market share when you're trying to sell OxyContin is the nonmalignant pain market. It's actually helping cells there cuz they don't think it's as strong as"
The topic is using effective methods.,They think that using effective methods is a good idea.,The facts are that using effective methods can help people achieve their goals.,They do not support their points with anecdotes.,N/A,Wanna use effective
The topic they are talking about is the positioning of OxyContin in the physician's mind.,They think it is important to allow the product to be positioned where it is in the physician's mind.,The facts are that the OxyContin controlled release is not as effective as morphine.,They do not support their point with anecdotes.,N/A,"Yeah. And then down at the bottom, he says, or let's take the middle paragraph since the non-cancer pain market is much greater than the cancer pain market. Is it important? We allow this product to be positioned where it currently is in the physician's mind. And that means, let 'em believe that, um, OxyContin controlled release is not as effective as morphine."
The topic is the power of OxyContin versus morphine.,They are summarizing the points made by someone else.,The facts are that OxyContin is more powerful than morphine.,There are no anecdotes.,N/A,"Sure. He says, if we stress the quote power of OxyContin in quote versus morphine, and that is, uh, it may help us in the smaller cancer pain market that him know that it is more powerful than morphine that'll help in the smaller cancer pain market. Correct."
The topic is the product.,"The person's points are that the product may be positioned where morphine is used, and that pain would have to be severe before using it.","The facts are that the product may be positioned where morphine is used, and that pain would have to be severe before using it.",There are no anecdotes.,There are no quotes.,"Yeah. But hurt us in the larger potential non-cancer pain market. Some physicians, physicians may start positioning this product where morphine is used and wait until pain is severe before using it."
The topic is a good idea.,They think it is a good idea and are happy with it.,The facts are that it is a good idea and they are happy with it.,They do not support their point with anecdotes.,N/A,"And in,"
The topic the person is talking about is the marketing department's decision to focus on expanding OxyContin use for non-cancer pain.,"The person's points are that if the misperception is cleared up, then the group may be less likely to prescribe OxyContin.","The facts are that if the misperception is cleared up, then the group may be less likely to prescribe OxyContin.",The person does not support their points with anecdotes.,N/A,"And then the marketing department has decided that the efforts of the phase four team should be predominantly focused on expanding OxyContin use for non-cancer pain. Right. Right. That's the, that's the group that if you clear up the misperception may be less likely to prescribe according to what he's written here. Correct."
The topic is whether Purdue Pharma allowing patients to believe that the drug they are prescribing them is weaker than morphine will compromise patient care.,"The person's points are that they are unsure if Purdue Pharma allowing patients to believe that the drug they are prescribing them is weaker than morphine will compromise patient care, and they would like to know if others think the same.",N/A,N/A,N/A,"Do, do you think it might compromise patient care if Purdue Pharma allowed patients, uh, physicians to believe that the drug they are prescribing them is weaker than morphine."
The topic is whether or not Purdue Pharma's OxyContin is weaker than morphine.,They are questioning if Purdue Pharma is aware that many physicians feel that OxyContin is weaker than morphine and if they have done anything to clear up the misconception.,The facts are that many physicians feel that OxyContin is weaker than morphine.,N/A,N/A,"Question. Do you think it might compromise patient care? If Purdue Pharma was aware that many physicians felt like, um, OxyContin was weaker than morphine and did nothing to clear up that misconception?"
The topic they are talking about is oxycodone.,They think it is important to be careful not to change the perception of physicians toward oxycodone.,"The facts are that after the launch, the package insert has been put out and all that.",They do not support their point with anecdotes.,N/A,"Right. And this is 1997. That's correct. Well, after the launch, well, after your package insert has been put out and all that, correct? Yes. And, and you and Michael CU says it is important that we be careful not to change the perception of physicians toward oxycodone when developing promotional pieces, symposia, review articles, studies, et cetera. Correct. Is that what he wrote?"
The topic they are talking about is clearing up a misconception.,"They think the person has the issue well in hand and if there are developments, they should be notified.","The facts are that the person has the issue well in hand and if there are developments, they should be notified.",They do not support their point with anecdotes.,N/A,"And you replied to him and did not say no, we need to clear up this misconception immediately. What you said is I think that you have this issue well in hand that's, if there are developments, please let me know."
The topic is unknown.,They do not state any points.,N/A,N/A,N/A,"We were reading from, uh,"
The topic is not stated.,They have not stated any specific points.,N/A,N/A,N/A,"From your top where you said, I think that"
"The topic they are talking about is that it is important to be careful not to change the perception of physicians toward oxycodone when developing promotional pieces, symposia, review articles or studies.","They think that it is important to be careful not to change the perception of physicians toward oxycodone when developing promotional pieces, symposia, review articles or studies.","The facts are that it is important to be careful not to change the perception of physicians toward oxycodone when developing promotional pieces, symposia, review articles or studies.",They do not support their point with anecdotes.,N/A,"Where he says it is important that we be careful not to change the perception of physicians toward oxycodone when developing promotional pieces, symposia, review articles or studies."
The topic is whether or not it is a good idea.,They think it is a good idea and they support their points with facts.,The facts are that it is a good idea.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"All right. Let me hand you, let's mark this as plaintiff's exhibit 13."
The interoffice memo.,They do not mention any points.,N/A,N/A,N/A,This is an interoffice memo dated 1994.
The O.J. Simpson trial,Michael Friedman's role in 1994,Michael Friedman was a member of the O.J. Simpson defense team,Michael Friedman was a member of the O.J. Simpson defense team,Michael Friedman was a member of the O.J. Simpson defense team,"And this is from Michael Friedman. Uh, what was his role in 1994?"
The topic is the umpire's call.,They are happy with the umpire's call.,"The facts are that the umpire called out ""two.""",They do not support their point with anecdotes.,N/A,"And it's two,"
,They support their points with facts.,They claim that the Sacklers are good people and that they have done a lot of good for the world.,The premises they rely on are that the Sacklers are good people and that they have done a lot of good for the world.,The topic they are talking about is the Sacklers.,"To. And that's Mor Sackler Raymond Sackler and Dr. Richard Sackler, which would"
They are talking about the FDA's potential restriction of OxyContin's initial launch to the cancer pain market.,They are discussing the FDA's potential restriction of OxyContin's initial launch to the cancer pain market.,The facts are that the FDA may restrict OxyContin's initial launch.,They do not support their point with anecdotes.,N/A,"And under discussion, if you go to page four, it says, we believe that the FDA will restrict our initial launch of OxyContin to the cancer pain market. Did you believe that at the time"
OxyContin,They think that physicians will perceive OxyContin.,N/A,N/A,N/A,"However, we also believe that physicians will perceive OxyContin."
They are talking about the idea of a number next sentence.,They think it is a good idea and that it will help people.,The facts are that it will help people and that it is a good idea.,They do not support their point with anecdotes.,N/A,"Number next sentence, 1.3"
The topic they are talking about is OxyContin.,They think that physicians will see OxyContin as a controlled release Percocet without acetaminophen and expand its use.,The facts are that OxyContin is a controlled release Percocet without acetaminophen.,They do not support their point with anecdotes.,N/A,"However, we also believe that physicians will perceive OxyContin as controlled release Percocet without acetaminophen and expand its use. Now is OxyContin controlled release Percocet"
The topic they are talking about is OxyContin controlled release versus Percocet.,They are asking a question about whether OxyContin controlled release is more powerful than Percocet.,N/A,N/A,N/A,"Uh, is, is OxyContin controlled release, more powerful than Percocet?"
The topic is OxyContin.,"The person's points are that studies have shown that 10 milligrams of OxyContin had the same effect as a placebo, and that it was really only the 20 milligram that was effective.","The facts are that studies have shown that 10 milligrams of OxyContin had the same effect as a placebo, and that it was really only the 20 milligram that was effective.",There are no anecdotes supporting the points.,N/A,"When you all did studies, did you find out that 10 milligrams of OxyContin had the same effect as a placebo? And it was really only the 20 milligram that was effective."
The topic is OxyContin.,They do not want to discourage physicians from using OxyContin for chronic non-malignant pain.,The facts are that they do not want to discourage physicians from using OxyContin for chronic non-malignant pain.,They do not support their point with anecdotes.,N/A,"Um, we do not want to position OxyContin in a way that will discourage physicians from using OxyContin for the chronic non-malignant pain. Okay."
The topic is using OxyContin to treat non-malignant chronic pain patients.,The person's points are that the study showed that OxyContin is effective and safe for treating non-malignant chronic pain patients.,The facts are that the study showed that OxyContin is effective and safe for treating non-malignant chronic pain patients.,There are no anecdotes.,There are no quotes.,"Next paragraph. Okay. We will. I mean, next sentence, especially when we have studies available that demonstrate efficacy and safety for this indication. Okay. Do you know what your study showed about non-malignant chronic pain patients developing, uh, uh, tolerance or dependency or withdrawal from OxyContin?"
Marking someone as correct.,The person is talking about marking someone as correct.,N/A,N/A,N/A,"Let's uh, mark been marked correct"
The topic they are talking about is OxyContin.,They are summarizing their points.,The facts are that OxyContin has a ceiling effect.,They are not supporting their point with anecdotes.,They are not quoting an anecdote.,"Um, I'm gonna hand you a document. It is, uh, dated April 23rd, 1997. And on the bottom of page, one is an email you sent, uh, regarding San Antonio and it says, uh, it's 4 20, 2 97. This is P D D 1 7 1 8 1 1 4 1. And it's to looks like Michael Friedman. Michael, I am somewhat surprised that 18 months into marketing, significant groups of experts, oncologists, for example, believe that OxyContin has a ceiling effect. What did you mean by ceiling effect"
The topic they are talking about is controlled release drugs.,They are discussing the idea of gathering materials to disprove a misconception about controlled release drugs.,The facts are that there are misconceptions about controlled release drugs and that many of these misconceptions are the result of residual attitudes associated with the immediate release forms.,They do not support their point with anecdotes.,N/A,"Okay. What materials could we pull together that would smash this critical misconception? Can we put together some approaches and test whether they would be potent weapons in this effort? And he writes back and says to you, there will always be misconceptions about drug substances for controlled release drugs. Many of these misconceptions are the result of residual attitudes associated with the immediate release forms. Um,"
The topic the person is talking about is the personality of a drug and how it can shape marketing.,"The person's points are that the personality of a drug can shape how it is marketed, and that success in marketing is due in part to the unique personality of the drug.","The facts are that the personality of a drug can shape how it is marketed, and that success in marketing is due in part to the unique personality of the drug.",The person does not support their points with anecdotes.,N/A,"Uh, I'll just read the whole thing. So for example, morphine has a personality quote that was shaped when it was an IV drug. Oxycodone has a personality quote that was influenced by many years of oxycodone use and Percocet. We built a large part of our platform on this personality and it is to differentiate OxyContin from Duragesic. This differentiation has led to much non-malignant business marketing. This next paragraph marketing is not only about what you are it's about what you are not. We have had success beyond our expectations. That is in part due to the unique personality of OxyContin. Even as we seek to increase the use of the drug in higher doses, we should be very careful as you know, the strength of the judge drug is principally a barrier in malignant pain. If we do not want to change the image in a way, or I'm sorry, we do not want to change the image in a way that will discourage non-malignant use a barrage would be ill advised and you wrote back. Excellent points. What about rifle shots? Is that correct?"
The topic is cancer research.,The person's points are that James Lang sat in on some oncology focus groups and that he found the experience to be eye-opening.,The anecdote is that James Lang found the experience to be eye-opening.,,"""And he found the experience to be eye-opening.""","And over here on the, before that there's a letter to you from James Lang and he's pointing out that he sat in some oncology focus groups and he, um,"
N/A,They are looking for something on page two.,N/A,N/A,N/A,"It's page two,"
The topic the person is talking about is defamation.,The person's points are that they are being sued for defamation and they are not sure why.,The facts are that the person is being sued for defamation.,The person does not support their points with anecdotes.,N/A,"It says, um,"
The topic the person is talking about is oncologists' utilization of OxyContin.,"The person's points are that oncologists don't feel that OxyContin is as strong as Ms. Cotton likes, and they are very comfortable with MS. Contin.","The facts are that oncologists don't feel that OxyContin is as strong as Ms. Cotton likes, and they are very comfortable with MS. Contin.",The person does not support their point with anecdotes.,N/A,"Issues affecting the oncologist utilization of OxyContin are MDs. Feel the product dosing has a ceiling. Don't feel it is as strong as Ms. Cotton like, and are very comfortable with MS. Contin and don't see a need for another product, except where MS. Contin fails or Ms. Cotton fails. Interestingly, when asked to describe what they like about OxyContin, they are for the most part cited, all the key points our reps are or should be stating in their sales presentation. Um, the anesthesiology focus group was of less Saturday evening was of less value. However, their primary concerns were that Medtronic pump being used by the orthopods and the need for Purdue to educate surgeons on proper post-surgery pain management in fears with opioid prescribing. Um, is that the email that prompted you to write the letter?"
The topic the person is talking about is an email.,The person's points are that they are sorry and that they want the email to be written.,The facts are that the person is sorry and wants the email to be written.,The anecdote is that the person is sorry and wants the email to be written.,"The person quotes the anecdote by saying ""I'm sorry. I want you to write your email.""",I'm sorry. I want you to write your email.
no,none,no,no,no,"Why don't we mark that as exhibit 14,"
,They are summarizing their points.,The facts are that it is the 1993.,They do not support their point with anecdotes.,They make no claims.,I about this. Okay. So this is the 1993.
N/A,They do not state any points.,N/A,N/A,N/A,All right.
The topic is whether or not the idea is a good one.,They think it is a good idea.,The facts are that it is a good idea.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"This? Yes, sir."
"The topic they are talking about is the May, 1993 memorandum.","They want to go back to the May, 1993 memorandum because it was a good thing.","The facts are that the May, 1993 memorandum was a good thing.",They do not support their point with anecdotes.,N/A,"I want to go back to the May, 1993 memorandum. And this is the"
N/A,They want to see what the person has.,N/A,N/A,N/A,"Wait a minute. Let me, can I see what you have?"
The topic they are talking about is the date of a memorandum.,"They are discussing a memorandum from April 2, 1993.",The facts are the date of the memorandum and what is written at the top.,They do not support their point with anecdotes.,N/A,"Lemme just clear this up. Yeah, it's not in yet. That's it? April 2nd, 1993. Yeah. All right. Let's um, I'm sorry, I'm gonna stop. Let's let's um, jump to the April 2nd, 1993 memorandum. Let's mark this as Sackler 15. What is P FRC at the top of this"
The topic is not mentioned.,They do not mention any points.,N/A,N/A,N/A,And it's the R and D meeting
They are talking about the date.,They think it is a good thing.,"The facts are that it is dated April 2nd, 1993.",They do not support their point with anecdotes.,N/A,"And it is dated April 2nd, 1993. Correct."
The topic is attendance at a meeting.,They are summarizing points.,The facts are that they were in attendance at a meeting.,They do not support their point with an anecdote.,N/A,"And part I wanted to ask you about, if you go back to page 10 and <affirmative> and you were in attendance at this meeting, correct?"
The topic they are talking about is the Sackler family.,"They point out that the Sackler family has donated to many institutions, including Harvard, and that they are not sure if the name should be removed from these places.","The facts are that the Sackler family has donated to many institutions, including Harvard.",They do not support their points with anecdotes.,N/A,Sackler
The topic they are talking about is the osteoarthritis study.,They are discussing the study on page 10.,The facts are that the study is about osteoarthritis.,They do not support their point with anecdotes.,N/A,"All right. Yes. So on page 10, it looks like you're discussing an osteoarthritis study. That was being"
It is not clear what topic they are talking about.,They have not made any points yet.,N/A,N/A,N/A,10? I am on the third paragraph.
They are talking about the new thing.,They think it is good because it is new and different.,The facts are that it is new and different.,They do not support their point with anecdotes.,N/A,Fourth paragraph.
,They think it is a good idea.,The facts are that it is a good idea.,They do not support their point with anecdotes.,They make the claim that it is a good idea.,Yes it
The topic is whether or not it is a good idea.,They think it is a good idea.,The facts are that it is a good idea.,They do not support their point with anecdotes.,N/A,Yeah.
The topic they are talking about is RR.,They are summarizing a section.,N/A,N/A,N/A,"Read along with me, uh, the section over here. Rrr, do you know who RR is?"
The topic the person is talking about is the other person's job at the time.,The person's points are that they are curious about the other person's job at the time and that they want to know more about it.,The facts are that the person is curious about the other person's job at the time and that they want to know more about it.,The person does not support their point with an anecdote.,N/A,Okay. What was his job at that time?
The topic they are talking about is the protocol for the study.,They are discussing the protocol for a study.,The facts are the protocol for the study.,There are no anecdotes.,There are no quotes.,"And he says here in this paragraph, the protocol for the placebo controlled study versus two dose levels in patients with osteoarthritis, what's discussed with C right now, would that be Curtis Wright?"
They are talking about Al's job in reviewing the OxyContin submission to the FDA.,They think that Al did a great job in reviewing the OxyContin submission to the FDA.,The facts are that Al did a great job in reviewing the OxyContin submission to the FDA.,They do not support their point with anecdotes.,N/A,Understand it. And at that time he was the person who was reviewing Al's OxyContin submission to the FDA.
The topic they are talking about is the FDA approval of a product.,They think it is good that the FDA approved it.,The facts are that the FDA approved it.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"Correct. And he's the guy that actually approved it to be sold or, you know, allow you all to sell it from the FDA. That's"
The topic they are talking about is whether or not the person is qualified for the job.,They think that the person is not qualified for the job.,The facts are that the person was not hired a few years later.,They do not support their point with anecdotes.,N/A,"Okay. You all ultimately hired him a few years later, didn't you?"
The topic is whether or not going to college is a smart move.,The person's points are that the person in question went to college for a short period of time and then came to work for the person listening.,The facts are that the person in question went to college for a short period of time and then came to work for the person listening.,There are no anecdotes.,N/A,He went there very smart. He went there for a short period of time and then came to work for you.
The topic is the protocol for the placebo controlled study.,The person summarizes the protocol and states that there are strong opinions against it.,The facts are that there are strong opinions against the protocol at the FDA.,There are no anecdotes.,N/A,"All right. Well, let's, let's take a look at page 10. The protocol for the placebo controlled study versus two dose levels in patients with a osteoarthritis was discussed with C wite. He stated there were very strong opinions of members at the FDA that opiates should not be used for nonmalignant pain. And this study,"
,They are summarizing the points made by C Wright.,"The facts are that the FDA does not accept the study as it is written, and that C Wright has suggested rewriting the protocol.",The person does not quote any anecdotes.,"The claims made are that the FDA does not accept the study as it is written, and that C Wright has suggested rewriting the protocol.","Well, I'll read it again. Okay. He stated there were very strong opinions of members at the FDA that opiates should not be used for nonmalignant pain. And this study would not be greatly accepted by the FDA as it is written. Now, for that reason, C Wright has suggested rewriting the protocol in order to make it clear. Osteoarthritis is being used as a convenient pain model. He would also like to the open label extension to be eliminated from the protocol. Now, what do you refer to as the open label extension"
They are talking about the use of oxycodone for treating osteoarthritis.,They want the protocol to be clear that oxycodone is not for general use in treating osteoarthritis and that more studies are necessary to investigate questions about its use.,The facts are that oxycodone is not for general use in treating osteoarthritis and that more studies are necessary to investigate questions about its use.,They do not support their points with anecdotes.,N/A,"P Goldenheim stated the open label extension could be done as a post-marketing study, B Keiko and R reader will meet with P Laur to communicate what is necessary to revise the protocol. The protocol must be clear that we are not going for a general indication for the treatment of osteoarthritis with osteo, with oxycodone. And then down below that, it says Dr. Richard Sackler asked if there was consensus within the pain group about the appropriate use of opiates for certain patient groups, B Keiko stated this is very, a very controversial area. And most people in the pain group say that well, controlled studies are necessary to investigate the questions Dr. Sackler next paragraph says, Dr. Sackler has suggested a smaller group meet in house to clarify the political issues. What were the political issues,"
The topic is opioids.,The person's points are that opioids are addictive and that there is a risk of overdose.,The facts are that opioids are addictive and that there is a risk of overdose.,There are no anecdotes.,There is no quote.,"Over whether you should prescribed opioids for nonmalignant pain,"
The topic is whether morphine should be prescribed for nonmalignant pain.,"The person's points are that morphine was stigmatized and not prescribed for nonmalignant pain, and that it was reserved for end of life, hospice care, and cancer pain in the medical community.","The facts are that morphine was stigmatized and not prescribed for nonmalignant pain, and that it was reserved for end of life, hospice care, and cancer pain in the medical community.",There are no anecdotes.,There are no quotes.,"And that's the reason that morphine was stigmatized and not prescribed, um, generally for nonmalignant pain. Uh, it was more reserved by physicians for end of life, hospice care and cancer pain, um, in the medical community."
Heroin,They are asking a question about heroin.,N/A,N/A,N/A,"What about heroin? Was it prescribed for, uh, uh,"
They are talking about whether something is controlled.,They want to know if it is controlled.,N/A,N/A,N/A,Is it controlled?
The topic the person is talking about is pain.,The person's points are that pain is mostly bad and that it is a part of life.,The facts are that pain is mostly bad and that it is a part of life.,There are no anecdotes.,There are no quotes.,"For, into life pain. Mostly."
The topic the person is talking about is a memo.,The person's points are that they are going to hand over a memo.,The facts are that the person is going to hand over a memo.,The person does not support their points with anecdotes.,N/A,I'm gonna hand you a memo.
The topic is the initial interest in having the five and 10 milligram oxycodone capsules produced.,"The person's points are that there is some initial interest in having the five and 10 milligram oxycodone capsules produced, and they are wondering why marketing wanted those produced.","The facts are that there is some initial interest in having the five and 10 milligram oxycodone capsules produced, according to the project team meeting minutes from August 17th, 1993.",There are no anecdotes.,There is no quote.,"Uh, yes. We are hand you a memo dated, um, project team meeting minutes of Tuesday, August 17th, 1993. It, it says here under marketing, there's some initial interest in having a five milligram and 10 milligram immediate release oxycodone camp capsule produced. Um, do you know why marketing wanted those produced?"
Studies,They want to know about potential studies.,N/A,N/A,N/A,"Well, if you don't mind, turn back to page four and on page four, what I really want to ask you about is potential studies."
The topic is Mike Innerato.,He supports his points with facts.,He does not support his point with anecdotes.,N/A,N/A,Mike Innerato is the guy we mentioned earlier who was
The topic is whether or not a company should have a marketing department.,They think it is a good idea to have a marketing department.,The facts are that a marketing department can help a company to be more successful.,They do not support their point with anecdotes.,N/A,"Yes. In, in the marketing department, correct? Yes."
The topic the person is talking about is the sales force.,The person's points are that they are not sure who is in charge and that they are concerned about the sales force.,The facts are that the person is not sure who is in charge and that they are concerned about the sales force.,The person does not support their point with an anecdote.,The person does not quote an anecdote.,"And he's the guy in charge of perhaps, uh, the sales force that goes out and tries to sell?"
The topic they are talking about is him and his job.,They think he is good at his job and will help increase sales.,The facts are that he is good at marketing and advertising.,They do not support their point with anecdotes.,N/A,"Let me rephrase it then. Sure. As part of marketing, he's the guy who is supposed to get the word out and, uh, hopefully increase sales by advertising the product and convincing people to write prescriptions."
The topic is a study on OxyContin versus Percocet.,They are summarizing a study.,The facts are from the study.,They do not support their point with anecdotes.,N/A,"Let's talk about, um, if you look at 4.3 potential studies, Mike, I'm gonna read that paragraph. Mike Innerato said that an OxyContin versus Percocet comparative study."
Having children,"They think that ""potential"" is not a good enough reason to have children",N/A,"The person talks about how they knew someone who had a child because they wanted to ""give them a chance"" and it turned out badly.","""I knew someone who had a child because they wanted to 'give them a chance' and it turned out badly.""",Potential
N/A,They do not make any points.,N/A,N/A,N/A,Okay.
The topic the person is talking about is an OxyContin versus Percocet comparative study.,The person's points are that it is unclear whether the study would be useful and that it is unusual for marketing people to decide what studies will be done.,The facts are that it is unclear whether the study would be useful and that it is unusual for marketing people to decide what studies will be done.,The person does not support their points with anecdotes.,N/A,"But Mike Innerato and unfortunately that's the way Purdue gave it to us. So, uh, we're stuck with it too. Potential studies. Mike Innerato said that an OxyContin versus Percocet comparative study would be useful for marketing purposes. Now in trying to decide whether the drug is safe, uh, is it normal to have the marketing people decide what studies will be done?"
The topic the person is talking about is the study.,"The person's points are that the study is a single dose study using non-GMP released material, and that a multiple dose study would be best to support claims relating to relief of post-surgical pain, low back pain and Heredic neurology pain.","The facts are that the study is a single dose study using non-GMP released material, and that a multiple dose study would be best to support claims relating to relief of post-surgical pain, low back pain and Heredic neurology pain.",The person does not support their points with anecdotes.,N/A,"Through such a stay. I'm gonna read the next sentence through such a study OC 88, 11 0 5 has previously been conducted and published an abstract form. It was a single dose study using non GMP released material. Mike Innerato stated that a multiple dose study would be best to support claims relating to relief of post-surgical pain, low back pain and Heredic neurology pain. Um, from my review of that, it looks like he's got claims he wants to make and is trying to design studies to support him. Is that what that appears to you?"
The topic they are talking about is positioning in marketing.,They are summarizing someone else's points.,N/A,N/A,N/A,"And then the next sentence says, Mike Innerato stated marketing would like to position differently than Ms. Cotton Robert reader and who was Robert re"
They are talking about the potential for marketing studies and strategies.,They are discussing the potential for marketing studies and strategies.,"The facts are that the FDA has suggested that they do not issue claims supporting the general use of a schedule, two opioid in patients with nonmalignant pain, and that decisions to make additional claims could be developed after the product is marketed.",They do not support their point with anecdotes.,N/A,"Robert reer stated that the FDA has suggested that we do not issue claims supporting the general use of a schedule, two opioid in patients with nonmalignant pain. Robert reader indicated that decisions to make additional claims could be developed after the product is marketed. Jim Conover agreed with Robert Reed, but added that any study conducted in patient with nonmalignant pain could be included in the clinical study section of the package, insert Robert reader added that any proposed marketing claims and their supported studies should be first reviewed with our legal and regulatory departments. Perhaps the marketing concepts could be reviewed. Now, Robert reader stated that the marketing could start thinking of a five year plan on potential marketing studies and strategies. Did I read that correctly?"
options,they are listing off different options,no,no,no,"Um, and then do you have another, this one here? Um, I'm gonna hand you"
The topic is the exhibit.,They want to know if the exhibit is a speech or publication.,N/A,N/A,N/A,"This. Yes, sir. Um, exhibit 17. Yeah. If I haven't done it, I'm, I'm gonna move to admit all these into evidence as exhibits one through 16 and 17. Um, and this is a appears to be a speech you gave. Is that what this is or a publication you made?"
The topic is the year 1996.,They are questioning whether 1996 is the right year.,The facts are that 1996 is the right year.,There are no anecdotes.,There are no quotes.,Whatever. And it's the winner of 1996. Is that right?
The topic is not clear.,They are asking the class to turn to a specific page in the textbook.,N/A,N/A,N/A,"And, um, if you'll turn to page eight for me please. I'm sorry. I misspoke. I turned to page two, please."
,They support their point with facts.,They make the claim that obsoleting OxyContin is the right decision.,They rely on the premise that the competition has not slowed their growth or sales.,They are talking about obsoleting OxyContin.,"Uh, over on the third column, yes. Uh, halfway down it says the development and launching of OxyContin tablets. Yes. Is the first time that we have chosen to obsolete our own product and we have done it before the competition has slowed our growth or of sales. And you were referring to Ms. Cotton that you obsoleted, is that correct?"
The topic is the package insert.,"The person's points are that the statement could be accurate, and they want to know if it is.",The facts are that the package insert is powerful and that the company is successful.,There are no anecdotes.,N/A,And then at the bottom it says we have the most powerful selling package insert in the category and in the industry. And is that accurate?
The topic they are talking about is the last paragraph.,They think it is a good idea and they support their points with facts.,The facts are that it is a good idea and it will help people.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Last paragraph
The topic is the speech.,The person's points are that the speech is good and that it is on page eight.,The facts are that the speech is on page eight.,There are no anecdotes.,There are no quotes.,"Is for, and if you'll turn to page eight, it says, uh, speech at the top continued from page two. So I'm assuming this is a speech you gave."
They are talking about OxyContin.,They cannot summarize the points.,N/A,N/A,N/A,"OxyContin was brought to NDA. Um, what's NDA"
The topic they are talking about is the work that was done in a compressed period of time.,They summarize their points by saying that the work was done in a compressed period of time.,The facts are that the work was done in a compressed period of time.,There are no anecdotes.,There are no quotes.,"Uh, from early phase one work on time and in an incredibly compressed period of two years time, that's because an NDA usually takes longer. Correct."
They are talking about the process of testing drugs.,They think it is important to do animal and human studies before drugs are released.,The facts are that animal and human studies need to be done to ensure drugs are safe.,They do not support their point with anecdotes.,N/A,"And lemme just preface it with the reason it takes longer is because there's a number of studies that have to be done, both animal and human to determine if a drug is safe and efficacious. Correct."
The topic is the event.,The person's points are that the event was well-coordinated and successful.,The facts are that the event was well-coordinated and successful.,There are no anecdotes.,There are no quotes.,"But in this case, you all got it done in an incredibly compressed period of time of two years. Robert reader set the goal in November of 93 to file by December 31st 95. And we submitted on December 28th, 95, 3 days ahead of schedule this didn't quote just happen. It was a deathly coordinated planned event that took dozens of worker years of effort to succeed true,"
They are talking about the NDA package.,They are summarizing the points that the NDA package was approved quickly and that it was a result of teamwork.,The facts are that the NDA package was approved in 11 months and that it was a result of teamwork.,There are no anecdotes.,There are no quotes.,"The most demanding NDA package for any analgesic product ever submitted didn't languish at the agency. Unlike the years that other filings linger at FDA, this product was approved in 11 months, 14 days. Our previous best approval time for other products was measured in years. Not months much can be attributed to the unparalleled teamwork of the product team and the FDA's approval team, which came into being as responsive, our joint desires to operate within the content of a new timeframe. Both we and the pilot, Doug division of FDA were motivated by the same goal to set the highest standard NDA with the broadest app indications approved in the shortest possible timeframe. Did I read that correctly?"
The topic they are talking about is whether or not the statement is accurate.,They want to know if the statement is accurate.,The facts are that they want to know if the statement is accurate.,There are no anecdotes.,There are no quotes.,That? Nope. I just wanted to know if that was the statement you got and is it accurate?
It is not clear.,"They think it is good that ""we're still bombs to the wall.""",N/A,N/A,N/A,"We're still bombs to the wall. One,"
The topic is not clear.,They are trying to get through a lot of documents.,N/A,N/A,N/A,"No, we got a lot of documents to get through. So I'm trying to hit the high"
The topic is insurance coverage.,The person is asking for more information about the topic.,N/A,N/A,N/A,"And ask you about the,"
The topic is not clear.,The person's points are that they are not sure and that they need more information.,N/A,N/A,N/A,"One of the things that they wrote you, um, um, do you have the other pages of this when you got your approval? If you'll look at the last page on overall conclusion, and this is a document, uh, from the medical officer review, uh, Curtis Wright,"
They are talking about the process.,They think that the process is good and that the guy who works for Purdue Pharma is correct.,The facts are that the process is good and that the guy who works for Purdue Pharma is correct.,They do not support their point with anecdotes.,N/A,"Process. And he he's the guy that now works for Purdue Pharma, correct?"
no,cannot summarize points,no,no,no,Okay. He was
The topic they are talking about is that she was hired by Purdue Pharma.,They think it is a good thing that Purdue Pharma hired her.,The facts are that she was hired by Purdue Pharma.,They do not support their point with anecdotes.,They do not quote any anecdotes.,But hired by Purdue Pharma subsequently. Correct.
The topic is the person's last work.,The woman believes that the person's last work was terrible and a huge disappointment.,N/A,N/A,N/A,"And his last,"
They are talking about CR oxycodone.,They are summarizing someone else's points.,The facts are that CR oxycodone is controlled release.,They do not support their point with anecdotes.,N/A,"And why don't we go ahead and mark this as exhibit 18. Um, his overall conclusion on the last page is CR oxycodone that's controlled release, correct?"
The topic is unclear.,"They are confused about the concept of ""competitive promotion.""",N/A,N/A,N/A,"Appears to be a B I D alternative to conventional Q I D oxycodone and, um, approval is recommended care should be taken to limit competitive promotion. What is competitive promotion?"
The topic they are talking about is the product.,"They are summarizing the points that the product has been shown to be good, but there is no significant advantage beyond reduction in frequency of dosing.","The facts are that the product has been shown to be good, but there is no significant advantage beyond reduction in frequency of dosing.",They do not support their point with anecdotes.,N/A,"On part. And then I think the next sentence explains it. He says the product has been shown to be as good as current therapy, but has not been shown to have a significant advantage beyond reduction in frequency of dosing. Other than you don't have to take it as much. The FDA, uh, has concluded that, that there's no benefit other than, uh, uh, has not been shown to have a significant advantage beyond reduction in frequency of dosing"
The topic is unknown.,They have not made any points yet.,N/A,N/A,N/A,"All right. Let's um,"
N/A,N/A,N/A,N/A,N/A,Probably. So just go off the record.
The topic is putting a mark on the 22nd.,They are ready to put the mark on the 22nd.,The facts are that it is the 22nd and they are ready to put the mark on.,They do not support their point with anecdotes.,N/A,You have this one mark 22nd. Ready to put that in.
The topic is whether or not to have a march.,They think it is a good idea and are looking forward to it.,The facts are that it is a good idea and they are looking forward to it.,They do not support their point with anecdotes.,N/A,Yeah. March
The topic they are talking about is that they are difficult.,They are summarizing their points.,The facts are that they are difficult.,They do not support their point with anecdotes.,They do not quote the anecdote.,Yeah. They're difficult. This is the OxyContin project team memo. Do you know if you ever reviewed this memo?
Unknown,Cannot summarize points,No,No,No,"Uh, I don't know if it was or not"
The topic they are talking about is why marketing would want to review the package insert.,They are questioning why marketing would want to review the package insert.,N/A,N/A,N/A,"Well, the, this list down here is yeah, there is a circulation list. Um, it appears that it was not. Um, and if you would go over to page four, the last paragraph down to the bottom 6.2, Mike Innerato asked if marketing would be able to review the package insert, do you have any idea why marketing wanted to review the package? Insert?"
The topic they are talking about is the package insert.,They do not mention any points.,N/A,N/A,N/A,"Robert Reeder stated the package insert will be circulated to marketing and other reviewers at the same time as the protocol review. Um,"
Marketing,Marketing won't improve the product,N/A,N/A,N/A,What is marketing gonna add to that?
The topic they are talking about is marketing.,They think that marketing is a good way to improve the company.,The facts are that marketing is a good way to improve the company.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Sure. You'll turn to page five under 7.0 marketing.
They are talking about postmarketing studies.,They think that postmarketing studies should be done in order to get data to support claims for non-cancer pain.,The facts are that postmarketing studies were done in order to get data to support claims for non-cancer pain.,They do not support their point with anecdotes.,N/A,"It says postmarketing studies QL. Pharmacoeconomic per Percocet. Duragesic Robert reader discussed some of the planned postmarketing studies. These included an OxyContin versus MS. Contin comparative study, the Duragesic comparative study, which is currently on hold and a relative potency study, comparing OxyContin to MS. Contin Robert reader stated that we would need additional studies to recruit several hundred patients in order to get data to support claims for non-cancer pain. Uh, this was on March of 1994. Do you know if that, uh, if those studies were done,"
The person is talking about drugs being put on the market before they are tested.,The person's points are that they are unsure if the drugs were put on the market before they were tested and would like to know if that is the case.,N/A,N/A,N/A,Okay. Do you know if they were done before the drug was put on the mark?
Robert Reeder,N/A,N/A,N/A,N/A,Okay. Who is Robert Reeder?
They are talking about Mike Innerato.,They think that Mike Innerato is a good marketing guy.,The facts are that Mike Innerato is a marketing guy.,They do not support their point with anecdotes.,N/A,"And then it says, Mike Innerato again, he's the marketing guy, correct? Right."
The topic is the Percocet comparative study.,"The person's points are that the study would be beneficial and that it would provide information on claims, benefits, and positioning.","The facts are that the study would provide information on claims, benefits, and positioning.",There are no anecdotes.,There are no quotes.,"Stated that a Percocet comparative study would be a benefit to marketing. Mike Innerato replied to Bob KACO's question on claims by answering that equal efficacy of OxyContin to Percocet with better quality of life would be a beneficial claim. Mike Innerato stated in the future, Tramadol would pose a threat to the OxyContin market. Um, and then down below that it says 7.2 marketing claims studies desired. Mike Innerato gave a presentation on the results from the focus groups, a copy of the market research results would be issued to the OxyContin team. The results of the focus groups are attached. The results, cover issues, such as benefits, positioning, and claims. Do you know whether the studies recommended by Robert reader were done before it went to market, or the studies requested by the marketing guy were done before it went to market?"
They are talking about OxyContin.,They think that OxyContin is a good presentation.,The facts are that OxyContin is a good presentation.,They do not support their point with anecdotes.,N/A,"Then there is a, if you go to page the very last page, I guess it is OxyContin presentation, 3 20, 2 94, up at the top,"
The topic they are talking about is OxyContin.,They are summarizing the points made by the OxyContin marketing campaign.,"The facts they mention are that OxyContin is an opioid that is effective and safe, and that it can be taken once every 12 hours.",They do not mention any anecdotes.,N/A,"And it says down at the bottom, uh, it's got all the list of, um, OxyContin will be positioned as the only opioid combining the efficacy and safety of oxycodone with the convenience of a 12 hour schedule, which allows for precise and accurate conversion and titration while allowing the patient could lead a more normal quality of life. OxyContin is the opiate to start with, for patients who may be on Percocet, lower Tabin and the opiate to stay with as the disease progresses. Now that was a marketing campaign, correct? To start with, stay with,"
"The topic they are talking about is the ""start with, stay with"" marketing campaign.",They think the campaign is a good idea and it is working.,The facts are that the campaign is working and that it is a good idea.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"And, and start with, stay with campaign. Do you know who came up with the start with, stay with marketing campaign?"
The topic is unknown.,The person is looking down at their phone.,N/A,N/A,N/A,"And then, um, it says, um,"
The topic they are talking about is Tramadol.,They are questioning the source of the claim that abuse potential for Tramadol is lower than other opioids.,N/A,N/A,N/A,"It says, uh, at very, at the bottom, less potential abuse than other opioids. Do you know where that, um, claim came from?"
The topic is whether OxyContin had less potential abuse than other opioids.,"The person's points are that they are unsure of whether OxyContin had less potential abuse than other opioids, but they have heard that it is easier to abuse.",The facts are that OxyContin is easier to abuse than other opioids.,There are no anecdotes.,There is no quote.,Do you know whether OxyContin had less potential abuse than other opioids?
,summarizes points,,,,Do you have this one? Do we mark that one?
no,cannot summarize points,no,no,no,Yeah. Let's mark that as 19
They are talking about the PD D 9 9 5 2 0 8 2 1 3 0 6.,They are summarizing their points.,The facts are that this is the PD D 9 9 5 2 0 8 2 1 3 0 6.,They are not supporting their point with anecdotes.,N/A,"Into evidence. And here is this one. This is PD D 9 9 5 2 0 8 2 1 3 0 6. This appears to be the,"
N/A,They want to do something.,N/A,N/A,N/A,"Yes, let's do that"
The topic they are talking about is the OxyContin tablets project.,They think the OxyContin tablets are a good idea and support their points with facts.,The facts are that the OxyContin tablets are a good idea.,They do not support their point with anecdotes.,They do not quote any anecdotes.,OxyContin tablets project team.
They are talking about the date.,They think it is a good thing.,The facts are that it is the correct date.,They do not support their point with anecdotes.,N/A,"And this is June 22nd, 1994, correct."
The topic is marketing.,They think that marketing is a good way to sell products.,The facts are that marketing is a good way to sell products.,They do not support their point with anecdotes.,N/A,"And on page two marketing, it says,"
The topic is the date.,They are confused about the date.,N/A,N/A,N/A,"Oh, the date it's sent is June 22nd. Over on the right. Whoops."
The topic is OxyContin tablets.,They think that OxyContin tablets will be targeted at the cancer pain market and that this is a good decision.,The facts are that OxyContin tablets will be targeted at the cancer pain market and that this is a good decision.,There are no anecdotes.,There are no quotes.,"So it's project team meetings from June 8th. You're you're correct. Uh, on page two, under 1.0, marketing under the OxyContin tablets project team meeting minutes, Mike Innerato gave an overview of the oxycodone market referring to sales and growth charts and prescription data. Mr. Innerato also presented our current strategy for introducing OxyContin tablets to the market. OxyContin tablets will be targeted at the cancer pain market, uh, was a decision subsequently made not to target, uh, specifically at the cancer pain Mar market."
They are talking about the cancer pain market.,They think that the plan is good and that it will help with cancer pain.,"The facts are that the plan was still to target the cancer pain market by June 8th, 94.",They do not support their point with anecdotes.,N/A,"But at least by June 8th of 94, the plan was still to target the cancer pain market."
The topic they are talking about is OxyContin.,They think that OxyContin will be successful in competition with Ms. Cotton tablets and that it will be used by patients who are currently receiving Ms. Cotton as well as those who are thought to eventually use Ms. Cotton tablets.,"The facts are that the bulk of opioid business comes from 7,500 physicians, 3000 of whom are oncologists.",There are no anecdotes.,N/A,"Okay. It says OxyContin, uh, OxyContin way targeted at the cancer pain market, since it is possible that morphine generic products may soon be in competition with Ms. Cotton tablets. We will target patients who are currently receiving Ms. Cotton as well as those patients thought to eventually use Ms. Cotton tablets, I E on the analgesic ladder late step one, step two. And step three, the bulk of opioid business comes from 7,500 physicians, 3000 of whom are oncologists. Um,"
The topic they are talking about is Ms. Cotton.,They think that Ms. Cotton is a good generic option that is priced lower than other options.,The facts are that Ms. Cotton has market share and is priced lower than other options.,They do not support their point with anecdotes.,N/A,"So you all had market share from Ms. Cotton, correct? Yes. And in order to keep from losing that market share to generics who are gonna be priced much lower than Ms. Cotton, uh, generally, correct."
The topic they are talking about is OxyContin.,"The person's points are that if OxyContin is put out, and MS. Contin is kept, then market share would not be lost. They also say that if OxyContin is expanded to non-malignant pain, then all of the market share would be gained.","The facts are that if OxyContin is put out, and MS. Contin is kept, then market share would not be lost. They also say that if OxyContin is expanded to non-malignant pain, then all of the market share would be gained.",The person does not support their point with anecdotes.,N/A,"Um, what you did is put out OxyContin an obsoleted MS. Contin, and if you could keep the MS Contin market through the use of OxyContin, you wouldn't lose any market share there. And if you could expand it to non-malignant pain, you would gain all of that market share. Correct?"
The topic the person is talking about is unknown.,The person's points are that they are unsure and that the other person can answer the question.,N/A,N/A,N/A,Sure. Go ahead. You can answer.
The topic is unknown.,They want the question to be read back to them.,N/A,N/A,N/A,"Um, can you read the question back, uh,"
The topic the person is talking about is advertising.,"The person's points are that marketing has been interviewing potential advertising groups and is close to selecting one, but the person does not know which group was selected.",The facts are that marketing has been interviewing potential advertising groups and is close to selecting one.,The person does not support their points with anecdotes.,N/A,Down below that it says marketing has been interviewing potential advertising groups and is close to selecting one. Do you know which advertising group was ultimately selected?
The topic of the conversation is the manuscripts that Purdue sends out to doctors.,The person's points are that they are unsure why Purdue is sending out manuscripts to doctors to be potential authors.,There are no facts given.,There are no anecdotes given.,There are no quotes given.,"Right. And then under publications right below that manuscripts for studies C 90 dash oh 7 0 8 and OC 93 0 1 0 1 have been sent to Dr. Stanski and mana for review as potential authors. Why was, um, Purdue sending out manuscripts to doctors to be potential authors?"
The topic they are talking about is the authorship of a manuscript.,They are questioning if the Purdue really authored the manuscript.,"The facts are that it says ""potential authors"" and they are questioning if that means Purdue authored the manuscript.",They do not support their point with anecdotes.,N/A,"Well, it says as potential authors, meaning it would, it would appear that they authored the manuscript, even though it really came from Purdue, correct?"
The topic is whether or not Dr. Stanski and man DMA were paid by Purdue.,"The person's points are that they are unsure if Dr. Stanski and man DMA were paid by Purdue, and they would like to know if anyone knows for sure.",N/A,N/A,N/A,Do you know if Dr Stanski and man DMA were paid by Purdue?
The topic is Purdue Pharma,Asking if manuscripts identify Purdue Pharma as being part of the author,N/A,N/A,N/A,"Um, do you know whether these manuscripts, um, ultimately identified, um, Purdue Pharma as being any part of the, uh, author?"
They are talking about the clinical status of the core clinical program.,They think the clinical status of the core clinical program is good.,The facts are that the clinical status of the core clinical program is good.,They do not support their point with anecdotes.,N/A,"And then if you'll turn over to page four of this document, it says clinical status of core clinical program. Robert Reeder. Now he's the"
The topic the person is talking about is a study on pain.,The person's points are that the 10 milligram tablet was similar to placebo in efficacy and that the 20 milligram tablet was significantly different compared to placebo.,The facts are that the 10 milligram tablet was similar to placebo in efficacy and that the 20 milligram tablet was significantly different compared to placebo.,There are no anecdotes.,There is no quote.,"Okay. Robert re stated that this OC 92, 1, 1 0 2 study, a pain has been completed and preliminary data is currently being reviewed. It appears that the 10 milligram tablet is similar to placebo in efficacy, but the 20 milligram tablet was significantly different compared to placebo. Um, were you aware that the 10 milligram tablet was similar to placebo and efficacy?"
The topic is the meeting of the international R and D.,They are summarizing the points of the meeting.,The facts are that Dr. RS Sackler was present at the meeting.,There are no anecdotes.,There are no quotes.,"You have this one <inaudible> then I'm gonna ask you about the meetings of the international R and D meeting. This is, did we mark that? We did. This is, uh, PDD. I'm sorry. That's fine. We can go ahead and mark it if you want PDD 1 7 0 1 8 2 4 7 2 3 exhibit 21, which appears to now we're into November of 94 and present was Dr. RS Sackler, correct?"
They are talking about the idea on page 13.,They think it is a good idea and support it.,The facts are that it is a good idea.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Then on page 13.
It is unknown.,They do not mention any points.,N/A,N/A,N/A,"It. Page 13, third paragraph."
no,Dr. Yang asked if there were any.,no,no,no,Dr. Yang asked if there were any
The topic they are talking about is reading from the middle of the paragraph.,They think that reading from the middle of the paragraph is a good way to improve reading comprehension.,The facts are that reading from the middle of the paragraph can help improve reading comprehension.,They do not support their point with anecdotes.,N/A,Yes. Reading from the middle of the paragraph.
The topic the person is talking about is the difference between the 20 milligram product and the 10 milligram product.,"The person's points are that the 20 milligram product was significantly better than the placebo, but the 10 milligram product was not.","The facts are that the 20 milligram product was significantly better than the placebo, but the 10 milligram product was not.",The person does not support their points with anecdotes.,N/A,"About the eighth line down Dr. Yang asked if there were any statistically significant results. It was confirmed that the 20 milligram product was significantly better than the placebo, but the 10 milligram product was not. And, um, was that brought up at the meeting?"
The topic is the contents of the document.,They are looking at a document and discussing its contents.,The facts are dates and specific details from the document.,They do not support their points with anecdotes.,N/A,"And if you'll turn over to page 11 and this is shortly before the launch of Oxy cotton, correct. We're now into November of 90. No, it was not. This is over year before the launch. No. Yeah. November of 94. Um, it says in the third paragraph, halfway down that paragraph."
The topic is the advantages of OxyContin over morphine.,"The person's points are that not all patients can be successfully treated with morphine, and that there is a stigma attached to morphine.","The facts are that not all patients can be successfully treated with morphine, and that there is a stigma attached to morphine.",There are no anecdotes.,N/A,"Dr. Reader, uh, it says advantages for OxyContin are that not all patients can be successfully treated with morphine and that there is a stigma attached to morphine so far as many patients and physicians are concerned. And that stigma is, um, what,"
The topic they are talking about is the potential side effects of the topic.,They are discussing the potential side effects of the topic.,"The facts are that addiction, dependency, and tolerance buildup are potential side effects of the topic.",They do not support their point with anecdotes.,N/A,"Were, were one of the negative associations side effects, uh, uh, addiction, dependency, tolerance buildup."
the product,summarizes points on page 12,efficacy of product,none,none,"And under this in summary, the efficacy of the product has been demonstrated in, uh, I'm sorry, go to page 12."
It is unclear what topic they are talking about.,They do not state any points.,N/A,N/A,N/A,"It's therapeutic. Uh, okay."
The topic they are talking about is whether or not something is a good idea.,They think it is a good idea and are summarizing the points.,The facts are that it is a good idea and the anecdotes are that it is a good idea.,They think it is a good idea and are summarizing the points.,They support their point with facts and anecdotes.,"Yeah. Third paragraph from the top, actually fourth. It says in summary."
The topic is the efficacy of the product.,The person's points are that the product is effective and that it is the equivalent of other drugs.,The facts are that the product has been demonstrated to be effective in six clinical trials involving 713 patients.,There are no anecdotes.,There are no quotes.,The efficacy of the product has been demonstrated in six double blind clinical trials involving 713 patients. Therapeutic conclusions are the equivalents of one milligram of oxycodone to two milligrams of morphine sulfate.
They are talking about the equivalence of oxycodone.,They think it is equivalent to IR oxycodone.,The facts are that it is equivalent to IR oxycodone.,They do not support their point with anecdotes.,N/A,All right. Number two says equivalence to IR oxycodone
The topic they are talking about is controlled release oxycodone.,They think controlled release oxycodone is equivalent to immediate release oxycodone.,The facts are that controlled release oxycodone is equivalent to immediate release oxycodone.,They do not support their point with anecdotes.,N/A,Yeah. So they're saying controlled release is equivalent to immediate release oxycodone
The topic they are talking about is dose titration.,They think that dose titration is necessary and it is a good thing.,The facts are that dose titration is necessary and it is a good thing.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Number three was the need for dose titration.
The topic is the need for a rescue formulation.,They are questioning why a rescue formulation would be needed.,N/A,N/A,N/A,"And number four says the need for the availability of a rescue formulation. And number five said the need for aggressive management of side effects. Um, why would you need the availability of a rescue formulation,"
The topic they are talking about is the medication lasting for 12 hours.,They are questioning if there were studies done at Purdue that showed the medication really lasted between eight and 12 hours.,The facts are that there were studies done at Purdue that showed the medication really lasted between eight and 12 hours.,They do not support their point with anecdotes.,N/A,Were there studies done at Purdue that showed that blood plasma levels that the medication instead of lasting for 12 hours really lasted between eight and 12 hours.
The topic is unknown.,They have no points.,N/A,N/A,N/A,Now. But
They are talking about the topic of OxyContin.,They are saying that the research shows that OxyContin controlled release provides pain relief for 8 to 12 hours.,The facts are that the research shows that OxyContin controlled release provides pain relief for 8 to 12 hours.,They do not support their point with anecdotes.,N/A,"Bit? Sure. Let me ask you this though. What your research actually showed is that OxyContin controlled release provides pain relief somewhere between eight and 12 hours,"
The topic the person is talking about is how Purdue Pharma should market their rescue drug.,"The person's points are that there is a debate at the company on how to market the rescue drug, and that depending on how it is marketed, it could either help or hurt the company.","The facts are that there is a debate at the company on how to market the rescue drug, and that depending on how it is marketed, it could either help or hurt the company.",There are no anecdotes.,There are no quotes.,"Do you recall Purdue Pharma running into a real problem with their rescue drug? Because they were trying to decide how to market it and whether to say it was for three to four hours or for six hours. And there was a real debate at the company of how we're gonna market this because we're gonna hurt ourselves one way or the other. Uh, depending on whether we say our rescue drug is three to four versus six, because it's the same and you're marketing it two different ways."
The topic they are talking about is the file studies.,They think that the file studies are good and that they help people.,The facts are that the file studies help people.,They do not support their point with anecdotes.,N/A,"So we'll go back to that in a second. Okay. And post, let me read and continue to read from this document. Uh, it says Dr. Keiko reported that file studies. Okay. Yes. It's fourth paragraph,"
The topic the person is talking about is the product.,"The person's points are that the product is bio equivalent and dose proportional in normal subjects, and that it has the same twofold fluctuation as the immediate release product.","The facts are that the product is bio equivalent and dose proportional in normal subjects, and that it has the same twofold fluctuation as the immediate release product.",There are no anecdotes.,There are no quotes.,"Undertaken to show that the 10 20 and 40 milligram tablets were bio equivalent and dose proportional in normal subjects. It has been demonstrated that at the same total daily dose, the controlled release product, given 12 hourly showed the same twofold fluctuation as the immediate release product, given six hourly, and that this held across the four fold dosage range. And were you all aware of that in 1994?"
The topic is asking somebody to the meeting.,They want to know if somebody was asked to the meeting.,N/A,N/A,N/A,"Um, did you ask anybody to when you were at the meeting?"
The topic the person is talking about is going down to the fifth paragraph.,The person's points are that they are undecided and they are going down to the fifth paragraph.,The facts are that they are undecided and they are going down to the fifth paragraph.,The anecdote is that they are going down to the fifth paragraph.,"Yes, the anecdote can be quoted.","Going down to the fifth paragraph, um,"
The topic is the clinical study comparing oxycodone.,"The person's points are that the study demonstrated that both products maintained baseline pain control and pain intensity was the same throughout the day, and that the acceptability score was the same throughout the study and the same for immediate and controlled release products.",The facts are that the study found that the 12 hour product was equivalent in efficacy to immediate release oxycodone.,The person does not support their points with anecdotes.,N/A,"A clinical study has been undertaking, comparing oxycodone, BD versus immediate release oxycodone Q I D in patients previously stabilized to pain relief. Um, and then if you drop down the study demonstrated that both products maintained baseline pain control and pain intensity was the same throughout the day. The acceptability score was the same throughout the study and the same for immediate and controlled release products. Uh, and then if you drop down to the next paragraph, uh, the conclusion from the study was that the 12 hour product was equivalent in efficacy to immediate release oxycodone. And is that why the FDA said other than how many times you take the product being the dosing requirements, uh, there's really not any other benefit it."
The topic is the dismissal of the study.,The person's points are that the study was dismissed and that they don't know why.,The facts are that the study was dismissed and that the person doesn't know why.,There are no anecdotes.,There are no quotes.,"Do you recall that study being dismissed, uh,"
The topic is euthanasia.,"The person's points are that euthanasia may not be effective if the person being euthanized is abused, because they may still feel pain even after being euthanized.",The facts are that euthanasia may not be effective if the person being euthanized is abused.,There are no anecdotes.,There is no quote.,"But whether it's effective or not also depends on another other factors, such as abused. I mean, you can kill somebody and take away their pain, but that certainly wouldn't be effective. Would it?"
The topic they are talking about is a drug that takes away pain.,They are questioning whether or not the drug is good just because it takes away pain.,N/A,N/A,N/A,"So just because it takes away pain doesn't mean it's a good drug, does it?"
The topic is unknown.,They want to ask a question about the exhibit.,N/A,N/A,N/A,"All right. Let's, let's look at Sackler exhibit 13. Again, I did want to ask you one question about this."
The topic the person is talking about is OxyContin.,"The person's points are that if physicians think OxyContin is Percocet, they will use it more often, and that if they become more comfortable with it, they will use it in place of other drugs.","The facts are that if physicians think OxyContin is Percocet, they will use it more often, and that if they become more comfortable with it, they will use it in place of other drugs.",There are no anecdotes.,There are no quotes.,"If you go to page four, 1.4, it says, if physicians perceive OxyContin as controlled release Percocet, it is likely that they will start to use it in place of oxycodone combinations. As physicians become more comfortable with the use of oxycodone combination market, it is possible. They will start to use OxyContin in place of class three, hydrocodone or codeine combination drugs and class three are not as regulated as class two, correct?"
They are talking about the importance of having a literature to support the use of OxyContin.,They think it is important to have a literature to support the use of OxyContin.,The facts are that Purdue Pharma was trying to establish a literature to support a class three use for OxyContin.,They do not support their point with anecdotes.,N/A,"Therefore, it is imperative that we establish a literature to support such use who at Purdue Pharma was trying to establish a literature to support a class three use for OxyContin,"
The topic is the development of literature.,They are asking for an opinion on what the development of literature is referring to.,N/A,N/A,N/A,"So you think that where it says, therefore it is imperative, we establish a literature to support such use as referring to physicians, believing where it says physicians perceive OxyContin as controlled release Percocet. It is likely they will start to use it in place of oxycodone combinations. Is that what that development of literature is referring to in your opinion?"
The topic is unclear.,They are asking a question about the topic.,N/A,N/A,N/A,"Okay. Who, who was"
The topic they are talking about is literature.,They think that developing the literature is important and beneficial.,The facts are that literature is important and beneficial.,They do not support their point with anecdotes.,N/A,To develop that literature?
The topic is not clear.,They are asking if the other person has the same thing.,N/A,N/A,N/A,Do you have that? Is that what this is?
N/A,N/A,N/A,N/A,N/A,Record? Yeah. You want to break for
what topic are they talking about?,can you summarize their points?,"if they support their point with facts, what are the facts?","if they support their point with anecdotes, what are the anecdotes?",can you quote the anecdote?,Did they bring lunch yet?
The topic is not stated.,They do not state any points.,N/A,N/A,N/A,"Are off the record. I thought you, I thought it wasn't. I'm sorry."
The person is talking about the issue of rescue OxyContin.,The person's points are that they need more information and they are not sure what the best course of action is.,The facts are that the person needs more information and they are not sure what the best course of action is.,The person does not support their point with an anecdote.,N/A,"Dr. Sackler picking back up, uh, after our break and we've taken a number of breaks, but I'll just remind you at any time you need to stop or, or need a break, just let us know. Thank you. We'll stop again. Um, we were talking earlier about this issue with rescue OxyContin."
The topic they are talking about is the idea.,They think it is a good idea and will help people.,The facts are that it will help people and is a good idea.,They do not support their point with anecdotes.,N/A,Let me hand you what we're gonna mark as
The topic they are talking about is the memo.,They are summarizing a memo.,The facts are the date and the author of the memo.,They do not support their point with anecdotes.,N/A,"If you go back to the last page, there is a memo dated 9 21 95 from Robert Reeder, R E D E R. And he says currently our draft PI that's package insert, correct?"
They are talking about the sales material.,They are summarizing their points.,The facts are that the sales material have the same dosing of rescue as Q3 dash four H PN.,They do not support their point with anecdotes.,N/A,"And therefore our sales material have the same dosing of rescue as Q3 dash four H PN. And, um, that is, um, means what"
The topic is OxyContin.,The person's points are that people become addicted to OxyContin easily and that it is a problem.,The facts are that people become addicted to OxyContin easily.,There are no anecdotes.,There are no quotes.,"And do you know if the people who were involved in the studies of OxyContin were given OxyContin, uh, for rescue pain,"
The topic is oxycodone.,The person's points are that they are unsure about oxycodone and need more information.,The facts are that the person is unsure about oxycodone and needs more information.,There are no anecdotes.,There is no quote.,Oxycodone? I'm sorry.
"The topic is that BK brought up the issue some time ago, and it is now resurfacing because of a review of sales material.","The person's points are that BK brought up the issue some time ago, and it is now resurfacing because of a review of sales material.","The facts are that BK brought up the issue some time ago, and it is now resurfacing because of a review of sales material.",There are no anecdotes.,There are no quotes.,"It says, um, BK brought this issue up some time ago. It is now surfacing again because of the review of our sales material. I else material Oxy IR. And is that oxycodone?"
The topic they are talking about is being promoted as rescue.,They are questioning if being promoted as rescue is every three to four hours.,The facts are that being promoted as rescue is every three to four hours.,They do not support their point with anecdotes.,N/A,"Is being promoted as rescue, uh, to be Q3 four H and that's every three to four hours, right? That's"
They are talking about the OxyContin package insert.,They are summarizing someone else's points.,N/A,N/A,N/A,"He said, well, this may be consistent with the OxyContin package insert. If it is approved as stands, it will be inconsistent with the Oxy IR five milligram package insert, which uses Q six H mean take it every six hours. Correct."
The topic they are talking about is whether or not to validate Roxanne's change in their package.,They are summarizing the points made by someone else.,"The facts are that if they use the Q3 four hours, it will help to validate Roxanne's change in their package.",They do not support their point with anecdotes.,N/A,"He says, moreover, if we use the Q3 four hours, it will help to validate Roxanne's change in their package. Insert. Uh, what was the reason that you all did not want to validate Roxanne's change in their package? Insert."
The topic is not stated.,They do not state any points.,N/A,N/A,N/A,Sure.
The topic the person is talking about is the dosing regimens for the same drug.,"The person's points are that there are two different dosing regimens for the same drug, and that this could be changed.",The facts are that there are two different dosing regimens for the same drug.,There are no anecdotes.,N/A,"Okay. Well, let me continue reading here. It says, finally it creates a problem for the Oxy 10 milligram and 20 milligram capsules. As the package insert would have two different dosing intervals, depending upon the use. Uh, I E Q4 for rescue and Q six for usual pain use, he says one suggestion would be to make everything consistent at Q six hours rescue would then be Q six, PRN as needed as would some acute pain prescriptions for ATC use. It would just Q six hours. Although I hate the thought of recommending a PI change package, insert change. I understand FDA may recommend a change or two such as removing the plasma curve graph. At this point, we could change the frequency of dosing in the PI. What do you guys think? So what he's saying here is we've got the exact same drug. We've marketed it for two different purposes, and we've got two different dosing regimens for the exact same drug, correct?"
Paul Goldenheim,They are asking who Paul Goldenheim is.,N/A,N/A,N/A,"And then Paul Goldenheim, if you turn to the next page and read the next one at the bottom, it says, uh, who is Paul Goldenheim?"
The topic they are talking about is an issue that won't go away.,They want to discuss the issue further.,N/A,N/A,N/A,"He says the issue that won't go away, Robert is right. We need to discuss again, Robert, please arrange a meeting round up the usual suspects. This is too complicated for email then Friedman. And what was his role?"
They are talking about the different dosages for a medication.,They are discussing the different dosages for a medication.,The facts are the different dosages for a medication.,They do not support their point with anecdotes.,N/A,"The head of marketing and sales writes back and says it is, is it unreasonable to have a Q six H dose meaning take it every six hours for normal dosing and a Q3 four hour for rescue. So the marketing guy's saying, well, Hey, can't we just take the exact same medication and say, if it's for a normal dosing, take it every six hours. But if it's for rescue, take it every three to four hours,"
The topic they are talking about is getting together soon.,They think the issue is too complicated to solve through written exchange and Paul should get them together soon.,The facts are that they think the issue is too complicated to solve through written exchange and Paul should get them together soon.,There are no anecdotes.,There are no quotes.,"And then up at the top, uh, you write back and say a second one down. I agree. This is too complicated to solve through written exchange. Paul, I think that you should get us together soon. Good. Pick up someone. Do you recall writing that email?"
They are talking about changing everything to Q six hours for immediate release oxycodone products.,They recommend changing everything to Q six hours for immediate release oxycodone products.,The facts are that they recommend changing everything to Q six hours for immediate release oxycodone products.,They do not support their point with anecdotes.,N/A,"It. Okay. And then Robert Keiko writes back and says, unfortunately soon may be too late. Robert question mark as previously. So he's saying I brought this up again as previously. I recommend we change everything to Q six hours for immediate release oxycodone products. And he is the head of what Robert Keiko."
The topic they are talking about is changing everything to Q six hours.,They are summarizing someone else's points.,N/A,N/A,N/A,"So he's saying, um, appears to me maybe perhaps to be a little frustrated in saying, uh, soon may be too late. I've as previously I recommend we change everything to Q six hours."
"The topic they are talking about is taking the same product and just saying, take it every six hours.","They think it is a good idea to take the same product and just say, take it every six hours.",The facts are that it is good for three or four hours.,They do not support their point with anecdotes.,N/A,"Why, but at least from the appearance of this, you've got Friedman the head of marketing saying, why don't we take the same product and just say, take it every six hours. And if it's for rescue, uh, it's good for three or four hours,"
N/A,They think that Friedman is a good choice.,N/A,N/A,N/A,And Friedman for
They are talking about the head of marketing.,They think that the head of marketing is not a physician and they think that this is a problem.,The fact is that the head of marketing is not a physician.,They do not support their point with an anecdote.,N/A,"And Friedman the head of marketing is not a physician, correct?"
They are talking about the head of the project for OxyContin.,They think that the head of the project for OxyContin is a good thing because he is a physician.,The facts are that the head of the project for OxyContin is a physician.,They do not support their point with anecdotes.,N/A,"Not Dr. Robert Keiko. The head of the project for OxyContin is a physician, correct?"
They are talking about making it Q six hours for immediate release oxycodone products.,They think that making it Q six hours for immediate release oxycodone products is correct.,The facts are that making it Q six hours for immediate release oxycodone products is correct.,They do not support their point with anecdotes.,N/A,"And he's saying, don't do what Friedman's saying. We need to make it Q six hours for immediate release oxycodone products. Correct."
The topic is a change.,They think the change is good and do not have a problem with it.,The facts are that they do not have a problem with the change.,There are no anecdotes.,There are no quotes.,"And then, uh, you write back the next day and say, I don't know how urgent this is. If it can't wait till tomorrow, let us know immediately. I don't have a problem with this change at all. Does anyone question it? And who's Mr. Alfonso,"
The topic is the head of marketing's decision to validate the Roxanne dosing.,They are summarizing the points made by the head of marketing.,The facts are that the drugs are written for Q4 six hours and that the problem with validating the Roxanne dosing is that it would take away from the rescue dosing.,There are no anecdotes.,N/A,"Okay. So the head of marketing comes back and he says, uh, the way these drugs are written are Q4 six. The rescue is for Q3 four hours. And he explains the problem might be that if we go Q3 four hour route, we will validate the Roxanne dosing. Do you, again, I'm gonna ask you, do you know what the problem was with validating the Roxanne dosing and why he thought it was a problem?"
They are talking about the possible implications of going the Q4 Q3 four hour route.,They are summarizing the points made by someone else.,"The facts they mention are that if they go the Q4 Q3 four hour route, they will validate the Roxanne dosing and possibly present a challenge to the OxyContin studies.",They do not mention any anecdotes.,N/A,"Okay. So he writes, the problem might be that if we go the Q4 Q3 four hour route, we will validate the Roxanne dosing and possibly present a challenge to the OxyContin studies. So if he's validating the Roxanne with a Q3 four, would it appear that perhaps the Roxanne, um, um, had required now that's an overseas company, correct?"
The topic is whether or not there is a dosing limit on OxyContin.,The person's points are that they are unsure if there is a dosing limit on OxyContin and they would like to know.,N/A,N/A,N/A,"Okay. Did they, um, did, did they put a dosing limit on OxyContin to your knowledge"
The topic is oxycodone.,The person's points are that oxycodone can be mean depending on the person and the situation.,The anecdotes are about the person's experiences with oxycodone.,The first anecdote is about the person's friend who was mean on oxycodone. The second anecdote is about the person's other friend who was not mean on oxycodone.,"""My friend was really mean to me when she was on oxycodone.""",Mean on oxycodone?
The topic the person is talking about is what Roxanne's dosing was.,"The person's points are that they are unsure of what Roxanne's dosing was, and they would like to know.",The facts are that the person does not know what Roxanne's dosing was.,There are no anecdotes.,There are no quotes.,Do you know what Roxanne's dosing was that he's referring to?
The topic they are talking about is which route to take.,They are summarizing the points of two different routes and the possible outcomes of each.,The facts are the different routes and the possible outcomes of each.,There are no anecdotes.,N/A,"Okay. So he says, uh, the problem might be that if we go the Q3 four H route, we will validate the Roxanne dosing and possibly present a challenge to the OxyContin studies. On the other hand, a much more dangerous scenario can occur. If we go the Q six R for maintenance and rescue, if we go this route and price continues to be a major issue when we narrow the value of OxyContin closer to the IRS, and that's immediate releases, is that what that is?"
The topic they are talking about is going Q six hours for maintenance.,They think that going Q six hours for maintenance will be beneficial and will not change the visual too much.,"The facts are that if they go Q six hours for maintenance, then they can maintain the integrity of their OxyContin studies.",They do not support their point with anecdotes.,N/A,"Yeah. You says the next sentence says, in essence, if you can use an IR Q six hours at a cheap price, then those doctors that use OxyContin Q eight hours, there will be some, regardless of what we say or do, will not see a benefit over the immediate releases. In addition, our promotional campaign has a visual six cups representing Q4 hours. If we go Q six hours, we will, might have to change the visual to four cups. And this will not have as much impact. We need to go Q six hours for maintenance and Q3 four hours for rescue so that we can maintain the integrity of our OxyContin studies. Um, did I read that correctly? You did. Do you know whether you went Q uh, three, four hours for rescue, uh, and six hours for maintenance?"
N/A,They have no points.,N/A,N/A,N/A,"All right. Let's uh, let me jump"
The topic they are talking about is the community.,They think it is a good idea and they support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,We've
The topic they are talking about is having another copy of the document.,They think it is a good idea to have another copy of the document.,The facts are that it is a good idea to have another copy of the document.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Have another copy of that's little document.
N/A,N/A,N/A,N/A,N/A,Why don't we go ahead and mark that as exhibit
The topic they are talking about is the price increase of OxyContin.,They support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,"This is from you dated April 20th, 2000. So OxyContin has been on the market over four years at this point, correct? Yes. And under number five, um, it says OxyContin tablets price increase is the central decision. Every zero 1.1% is one M I'm assuming that's 1 million"
They are talking about a price increase.,They think that a 4% increase would be better than a 3% increase.,The facts are that a 4% increase would be better than a 3% increase.,They do not support their point with anecdotes.,N/A,"Correct. 1 million to the bottom line. What would the risk of having a 4% increase instead of a, what would the risk be of having a 4% increase instead of a 3% increase? And you're talking about price increase, correct?"
They are talking about the average realized price and rebates.,They think that the average realized price is constant and that rebates and other discounts are taking a larger share of their business.,The facts are that the average realized price is constant and that rebates and other discounts are taking a larger share of their business.,They do not support their point with anecdotes.,N/A,"Um, our average realized price is constant suggesting that rebates and other discounts are taking a larger share of our business. 3% annual notional increases seems to hold our per kg. That's is that kilogram"
They are talking about the topic of prices.,They are saying that Purdue Pharma increased prices even though many other prices were going up.,The facts are that Purdue Pharma increased prices.,They do not support their point with anecdotes.,N/A,"Price constant in an environment where many prices are going up? Was it true that every time you increased the price, 0.1%, uh, you added 1 million to the bottom line of Purdue Pharma?"
The topic is whether the employees that engaged in improper conduct were employees of Purdue Frederick or Purdue Pharma.,They are asking if the person ever determined which company the employees worked for.,N/A,N/A,N/A,"Did you have that deposition of Friedman? I'm sorry, Shapiro. We were talking earlier about Purdue Frederick versus Purdue Pharma. Did you ever determine whether the employees, the sales force that engaged in improper conduct, um, as referenced in the felony plea agreement, were employees of Purdue Frederick or employees of Purdue Pharma? Well, I"
The topic is whether the employees who engaged in illegal activity were employees of Purdue Frederick or Purdue Pharma.,They want to know if a determination has been made on which company the employees worked for.,N/A,N/A,N/A,"Sure. Um, did you ever make a, we've talked about Purdue Pharma and Purdue Frederick. Uh, did you ever make a determination whether the employees who engaged in illegal activity, um, um, as referenced in the felony plea agreement or improper activity as referenced in the felony plea agreement, were employees of Purdue Frederick or employees of Purdue Pharma."
The topic of the conversation is unknown.,The person's points are that they are not sure and they want to know if the other person has looked at the call notes of the reps in Kentucky.,There are no facts given.,There are no anecdotes given.,There is no quote given.,"Sure. Uh, have you looked at the call notes of the reps in Kentucky?"
The topic they are talking about is the documents that the lawyer put together.,They think the documents are helpful and well-organized.,The facts are that the documents are helpful and well-organized.,They do not support their point with anecdotes.,N/A,"Okay. Did you review the documents that Mr. Uh, Shapiro, uh, the lawyer that you all hired put together for the, uh, us attorney in Virginia?"
The topic is the amount of money that the company paid to the attorney.,"The person's points are that the attorney was hired to defend the company in a case, and that the company paid approximately 50 million dollars to the attorney's firm.","The facts are that the attorney was hired to defend the company in a case, and that the company paid approximately 50 million dollars to the attorney's firm.",There are no anecdotes.,There are no quotes.,"Me. And that was the attorney that you all hired to defend you, uh, in the case, uh, brought by the us attorney in Virginia, is that correct? Yes. Um, you all paid him, uh, approximately 50 million, uh, to defend you in that CA or paid his firm approximately 50 million to defend Purdue in that case?"
The topic is not clear.,They are questioning if the person would dispute it if he testified to it.,N/A,N/A,N/A,"Uh, if he testified to that, would you dispute it?"
The topic is whether the submission and call notes are accurate.,They want to know if anybody made an effort to determine whether the submission and call notes were accurate.,N/A,N/A,N/A,"Um, and do you know if anybody at Purdue, um, uh, made an effort to determine whether the, the submission, uh, and the, uh, uh, call notes that were pulled by the lawyer hired to represent you were accurate or not?"
The topic is that he is a criminal.,They think he is a criminal.,The facts are that he made a submission on behalf of Purdue to the US attorney's office.,They do not support their point with anecdotes.,N/A,"Um, are, are you aware that he made a submission on behalf of Purdue to the, um, us attorney's office?"
The topic is his qualifications.,They think he is not qualified because he has not reviewed any of the materials he submitted to the us attorney's office when he was defending Purdue.,The facts are that he has not reviewed any of the materials he submitted to the us attorney's office when he was defending Purdue.,They do not support their point with anecdotes.,N/A,You've not reviewed any of the materials he submitted to the us attorney's office when he was defending Purdue.
The topic of the conversation is the call notes and whether or not they are evidence of improper behavior.,The person's points are that they are not sure if the call notes are evidence of improper behavior and they want to know if the person is aware of this.,There are no facts given.,There are no anecdotes given.,There is no quote given.,"Okay. Uh, were you aware of the call notes that he pulled and purported were evidence of improper behavior? Um, uh, on behalf of Purdue salespeople?"
The topic is Purdue Pharma and Purdue Frederick.,The person's points are that Purdue Pharma and Purdue Frederick did not try to stop their employees from breaking the law and that they should have.,The facts are that Purdue Pharma and Purdue Frederick did not try to stop their employees from breaking the law and that they should have.,There are no anecdotes.,There are no quotes.,"Did anyone at Purdue to your knowledge, Purdue Pharma or Purdue Frederick make any attempt to ascertain? What percentage of reps in Kentucky were engaging in the type of behavior that the plea agreement says was improper?"
It is unclear what the person is talking about.,They do not state any clear points.,N/A,N/A,N/A,"Yeah. Did you ever instruct anybody to do it to, to"
The topic the person is talking about is an investigation into improper conduct by reps in Kentucky.,The person's points are that an investigation should be done and that it will reveal which reps were engaging in improper conduct.,The facts are that there was a felony plea agreement that referenced improper conduct.,There are no anecdotes.,N/A,"Instruct anybody at Purdue to undertake an investigation, uh, to find out what percentage of reps in Kentucky and which ones were engaging in conduct that was referenced as improper in the felony plea agreement?"
Deposition by Shapiro in a case,The person is asking if the other person has reviewed a deposition by Shapiro in a case.,N/A,N/A,N/A,"Uh, have you reviewed, hired Shapiro's deposition in this case?"
The topic is not clear.,They do not state any clear points.,N/A,N/A,N/A,"He was asked, um,"
,They support their points with facts.,The claims they make are that the employees in question worked for Purdue Frederick company and that they did a sufficient investigation.,The premises they rely on are the facts of the case and their own investigation.,The topic they are talking about is the identity of the employees in question.,"Let me read this question in, in his answer, Mr. Shell, before the break, we were discussing the agreed statement of five specifically, paragraph 20. One of the questions that I had asked you previously about the conduct described in the agreed statement of facts was, did you ever figure out who the employees referenced in the agreed statement of facts worked for? Was it Purdue Frederick company? Was it Purdue Pharma, LLP, or some other entity with respect to the employees that we've been discussing? And those are employees whose conduct is described in paragraph 20 in its various subparts. Did you ever do a determination to determine whether those employees were employees of Purdue Frederick company who signed the agreed statement of facts or some other Purdue entity? And his answer is without going into too much work product. Let me state, we did sufficient investigation once,"
They are talking about the conduct of Purdue Frederick employees.,They think that there were Purdue Frederick employees who engaged in the conduct and that this forms the basis for the guilty plea question.,The facts are that there were Purdue Frederick employees who engaged in the conduct.,They do not support their point with anecdotes.,N/A,"Once it turned this direction to satisfy ourselves and our client, that there were Purdue Frederick employees who engaged in the conduct, that's referenced in here. And that forms the basis for the guilty plea question. Were there any employees of Purdue Pharma LP that are referenced here or any other Purdue entity answered? Well, again, and I'm just what I said before. The, I don't know whether at, at which point in time, Michael Friedman hired UDel, Paul Goldenheim, whether they were Purdue farmer or Purdue Frederick, or some of the, some of them had been won. And then the other beyond them, there were, when we look for instance, at the names that are associated with the, in the first supplemental responses to whatever that was 23, I think. Did you understand that answer?"
N/A,They have not made any points.,N/A,N/A,N/A,Sure. Do we have another question? Some
The topic they are talking about is reading along with the person.,They are summarizing their points.,The facts are that they are reading along with the person.,They are not supporting their point with anecdotes.,They are not quoting an anecdote.,Here. I'll tell why you can just read along with me if you want to do that. I'll hold it over
N/A,N/A,N/A,N/A,N/A,"Um, yeah. Why don't we go off the record? Why don't we get some copies of this?"
The topic is unknown.,They want the person to read the next question and answer.,N/A,N/A,N/A,"Sure. And to save time, I'll let you read it. Can you start with the next question, which was Ah-huh and read the answer."
The topic is accuracy of testimony.,They are questioning the accuracy of the testimony.,The facts are that the testimony may not be accurate.,They do not support their point with anecdotes.,N/A,And is that testimony accurate?
no,summarizes questions,no,no,no,"So the next question says, so it could have been either or one or both."
The topic they are talking about is Michael Friedman.,They cannot summarize their points.,N/A,N/A,N/A,"Now in 2001, who did Michael Friedman work for?"
The topic they are talking about is Purdue Pharma.,They think that Purdue Pharma is a terrible company and they don't want to work for them.,The facts are that Purdue Pharma is a terrible company.,They do not support their point with anecdotes.,N/A,You don't know if he worked for Purdue Pharma in 2001?
The topic the person is talking about is Howard UDel.,The person's points are that they are unsure of who Howard UDel worked for.,There are no facts given.,There are no anecdotes given.,There are no quotes given.,How about Howard UDel? Do you know who he worked for?
Paul Goldenheim,They do not mention any specific points.,N/A,N/A,N/A,What about Paul Goldenheim? Do you
The topic is whether the person worked for Purdue Pharma or Purdue Frederick in 2001.,The person's points are that they are unsure of which company they worked for and they would like to know.,N/A,N/A,N/A,Do you know whether you worked for Purdue Pharma or Purdue Frederick in 2001?
They are talking about the OxyContin launch team.,They don't make any points.,N/A,N/A,N/A,"All right. You have this one. So, um, going back to our OxyContin launch team, that's what I'm. Um, okay. I don't think its that's I'm sorry. Yes. The last one that can we do that?"
The topic is whether or not this is a good idea.,They think it is a good idea and are in favor of it.,The facts are that this is a good idea and they are in favor of it.,They do not support their point with anecdotes.,N/A,"This? Yes, let's mark that as exhibit"
The topic is not clear.,They have not made any points yet.,N/A,N/A,N/A,"And I've just got a couple of paragraphs when I ask you. So, uh, this is dated April 4th, 1995. Um, and it says at the first paragraph second sentence, Mike Innerato. Oops."
They are talking about a specific paragraph in a document.,They are looking for a specific paragraph.,N/A,N/A,N/A,"I'm sorry. Uh, page one second paragraph."
The topic is Mike Innerato's job title.,"The person's points are that they are unsure if Mike Innerato is the marketing guy, and they would like clarification.",N/A,N/A,N/A,"Okay. Mike Innerato he's the marketing guy again, correct?"
The topic they are talking about is OxyContin being marketed as a cancer pain medication.,They think that OxyContin will be a good medication for cancer pain and that it should not be niched just for cancer pain.,The facts are that OxyContin will be a good medication for cancer pain and that it should not be niched just for cancer pain.,They do not support their points with anecdotes.,They do not quote any anecdotes.,"Discuss the marketplace that OxyContin will enter and how OxyContin will expand out of the cancer pain market. Um, OxyContin will be launched in 10 20, 40 milligram tablet, strength, 80 and 160 milligram tablet, strength to follow. Um, and if you go on down a little bit further, he says OxyContin will be indicated for the relief of pain with the convenience of Q 12 dosing Oxycontin's primary market positioning will be for cancer pain, and the secondary market will be for non-malignant pain, musculoskeletal injury and trauma. It was reinforced that we do not want to niche OxyContin just for cancer pain. Um, and <affirmative> um, and was it, um, part of your all's marketing strategy, not to niche OxyContin for cancer pain,"
They are talking about the drug Ms. Cotton.,They point out that the drug is already being sold and that focus groups have had positive reactions to it.,The facts are that the drug is already being sold and that focus groups have had positive reactions to it.,There are no anecdotes.,There are no quotes.,"Below that it says, uh, on the last paragraph in our market research office, focus groups, personal one-on-one interviews and telephone interviews were conducted with more than 500 healthcare professionals in our focus group findings. We learned that Ms. Cotton that's the drug that you already sold, correct?"
The topic they are talking about is the abuse or diversion of a medication.,They are questioning whether the person is correct about the abuse or diversion of a certain medication.,N/A,N/A,N/A,"Question. Yes. That's morphine sulfate, correct? Yes. Um, that's the one that you had not had any reports of abuse or diversion with that you could recall,"
The topic is cancer pain.,"The person's points are that MS. Contin is the gold standard for cancer pain, and that OxyContin is likely to be used by physicians and nurses.","The facts are that MS. Contin is the gold standard for cancer pain, and that OxyContin is likely to be used by physicians and nurses.",There are no anecdotes.,There are no quotes.,"Yes. And it says, we learned that MS. Contin is the gold standard for cancer pain. Our creative concept testing showed the likelihood of OxyContin usage by physician and nurses were 4.6 on a scale of one to five, which is very favorable. Um, were you aware of this, uh, creative concept testing and focus groups that were being conducted?"
The topic is the document itself.,They are summarizing the points on page two of the document.,The facts are on page two of the document.,They do not support their points with anecdotes.,N/A,"And then if you go to the next page, page two, last paragraph,"
The topic is the establishment of OxyContin.,The person's points are that AB rated generics will eventually be launched and that it is important to establish OxyContin now.,The facts are that AB rated generics will eventually be launched and that it is important to establish OxyContin now.,There are no anecdotes.,There are no quotes.,"Our meeting ended with a question and comment period. Michael Friedman emphasized the threat that AB rated generics posed to MS. Contin. We're not sure when AB rated generics will be launched, but we don't think it will be until 1996. Inevitably the AB rated generics will arrive. And this is why it is extremely timely importance that we must establish OxyContin. OxyContin can cure the vulnerability of the AB rated generic threat. And that is why it is so crucial that we devote our fullest efforts now to a successful launch of OxyContin. And were you aware that was part of the strategy?"
They are talking about the importance of establishing OxyContin.,They think it is important to establish OxyContin because of the arrival of AB rated generics.,"The facts are that it is written that they must establish OxyContin and that it is crucial to devote the fullest efforts to a successful launch because of AB Reagan, generic.",They do not support their point with anecdotes.,N/A,"Uh, that the AB rated generics were going to arrive and that, uh, is why it was extremely timely important. That's the way it's written that we must establish OxyContin. Uh, and it was crucial to devote the fullest efforts to a successful launch, um, be because of AB Reagan, generic"
The OxyContin product team,They want to know if the person is familiar with the OxyContin product team.,N/A,N/A,N/A,Are you familiar with the OxyContin product team
The topic they are talking about is the photograph and whether or not it should be marked as an exhibit.,They think the photograph should be marked as an exhibit and then they want to move on.,The facts are that the detective wants to mark the photograph as an exhibit and move on.,They do not support their point with anecdotes.,N/A,"Let's mark this as exhibit,"
The topic they are talking about is the product.,They think that the product is good and that it is helping people.,The facts are that the product is helping people and that it is working well.,They do not support their point with anecdotes.,N/A,"And this is, uh, minutes of the OxyContin product team dated. Uh, the meeting is February 22nd, 1996. Um, up at"
The person is talking about the clinical studies done by the OxyContin product team.,They think that the clinical studies are unnecessary and a waste of time and resources.,N/A,N/A,N/A,"It says first paragraph, the OxyContin product team met on Friday, February 22nd, 1996. And topics discussion included the following number one is marketing's wishlist for clinical studies. Uh, and then it's got a list of studies. Uh, number one is post-operative pain to support the Abbott agreement. Why did you need studies on post-operative pain to support the Abbott"
The topic is pharmacoeconomic studies.,"The person's points are that they don't remember why pharmacoeconomic studies are needed, and they want to know.",N/A,N/A,N/A,Uh pharmacoeconomic what was the reason for pharmacoeconomic studies being needed? If you recall?
They are talking about how the subcategories are low back pain and osteoarthritis long-term safety data.,They are talking about how the subcategories are low back pain and osteoarthritis long-term safety data.,The facts are that the subcategories are low back pain and osteoarthritis long-term safety data.,They do not support their point with anecdotes.,N/A,"And then it says non-malignant pain exam example, functional improvement, and then the subcategories are low back pain, osteoarthritis long-term safety data."
"The topic the person is talking about is marketing needing on March 7th, 1996 after the product had already launched long term safety data.","The person's points are that they are unsure why marketing needed was needed on March 7th, 1996 after the product had already launched long term safety data.",The facts are that the product had already launched long term safety data.,The person does not support their point with anecdotes.,N/A,"Why did you think that marketing needed was needing on March 7th, 1996 after the product had already launched long term safety data?"
The topic is the safety of OxyContin.,They are questioning the safety of the product.,The facts are that the head of the OxyContin product team said they need long-term safety data.,There are no anecdotes.,N/A,"Sure. Then can you explain why the head of the OxyContin or the, uh, OxyContin product team on February 22nd, 1996, after the product launched said we need long-term safety data term safety down."
,They are summarizing their points.,The facts are that it is a subcategory of non-malignant pain.,They do not support their point with an anecdote.,They make the claim that it is a subcategory of non-malignant pain.,"And this that is a subcategory of non-malignant pain, correct."
The topic they are talking about is the company's marketing wishlist.,They are saying that the company is looking for long-term safety data on prescribing OxyContin for non-malignant pain.,The facts are that the company is looking for long-term safety data on prescribing OxyContin for non-malignant pain.,They do not support their point with anecdotes.,N/A,They've included long-term safety data under their marketing wishlist under nonmalignant pain. Correct? They did. So it looks like they're saying we need long-term safety data on prescribing OxyContin for non-malignant pain. Do you read that the same way or differently?
The topic they are talking about is the FDA's role in approving drugs.,They are discussing the FDA's role in approving drugs.,The facts are that the FDA approves drugs.,They do not support their point with anecdotes.,N/A,"And then we talked about the FDA's, um,"
The topic they are talking about is comparative studies.,They are questioning whether comparative analysis is helpful.,N/A,N/A,N/A,"Statement about comparative studies. Um, did, do you remember that where they said you should refrain from comparative analysis of, uh, analysis?"
The topic is the OxyContin marketing team's wishlist.,"The person's points are that the OxyContin marketing team wishes for comparative studies, especially versus combination opioids, and that Duragesic MS. Contin Casian and Tran NSAIDs are non-steroidal anti-inflammatory drugs.","The facts are that the OxyContin marketing team wishes for comparative studies, especially versus combination opioids, and that Duragesic MS. Contin Casian and Tran NSAIDs are non-steroidal anti-inflammatory drugs.",There are no anecdotes supporting the points.,N/A,"Would be great. Um, one of the things that the OxyContin marketing team's wishlist has under number five is comparative studies, especially versus combination opioid <affirmative>, combination opioids, such as hydrocodone combinations. Duragesic MS. Contin Casian and Tran NSAIDs. Those are non-steroidal anti-inflammatory drugs. Is that"
They are talking about the benefits of eating insects.,They think that insects are a good source of protein and are easy to farm.,The facts are that insects are a good source of protein and are easy to farm.,They do not support their point with anecdotes.,N/A,Right? Insects.
NSAIDs,They are asking what NSAID stands for.,N/A,N/A,N/A,"Right? No, no, I get it. I'm just, I'm asking you, is that what NSAID stands"
The topic is unknown.,They want to know if it has been marked.,N/A,N/A,N/A,Has that been marked?
The topic the person is talking about is the launch plan.,The person's points are that the launch plan is dated and on page 42.,"The facts are that the launch plan is dated September 27th, 1995 and is on page 42.",The person does not support their points with anecdotes.,N/A,"All right. Now let's go to the launch plan. And this is dated September 27th, 1995. And if you'll go to page 42 of the launch plan"
The topic they are talking about is the public relations campaign for the launch of OxyContin.,They think the objective of the public relations campaign is to create broad awareness of the launch of OxyContin and that the awareness will be directed at the consumer and healthcare professionals through various media channels.,"The facts are that a consumer survey conducted by a company such as the Gallup pole is being proposed and that the release of the results of such a survey would be publicized along with the recent FDA approval of the new controlled release, oxycodone preparation, OxyContin.",They do not support their point with anecdotes.,N/A,"Under 5 8, 5, 1 under public relations at the top, it says the objective of the public relations campaign is to create broad awareness of the launch of OxyContin. This awareness will be directed at the consumer and healthcare professionals through various media channels, such as print, TV, and radio in an effort to create a quote media hook in quote that would coincide with the launch of OxyContin. A consumer survey conducted by a company such as the Gallup pole is being proposed. This survey would focus on the prevalence and problems of chronic pain, both malignant and nonmalignant. The release of the results of such a survey would be publicized along with the recent FDA approval of the new controlled release, oxycodone preparation, OxyContin. This is a classic problem solution strategy to create a need for the launch of a product such as OxyContin. Did I read that correctly?"
The topic is the validity of a poll.,They are questioning the validity of a poll.,N/A,N/A,N/A,You know if a poll was conducted by someone such as the Gallup poll?
The topic they are talking about is the expansion of Purdue Frederick's partners against pain program.,They are summarizing the points.,"The facts are that Purdue Frederick's partners against pain program was developed to improve pain management knowledge among healthcare professionals and patients, caregivers.",They are not supporting their point with anecdotes.,N/A,"Then, then the next paragraph says 5 8, 5 2. It says in an effort to continue the publicity about the launch of OxyContin, approximately two to three months after the initial public relations campaign, another campaign would be launched focusing on the expansion of Purdue Frederick's partners against pain program developed to improve pain management knowledge among healthcare professionals and patients, caregivers, partners against pain was a creation of Purdue Frederick. Correct."
The topic they are talking about is the lack of partners.,They think that it is a good thing that there were no partners.,The facts are that there were no partners.,They do not support their point with anecdotes.,They do not quote any anecdote.,"And there were no partners, correct?"
They are talking about the government's involvement in healthcare.,They think that the government shouldn't be involved in healthcare.,The facts are that the government wasn't involved in setting up partners against pain.,They don't support their point with anecdotes.,N/A,"Oh, okay. So, but as far as setting it up, there weren't any other partners, uh, involved in setting up partners against pain. I mean, the government wasn't involved in partners against pain, other healthcare companies weren't"
The topic the person is talking about is a campaign to improve the level of care for patients suffering from pain.,"The person's points are that the campaign would reiterate the prevalence and problems uncovered in the consumer survey and explain how Purdue Frederick has made a commitment to improving the level of care for patient suffering and pain. In addition, the campaign would expand the recent launch of Purdue Frederick's newest partner against pain OxyContin.","The facts are that the campaign would reiterate the prevalence and problems uncovered in the consumer survey and explain how Purdue Frederick has made a commitment to improving the level of care for patient suffering and pain. In addition, the campaign would expand the recent launch of Purdue Frederick's newest partner against pain OxyContin.",The person does not support their points with anecdotes.,N/A,"And it says this campaign would reiterate the prevalence and problems uncovered in the consumer survey and explain how Purdue Frederick has made a commitment to improving the level of care for patient suffering and pain. In addition, the campaign would expand the recent launch of Purdue Frederick's newest partner against pain OxyContin. Um,"
The topic they are talking about is sponsoring a pain management foundation.,They want to know if there are any benefits to sponsoring a pain management foundation.,N/A,N/A,N/A,"I thought I said explain, but, um, and then the next paragraph says, in addition to the public relations campaigns, we are exploring the possibility of Purdue Frederick sponsoring a pain management foundation in association with an organization such as Gilda's club. Uh, do you know if you sponsored a pain management foundation?"
The topic they are talking about is the marketing and promotion of OxyContin.,They are saying that the main way that the company marketed and promoted OxyContin was through their sales force.,The facts are that the company marketed and promoted OxyContin through their sales force.,There are no anecdotes.,There are no quotes.,Can we agree that the main way you marketed your and promoted OxyContin was with your sales force?
The topic they are talking about is OxyContin.,They think that OxyContin is a good thing because it helps people.,The facts are that OxyContin helps people.,They do not support their point with anecdotes.,N/A,And those are the people that actually go out to the physician's offices and pharmacies and to the communities and sell OxyContin. Correct.
The topic is Purdue's sale of OxyContin.,The person's points are that Purdue's sale of OxyContin is the most valuable resource and that OxyContin is a good product.,The facts are that Purdue's sale of OxyContin is the most valuable resource and that OxyContin is a good product.,There are no anecdotes.,There are no quotes.,"Okay. And you would consider them the most valuable resource that Purdue had to sell OxyContin, correct?"
The topic the person is talking about is getting physicians to prescribe and keep prescribing OxyContin.,The person's points are that the key to getting physicians to prescribe and keep prescribing OxyContin is through regular visits from the Salesforce.,The fact is that regular visits from the Salesforce is the key to getting physicians to prescribe and keep prescribing OxyContin.,There are no anecdotes.,There are no quotes.,"Um, <affirmative> um, at some point, did you figure out that the key to getting physicians to prescribe and keep prescribing OxyContin was through regular visits from the Salesforce."
The topic they are talking about is that some physicians are more likely to prescribe OxyContin.,They are saying that some physicians are more likely to prescribe OxyContin.,The facts are that some physicians are more likely to prescribe OxyContin.,They do not support their point with anecdotes.,They do not quote any anecdotes.,And was there a realization that developed that certain physicians so-called core physicians were more likely to prescribe OxyContin?
The topic is companies sending sales representatives to physicians to talk to them about opioids.,The person's points are that companies are sending sales representatives to physicians to talk to them about opioids and that this is a problem.,The facts are that companies are sending sales representatives to physicians to talk to them about opioids.,There are no anecdotes.,There are no quotes.,"And how many companies were sending sales representatives to physicians, offices to talk to them about opioids during this time?"
The topic is the compensation of the sales force.,The person's points are that the sales force was compensated well for selling OxyContin and that this created an incentive to sell more.,The facts are that the sales force was compensated well for selling OxyContin.,There are no anecdotes.,There are no quotes.,"And you compensated your sales force, um, very well based predominantly on how much OxyContin they sold, is that correct?"
The topic is the sales scheme for OxyContin.,"The person's points are that the scheme was set up so that if more OxyContin was sold, more money was made, and that this is a bad thing.","The facts are that if more OxyContin was sold, more money was made.",There are no anecdotes.,There are no quotes.,"Time. The way the sales scheme was set up. If they sold more OxyContin, they made more money, basically."
The topic is that the reps were given an incentive to sell OxyContin.,"The person's points are that the reps were given an incentive to sell OxyContin, and that this is a bad thing.",The facts are that the reps were given an incentive to sell OxyContin.,There are no anecdotes.,There are no quotes.,"And then you all gave your reps an additional incentive because you Des them to sell Ms. Cotton, but you increased the incentive for selling OxyContin. Is that true?"
The topic is the sales force.,The person's points are that the sales force was one of the highest paid in the country.,The facts are that the sales force was one of the highest paid in the country.,There are no anecdotes.,There are no quotes.,And then you had one of the highest paid sales forces in the country. Is that accurate?
"The topic is whether or not reps that promoted and sold OxyContin made over $250,000 a year.","The person's points are that they are unsure if reps that promoted and sold OxyContin made over $250,000 a year, and they would like to know if this is true.",N/A,N/A,N/A,"Do you know if reps that promoted and sold OxyContin, um, sometimes ended up making over $250,000 a year?"
The topic is the toppers program.,The person's points are that the top sellers were rewarded with trips and that the program was called the toppers program.,The facts are that the top sellers were rewarded with trips and that the program was called the toppers program.,There are no anecdotes.,There are no quotes.,"And then your top sellers were rewarded with trips, uh, to, um, Bermuda or London in what was called the toppers program. Is that"
The topic is OxyContin.,"They point out that during the first five years of OxyContin's release, Purdue's sales more than doubled.","The facts are that during the first five years of OxyContin's release, Purdue's sales more than doubled.",There are no anecdotes.,There are no quotes.,"Yes. And during the first five years of OxyContin release Purdue, more than double the size of its sales"
They are talking about the sales force during the first five years.,They point out that the sales force during the first five years was mostly Purdue Frederick employees.,The facts are that the sales force during the first five years was mostly Purdue Frederick employees.,They do not support their point with anecdotes.,N/A,Correct. And do you know how much of this sales force during the first five years was Purdue Frederick versus Purdue Pharma employees?
They are talking about the designation of new hires at Purdue Pharma.,"They point out that new hires were designated as Purdue Pharma, as opposed to Purdue Frederick.","The facts are that new hires were designated as Purdue Pharma, as opposed to Purdue Frederick.",They do not support their point with anecdotes.,N/A,"Um, at some point were salespeople designated, uh, all new hires, designated Purdue Pharma, as opposed to Purdue Frederick."
The topic is the date that something started.,"The person's points are that they are unsure of the date that something started, and they would like clarification.",The facts are that the person is unsure of the date that something started.,There are no anecdotes.,There are no quotes.,Okay. But you're not sure what date that started.
Purdue Pharma,the person is asking if Purdue Pharma started after the creation of it,N/A,N/A,N/A,Do you know if it was after the creation of Purdue Pharma that that started
The topic is Purdue Pharma.,They are asking if it was immediately after the creation of Purdue Pharma that all reps were hired by Purdue Pharma.,N/A,N/A,N/A,"But I mean, was it immediately after that, that all, once it was created, all reps were hired by Purdue Pharma as opposed to Purdue?"
It is unclear what topic they are talking about.,They do not state any points.,N/A,N/A,N/A,Who would know that at Purdue.
The topic is targeting wholesalers.,They point out that targeting wholesalers is an effective way to reach more potential customers.,The facts are that wholesalers are an effective way to reach more potential customers.,There are no anecdotes.,There are no quotes.,"And then in addition to targeting, um, while providing initiatives to the sales force, you also targeted wholesalers, correct?"
The topic is the retail distribution of OxyContin.,The person's points are that the retail distribution of OxyContin will be successful and profitable for pharmacists.,The facts are that OxyContin has a large market potential and that there is a large number of prescriptions written for class two and three opioids every year.,There are no anecdotes.,N/A,"And in fact, I think if you go to page 27 of the initial launch plan, the last paragraph, um, yeah. Um, it says, um, all promotional efforts for the retail distribution of OxyContin will focus on the incredible success that Purdue Frederick has achieved and sustained with Ms. Cotton product line, wholesale pharmaceutical buyers and retail pharmacists should be reminded of how Ms. Cotton created such a large market for the use of sustained release opioids in the, for the treatment of pain. This in turn created profits for pharmacists, helping to grow their businesses. Promotional copies should focus on the market potential for OxyContin and patient populations to be targeted, including the number of prescriptions written for class two and class three opioids every year."
The topic they are talking about is how to make more money with OxyContin prescriptions.,"They think that the executive director of national accounts should work with drug wholesalers in developing programs to utilize the wholesaler sales representatives to ensure adequate distribution consideration should begin given to advertisements in drug wholesaler, ad books and computer programs.",The facts are that the sales force was told to emphasize with pharmacists that they could make more money with OxyContin prescriptions.,They do not support their point with anecdotes.,N/A,"The executive director of national accounts should work with drug wholesalers in developing programs to utilize the wholesaler sales representatives to ensure adequate distribution consideration should begin given to advertisements in drug wholesaler, ad books and computer programs, um, were the sales force told to emphasize with pharmacists that they could make more money, uh, with OxyContin prescriptions."
The topic they are talking about is Ms. Cotton's market for the use of sustained release opioids for the treatment of pain.,"They think that Ms. Cotton created a large market for the use of sustained release opioids for the treatment of pain, which in turn created profits for pharmacists.","The facts are that Ms. Cotton created a large market for the use of sustained release opioids for the treatment of pain, which in turn created profits for pharmacists.",They do not support their point with anecdotes.,N/A,"And let me go back to my question where it says wholesale pharmaceutical buyers and retail pharmacists should be reminded of how Ms. Cotton created such a large market for the use of sustained release opioids for the treatment of pain. This in turn created profits for pharmacists. Um, am I reading that incorrectly? Sorry."
The topic is that Salesforce is making a lot of money from selling their product.,They are saying that Salesforce is making a lot of money from selling their product.,The facts are that Salesforce is making a lot of money from selling their product.,There are no anecdotes.,There are no quotes.,"Correctly. Yeah. What you're telling, uh, what this launch plan Salesforce under the title, Salesforce allocation, um, uh, and representative delivered promotional materials is saying, Hey, remind 'em, they're making a bunch of money selling our product,"
The topic is the OxyContin sales sheet.,They are summarizing the points of the OxyContin sales sheet.,The facts are that the OxyContin sales sheet offers a rebate to retail pharmacists.,There are no anecdotes.,There are no quotes.,"Um, says a cooperative direct mail advertising sales sheet, offering a rebate on the initial order of OxyContin to retail. Pharmacists will be mailed every month during the first three months of lunch. What was the rebate? You all were offering to pharmacist"
The topic is whether OxyContin's marketing campaign was unprecedented.,The person's points are that they are not sure if OxyContin's marketing campaign was unprecedented and they want to know if the company has seen another company with a more broad marketing campaign.,N/A,N/A,N/A,"Well, like some of your other literature talks about you all had an unprecedented marketing campaign. Uh, have you ever seen another company that instituted a more broad ranging marketing campaign than you all did for OxyContin?"
The topic they are talking about is how OxyContin was marketed.,They are talking about how OxyContin was marketed and how it was done through third-party organizations.,The facts are that OxyContin was marketed and how it was done through third-party organizations.,There are no anecdotes.,N/A,"All right. Um, you all also were involved with third party organizations, uh, partners in pain. Um, they were, uh, referenced in the launch campaign. Um, and did you use partners in pain to drum up demand for OxyContin?"
They are talking about how Purdue Pharma funded the American pain societies.,They are talking about how Purdue Pharma funded the American pain societies.,The facts are that Purdue Pharma funded the American pain societies.,There are no anecdotes.,There are no quotes.,"That later there was also, um, Purdue funded, a variety of so-called pain societies. The American pain societies was that funded by a Purdue Pharma."
The topic the person is talking about is whether or not they funded the American Association for Pain Management.,"The person's points are that they are not sure if they funded the American Association for Pain Management, and they want to know if the person they are speaking to did.",The facts are that the person is not sure if they funded the American Association for Pain Management.,There are no anecdotes.,There are no quotes.,"Did, did you also fund the American association for pain management?"
The Appalachian pain society,They are critical of the Appalachian pain society and question whether it was funded.,N/A,N/A,N/A,Did you also fund the Appalachian pain society?
"They are talking about the target market for physicians including cancer, malignant pain, and non-malignant pain across the US.","They are looking at a figure that says there is a target market for physicians including cancer, malignant pain, and non-malignant pain across the US.","The facts are that there is a target market for physicians including cancer, malignant pain, and non-malignant pain across the US.",They do not support their point with anecdotes.,N/A,"Yeah. There was a figure we looked at a while ago that said there was basically the target market for physicians was about 7,500 physicians, including the cancer, malignant pain and the non-malignant pain, uh, across the us. Do you remember seeing that?"
The topic is the number of physicians in the market.,They do not provide any points.,N/A,N/A,N/A,"Do you think the market was more than 7,500 physicians,"
The topic the person is talking about is larger doses of pain medication.,The person's points are that larger doses of pain medication are more effective and that they have personal experience with this.,The facts are that larger doses of pain medication are more effective.,The anecdote is about the person's personal experience with being in an accident and needing pain medication.,"""I was in an accident. I was T-boned by a car.""","Larger for pain,"
They are talking about Purdue Pharma's possible speakers bureau.,They are asking if the person recalls whether Purdue Pharma set up a speakers bureau.,N/A,N/A,N/A,"Do you recall whether Purdue Pharma set up a speakers bureau in which it allowed physicians, uh, who were recommended by salespeople to be put on the so-called speakers bureau?"
,They are saying that there were over 3000 physicians on the speaker's bureau.,The facts are that there were over 3000 physicians on the speaker's bureau.,They do not support their point with anecdotes.,They make the claim that there were over 3000 physicians on the speaker's bureau.,Do you recall that there were over 3000 physicians on the speaker's bureau?
The topic the person is talking about is whether all 3000 physicians on the speakers bureau were vetted.,The person's points are that there are 3000 physicians on the speakers bureau and it's unclear if they were all vetted.,The facts are that there are 3000 physicians on the speakers bureau.,N/A,N/A,Do you think somebody vetted all 3000 physicians that were internally that were on the speakers bureau?
The topic is the speaker's bureau for OxyContin.,They think that putting 3000 doctors on a speaker's bureau for OxyContin caused them to write more prescriptions for the drug.,"The facts are that 3000 doctors were put on a speaker's bureau for OxyContin, and that this caused them to write more prescriptions for the drug.",They do not support their point with anecdotes.,N/A,"Do you think putting these 3000 doctors on your speaker's bureau, um, caused them to write more prescriptions for OxyContin or less prescriptions for OxyContin?"
The topic is the Train the Trainers program.,The individual recalls the program.,N/A,N/A,N/A,"And there were also individuals, you started a program called train the trainers where you would fly physicians around the country, uh, to speak, uh, on perhaps on behalf of Purdue. Do you recall that,"
The topic is whether or not business meetings should take place at resorts in Florida and Arizona.,"The person's points are that business meetings could take place at resorts in Florida and Arizona, but it is unknown if that is practical or not.",The facts are that business meetings could take place at resorts in Florida and Arizona.,There are no anecdotes.,N/A,"And would these take place at resorts, like in Florida and Arizona, these meetings"
The topic they are talking about is whether or not a prophet could come from Galilee.,"They are saying that if the woman looks, she will see that no prophet has come from Galilee in the past, so it is not likely that one will come from there in the future.",The facts are that no prophet has come from Galilee in the past.,They do not support their point with anecdotes.,N/A,"And you also,"
The topic is whether or not Purdue paid for a student's education.,They are questioning whether or not Purdue paid for a student's education.,The facts are that they are questioning whether or not Purdue paid for a student's education.,There are no anecdotes.,There are no quotes.,And did Purdue pay for that or did they pay their own way
The industry,They think it is not customary in the industry.,N/A,N/A,N/A,Who told you that was customary in the industry?
The topic is whether pharmaceutical companies and medical device companies have come under criticism for giving incentives to doctors to write prescriptions or use their medical devices.,"The person's points are that they are unsure whether these companies have come under criticism and, if so, whether the criticism is warranted.",N/A,N/A,N/A,"Do you know whether pharmaceutical companies and medical device companies have come under criticism for giving incentives to doctors to write prescriptions, uh, or use their medical"
N/A,They don't state any points.,N/A,N/A,N/A,And the answer is they have come under criticism for that.
The topic the person is talking about is unknown.,The person's points are that they are not sure if the thing is good and they do not know if it is worth the money.,The facts are that the person is unsure if the thing is good and does not know if it is worth the money.,The person does not support their point with anecdotes.,N/A,"Um,"
The topic is whether or not Russell Portnoy is a good speaker.,"The person's points are that they do not know if Russell Portnoy is a good speaker, and that they have heard mixed reviews.",The facts are that the person has heard mixed reviews about Russell Portnoy's speaking abilities.,There are no anecdotes.,N/A,"Yeah. Was Russell Portnoy, one of the speakers that spoke on behalf of Purdue Pharma at these"
The topic is whether or not the company hired outside firms to help with the marketing of OxyContin.,They are questioning whether or not the company hired outside firms to help with the marketing of OxyContin.,N/A,N/A,N/A,"Um, in addition to the stuff we've just talked about, you also hired a number of third parties to assist in the marketing of OxyContin, such as marketing firms, correct?"
The topic is Purdue retaining lion's levy to market OxyContin.,"The person's points are that they don't know if Purdue retained lion's levy to market OxyContin, and they are asking if the other person knows.",There are no facts given.,There are no anecdotes given.,There is no quote given.,"Uh, do you know if Purdue retained lion's levy to market OxyContin?"
The topic they are talking about is public relations firms being hired to assist in the marketing.,They are asking if public relations firms were hired to assist in the marketing.,N/A,N/A,N/A,"Do you know if public relation firms were also hired to assist in the marketing? Uh, and the no"
N/A,They want to finish their question.,N/A,N/A,N/A,"Okay. You gotta, let me finish my question."
The topic is the court reporter's stenographer taking.,They point out that there is a court reporter's stenographer taking.,The fact is that there is a court reporter's stenographer taking.,They do not support their point with an anecdote.,They do not quote an anecdote.,"That's okay. You, you we've got a video, but we also have a court reporter's stenographer taking."
The topic is unclear.,They want to know if the other person can understand their question.,N/A,N/A,N/A,"She can't get it if we both talk the same time. So my question is, do you know, um, can you read my question back?"
They are talking about OxyContin.,They think that OxyContin is a good painkiller and that it has helped them a lot.,The facts they mention are that OxyContin is a very effective painkiller and that it has helped them a lot.,The anecdote they mention is about how OxyContin has helped them with their pain.,"""It's helped me a lot.""",For OxyContin?
The topic is the company Fleshman Hilliard.,The person has not heard of the company.,N/A,N/A,N/A,Have you heard of a company called Fleshman Hilliard?
They are talking about the problem with abuse occurring with OxyContin and that Purdue Pharma hired a crisis management firm.,They point out that there was a problem with abuse occurring with OxyContin and that Purdue Pharma hired a crisis management firm.,The facts are that there was a problem with abuse occurring with OxyContin and that Purdue Pharma hired a crisis management firm.,They do not support their points with anecdotes.,N/A,"Do you recall at some point being notified of a problem with, um, abuse occurring with OxyContin and Purdue Pharma hiring a crisis management firm?"
The topic is a crisis management firm.,They are asking if the other person remembers when a crisis management firm was hired.,N/A,N/A,N/A,Do you recall when that crisis management firm was hired?
The topic is the interview given by Michael Friedman to the crisis management firm.,The person has not read the interview and does not know what it is about.,N/A,N/A,N/A,Have you ever read the interview Michael Friedman gave to the crisis management firm?
The topic is the videos they put out.,They put out videos that help people.,The facts are that they put out videos that help people.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"And in addition to all that, you also put out videos. Are you familiar with the, I got my life back video."
"The person is talking about the ""I got my life back"" video, and the long-term effects of the participants featured in it.","The person's points are that they are curious about the long-term effects of the participants in the ""I got my life back"" video, and whether or not they experienced any negative consequences, such as dependency on OxyContin.",N/A,N/A,N/A,"Uh, did you ever do any follow up to find out whether the participants in there? I got my life back video actually got their life back or wound up having problems with, um, dependency on OxyContin?"
The topic is Purdue.,The person's points are that Purdue gave away coupons for a free week's supply of OxyContin and that this is a bad thing.,The facts are that Purdue gave away coupons for a free week's supply of OxyContin.,There are no anecdotes.,There are no quotes.,"Uh, did Purdue also give away coupons so people could get a weeks free supply of OxyContin?"
The topic is the marketing efforts to sell more OxyContin.,The person's points are that the marketing efforts will be successful and that more OxyContin should be sold.,The facts are that the marketing efforts will be successful.,There are no anecdotes.,There are no quotes.,"And all of the things we've just discussed would be done, um, these marketing efforts to sell more OxyContin, correct con correct."
The topic is OxyContin.,"The person's points are that there is a link between the number of sales representatives and how much OxyContin is prescribed, and that this is a bad thing.",The facts are that there is a link between the number of sales representatives and how much OxyContin is prescribed.,There are no anecdotes.,There are no quotes.,"Um, were you aware that there was a direct link between the number of sales representatives that were out promoting OxyContin and how much OxyContin would be prescribed?"
The topic is whether there is a link between the number of sales representatives and how much OxyContin would be prescribed.,The person's points are that they are unsure if there is a link and would like more information.,N/A,N/A,N/A,"Again? Yeah. Was there a link, a direct link between the number of sales representatives that were out promoting OxyContin and how much OxyContin would be prescribed?"
,"The person's points are that they are unsure if more sales representatives promoting OxyContin would lead to more prescriptions being written, and they want to know if that is the case.",The facts are that the person is unsure if more sales representatives promoting OxyContin would lead to more prescriptions being written.,The claims the person makes are that they are unsure if more sales representatives promoting OxyContin would lead to more prescriptions being written.,The premises the person relies on are that the person is unsure if more sales representatives promoting OxyContin would lead to more prescriptions being written.,"Do you believe that the number of sales representatives that promoted OxyContin, uh, would increase, uh, the more sales represent representatives that promoted OxyContin? The more prescriptions would be written?"
The topic is the correlation between the number of times a sales representative called on a physician and how much OxyContin that physician would prescribe.,The person's points are that the correlation is wrong and that it is harmful.,The facts are that the correlation is between the number of times a sales representative called on a physician and how much OxyContin that physician would prescribe.,There are no anecdotes.,There are no quotes.,Was there also a correlation between the number of times a sales representative called on a physician to how much OxyContin that physician would prescribe?
The topic is not stated.,They do not state any points.,N/A,N/A,N/A,"Why don't we mark the OxyContin lodge plan as 27, 26? I'm sorry."
It is not clear what they are talking about.,They are saying that something is for the person listening.,N/A,N/A,N/A,This is for you. This is for you. This is gonna be
They are talking about the email from you that is dated 10/23/96.,"They think that brackets were not adding, so thank you.",The facts are that the email is from you and it is dated 10/23/96.,They do not support their point with anecdotes.,N/A,"Tony it's okay. Brackets were, uh, were not adding, so, okay. Thank you. Uh, Sackler exhibit 27. And this is an email from you phase four OxyContin team minutes dated 10 23 96."
The topic they are talking about is the idea of having a copy of it.,They think it is a good idea to have a copy of it.,The facts are that it would have been after the launch of OxyContin.,They do not support their point with anecdotes.,They do not quote any anecdote.,"And uh, you have a copy of it. Um, and okay. And so this would've been after the launch of OxyContin, correct?"
the Oxy men 12,Michael is asking what the Oxy men 12 is.,no,no,no,"Okay. And it says here, um, Michael, the Oxy men 12 said, what was the Oxy men 12?"
The topic is the impact of physician attendance at dinner programs or weekend meetings on prescription rates for OxyContin.,The person's points are that the results are encouraging and that the number of increased prescriptions is commercially significant.,The facts are that the results will be presented in more detail at a later date and that the absolute difference persisted.,There are no anecdotes.,There are no quotes.,"Reef that it says results showed the following physicians who attended the dinner programs or the weekend meetings wrote more than double the number of new prescriptions for OxyContin compared to the control group. And this was sustained over the three month post meeting evaluation period weekend meetings had the greatest impact increasing new prescriptions for OxyContin by a factor between 2.16 and 2.62. These results will be presented in more detail at a later date. This is very encouraging. Although I must allow that a proportion of the percentage without the associated absolute numbers is inherent inherently meaningless was the number of increased prescriptions, commercially significant. If so, what would the cost per increased prescription be assuming that the absolute difference persisted, when will a more complete report be available and, um, was that your, um,"
The topic is getting more information.,They want more information.,N/A,N/A,N/A,Did you ever get a more complete report?
N/A,They cannot summarize their points.,N/A,N/A,N/A,"And then above that, it looks like Alfonz writes back to you. And Alfonz was"
The topic they are talking about is Alfonso.,They think Alfonso is a good head of marketing.,The facts are that Alfonso was head of marketing.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Alfonso was head of marketing.
The topic is whether or not the dinners that the representatives took the doctors on were effective in selling OxyContin.,"The person's points are that they wonder if there was a bias in the form of representatives increasing calls to the selected physicians, and they question if the dinners that the representatives took the doctors on were actually helping to sell OxyContin.","The facts are that the representatives increased the call rate to the selected group, and the cost of the dinners would unnecessarily increase the cost per prescription.",There are no anecdotes.,N/A,"And he says interesting comments from Dr. Richard. I also wonder if there was a bias in the form of representatives increasing calls to the selected physicians. Would we get the same ROI? Is that return on investment? Yes. In prescriptions. Sorry. Would we get the same return on investment in prescriptions as a result of the representatives increasing the call rate to the selected group, regardless of dinners, I don't have the list. Therefore, I don't know if there was a selected preference toward this group in the part of the reps. It's reasonable that these core doctors were already receiving special attention, which would've generated an increase in prescriptions. If this is the case, the cost of the dinners would unnecessarily increase the cost per prescription. Right. Did you all ever determine whether the dinners that you were taking the doctors on were helping sell OxyContin?"
Marking something,The person is talking about marking something and then lists off a series of instructions.,No,No,No,"And then let's mark this, uh,"
The topic of the memorandum is an increase in reps selling OxyContin.,The points in the memorandum are that there will be a substantial increase in reps selling OxyContin and that it will be at Abbott's expense.,The facts in the memorandum are that there will be an increase in reps selling OxyContin and that it will be at Abbott's expense.,There are no anecdotes in the memorandum.,There are no quotes in the memorandum.,"And this says 6, 9 99, Dr. Richard Sackler subject promotion of OxyContin by Abbott. And if you go down to the bottom, it says in close for your information is a memorandum that mark Alfonso that describes a substantial increase in Abbott's field force allocation toward OxyContin, one 20 Abbott reps previously selling kinase, which has been temporarily withdrawn from the market will be assigned full time to OxyContin. This will be totally at Abbott's expense and should have a very positive effect on OxyContin sales. Um, that is from Michael Friedman, right? Correct. Um, what was the agreement reached with Abbott to sell"
The topic they are talking about is the possible success of the OxyContin brand.,They think it is good for the brand and hope they can supply the surge that may follow the program.,The facts are that it is good for the brand and there may be a surge in demand.,They do not support their point with anecdotes.,N/A,"Agreement and then up at the top, it says sender Dr. Richard Sackler. So this would be, I think your, your reply to that. And it says, this sounds very good for the brand. I just hope that we can supply the surge that may follow this program. And were you referring to a surge of OxyContin cells?"
The topic they are talking about is helping sexual assault victims.,"They think that by coming forward, sexual assault victims will be helped.",The facts are that sexual assault victims will be helped by coming forward.,They do not support their point with anecdotes.,N/A,"And was it your expectation that,"
The topic is whether or not sales representatives will create a surge in OxyContin sales.,"The person's points are that they are unsure if sales representatives will create a surge in OxyContin sales, and they would like more information on the topic.",N/A,N/A,N/A,"Thank you. These sales representatives, uh, were going to create a surge in OxyContin sales?"
The topic is OxyContin.,The person's points are that they had a discussion with the officers about OxyContin and that the officers said that OxyContin is not as strong as morphine.,The facts are that the officers said that OxyContin is not as strong as morphine.,There are no anecdotes.,There are no quotes.,"And then this is a document, um, that I wanted to bring to your attention, cuz we were talking earlier than today where you said, you know, uh, when I was pointing out to you, the documents that, uh, from your, uh, officers that said OxyContin is believed by other physicians to be not as strong as morphine. Remember us having that discussion."
The topic is being thankful.,They think it is good to be thankful.,The facts are that being thankful is good for you.,They do not support their points with anecdotes.,N/A,Thank
The topic is OxyContin.,They point out that OxyContin has been on the market for over a year and a half and that it is doing well.,The facts are that OxyContin has been on the market for over a year and a half.,They do not support their point with anecdotes.,N/A,"And this is a phase two OxyContin tablets team meeting June 13th, 1997. So this would be, um, well over a year after a year and a half after OxyContin has been launched and on the marketplace, correct?"
The topic is marketing and sales update.,"The person's points are that they want to expand into the non-cancer market segment and that they can show that they are as effective as morphine, but do not want to say that OxyContin is more powerful than morphine.","The facts are that they want to expand into the non-cancer market segment and that they can show that they are as effective as morphine, but do not want to say that OxyContin is more powerful than morphine.",There are no anecdotes.,N/A,"And S and if you could go to the, um, it says marketing and sales update. First paragraph Mike CU discussed in detail marketing's positioning of OxyContin. He explained we want to expand extensively in the non-cancer market segment while promoting OxyContin as the one to start with in cancer pain and the one to stay with through proper. And the next paragraph reads, we can show that we are as effective as morphine, but do not want to say OxyContin is as powerful as morphine. Uh, now did I read that correctly?"
The topic they are talking about is a drug.,"They think that some people may think the drug is dangerous because of the word ""powerful.""",N/A,N/A,N/A,"Words such as powerful may make some people think the drug is dangerous and should be reserved for the more severe pain,"
"The topic they are talking about is including that OxyContin is effective in as morphine, but not saying it is as powerful as morphine.","The person's points are that they want to include that OxyContin is effective in as morphine, but does not want to say that it is as powerful as morphine because it may make some people think the drug is dangerous.","The facts are that if they say OxyContin is as powerful as morphine, it may make some people think the drug is dangerous.",There are no anecdotes.,There is no quote.,"Yes. Um, we'll read it again and include that we can sh second paragraph. We can show that we are effective in as morphine, but do not want to say OxyContin is as powerful as morphine words such as powerful may make some people think the drug is dangerous and should be reserved for the more severe pain. This could have a negative effect in the much larger non-cancer pain market. Mike reminded the team that we should keep this positioning in mind as we develop future marketing programs, symposia clinical study manuscripts, and any other items that discussed the use of OxyContin. Um, did I read that correctly?"
The topic is OxyContin.,"The person's points are that the marketing and sales team were being careful not to say that OxyContin is as powerful as morphine, and that this is a problem.",The facts are that the marketing and sales team were being careful not to say that OxyContin is as powerful as morphine.,There are no anecdotes.,There is no quote.,"All right. Were you aware that that your marketing and sales team were being careful not to, uh, and did not want to say that OxyContin is as powerful as morphine?"
The topic is whether or not the person thinks it is a good idea.,They think it is a good idea because it is twice as powerful as morphine.,The fact is that it is twice as powerful as morphine.,They do not support their point with anecdotes.,N/A,"And in effect it's twice as powerful as morphine, correct?"
The topic is whether OxyContin is as powerful as morphine.,"The person's points are that doctors may think OxyContin is not as powerful as morphine, and that this could be a problem.",The facts are that doctors may think OxyContin is not as powerful as morphine.,There are no anecdotes.,There are no quotes.,"When you go in and see a doctor and you say, uh, if they say OxyContin is not as powerful as morphine, what do you think the doctor thinks"
,They think he is a good person because he gave them something.,The anecdote is that he gave them something.,They think he is a good person because he gave them something.,"""That he gave.""",That he gave
N/A,They want to know what it is.,N/A,N/A,N/A,Go ahead. We'll come back to that. What is this?
,They think it will be a great time.,The anecdote is about a great time they had.,They claim that it will be a great time.,They rely on the premise that it will be a great time.,Be a great time.
The topic is whether or not the number of calls made by a salesperson affects the number of prescriptions for OxyContin.,They are asking if the number of calls made by a salesperson affects the number of prescriptions for OxyContin.,N/A,N/A,N/A,"Okay. Um, a while ago when we were talking about salespeople making calls, did I understand you to say that you did not believe the number of calls made by a salesperson affected the number of prescriptions for OxyContin?"
The topic they are talking about is that Purdue had requirements on their salespeople that they had to make certain number of calls every day to physicians.,They think that Purdue had requirements on their salespeople that they had to make certain number of calls every day to physicians and this is correct.,The facts are that Purdue had requirements on their salespeople that they had to make certain number of calls every day to physicians.,They do not support their point with anecdotes.,N/A,"Thank you. Uh, in fact, Purdue had, uh, requirements on their salespeople that they had to make certain number of calls every day to physicians, correct."
The topic they are talking about is how to change the perception of OxyContin by physicians.,They are discussing an email from 1997 that discussed how physicians did not think OxyContin was as strong as MS Contin and that it was important to be careful not to change the perception by physicians toward oxycodone when developing promotional pieces.,"The facts are that in an email from 1997, it was discussed how physicians did not think OxyContin was as strong as MS Contin and that it was important to be careful not to change the perception by physicians toward oxycodone when developing promotional pieces.",They do not support their point with anecdotes.,N/A,"And, uh, before we broke, we were discussing this, um, phase two OxyContin, uh, tablets team meeting. And to kind of put this in perspective, there was this email dated 6, 2 97. So that's June 2nd 97 that we were discussing earlier where we discussed that physicians did not think OxyContin was as strong as MS Contin and that perception was out there. And, uh, and, uh, noted that it was important to be careful not to change the perception by physicians toward oxycodone when developing promotional pieces. Um,"
N/A,They are not making any points.,N/A,N/A,N/A,We've already talked about it earlier. I'm just asking a question right now.
The topic they are talking about is a conversation they had with the person.,They are asking if the person recalls a conversation they had.,N/A,N/A,N/A,"Document. I won't read from it then. Uh, let me ask you, do you recall us having that conversation?"
The topic they are talking about is the effectiveness of the vaccine.,They think it is effective.,The facts are that it is effective.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"Yes. And, and your comment was, well, we're not saying that it's not as strong. We're saying it's not as effective. Um, uh, I'm sorry. I object to the form in that question, your comment was, we're not trying to convey that. Um, it's not as powerful, uh, is that correct?"
The topic they are talking about is the song.,They think it is a good song and they like it.,The facts are that it is a good song and they like it.,The anecdote is that they wrote it.,"""Here's the one we were talking about when we wrote,""","Here's the one we were talking about when we wrote,"
They are talking about the placement of something.,They think it is good because it is on the bottom.,The fact is that it is on the bottom.,They do not support their point with an anecdote.,They do not quote an anecdote.,It's on the bottom
"The topic the person is talking about is the use of the words ""effective"" and ""powerful"" in relation to OxyContin.","The person's points are that the words ""effective"" and ""powerful"" are in quotes and that the sentence reads that OxyContin is not as powerful as morphine.","The facts are that the words ""effective"" and ""powerful"" are in quotes and that the sentence reads that OxyContin is not as powerful as morphine.",There are no anecdotes.,There is no quote.,"And they've actually used two words here that are in quotes, correct. One is effective and one is powerful. And the sentence reads, we can show that we are as effective as morphine, but we do not want to say OxyContin is as powerful as morphine. Did I read that correctly?"
The topic they are talking about is the GAO report on OxyContin abuse and diversion.,They think the efforts to address the problem are good.,"The facts are that the GAO put out a report in December, 2003 about OxyContin abuse and diversion.",They do not support their point with anecdotes.,N/A,"All the, have you reviewed the OxyContin abuse and diversion and efforts to address the problem that was put out in December, 2003 by the GAO?"
The topic is giving a copy of the document.,They think it is a good idea and they want to show it to the person.,The facts are that the document exists and the person has never seen it.,They do not support their point with anecdotes.,N/A,Give you a copy of that. You've never seen that document. Is that correct?
The topic is not clear.,The person's points are that they are not sure and they need more information.,N/A,N/A,N/A,"Uh, I will, yes. Okay. But have you ever seen that document?"
They are talking about the sales of OxyContin.,They are questioning whether the information is correct.,"The facts are that in 2001 and 2002, OxyContin sales exceeded 1 billion and prescriptions were over 7 million.",They do not support their point with anecdotes.,N/A,"If you would turn to page nine and I'm looking at the second paragraph last two sentences in both 2001 and 2002 OxyContin sales exceeded 1 billion, 1 billion and prescriptions were over 7 million. The drug became Purdue main product accounting for 90% of the company's total prescription sales by 2001. Um, is that information correct?"
They are talking about Purdue's marketing of OxyContin.,They think that Purdue was trying to get OxyContin prescribed for more people even though it wasn't always necessary. They think that this was done by targeting primary care physicians and giving them incentives to prescribe the drug.,The facts are that Purdue was trying to get OxyContin prescribed for more people and they did this by targeting primary care physicians.,They do not support their points with anecdotes.,N/A,"And if you'll turn to page 17, it under the heading Purdue focused on promoting OxyContin for treatment of non-cancer pain. And if you go down to the last sentence of the second paragraph, it says one of Purdue's goals was to identify primary care physicians who would expand the company's OxyContin prescribing base sales representatives were also directed to call on oncology nurses, consultant, pharmacists, hospices, hospitals, and nursing homes. And is that information accurate,"
The topic the person is talking about is the accuracy of the statement that by 2003 primary care physicians had grown to constitute nearly half of all OxyContin prescribers.,"The person's points are that Purdue has stated that by 2003 primary care physicians had grown to constitute nearly half of all OxyContin prescribers based on data, and that this data is from IMS health and information service providing pharmaceutical market research.","The facts are that Purdue has stated that by 2003 primary care physicians had grown to constitute nearly half of all OxyContin prescribers based on data, and that this data is from IMS health and information service providing pharmaceutical market research.",There are no anecdotes.,There are no quotes.,"And then down second sentence from the bottom, Purdue has stated that by 2003 primary care physicians had grown to constitute nearly half of all OxyContin prescribers based on data, data from IMS health and information service providing pharmaceutical market research. Is that information accurate?"
They are talking about the OxyContin.,They point out that the scope of medical specialties was wider for OxyContin than five other controlled release scheduled to narcotic animal DEA.,The facts are that the scope of medical specialties was wider for OxyContin than five other controlled release scheduled to narcotic animal DEA.,They do not support their point with anecdotes.,N/A,"The next sentence says Deas analysis of physicians, prescribing OxyContin found that the scope of medical specialties was wider for OxyContin than five other controlled release scheduled to narcotic animal DEA. And is that the drug enforcement agency?"
The topic is the DEA expressing concern.,The individual's points are that the DEA expressed concern and that they want to know if the person recalls the DEA expressing that concern.,The facts are that the DEA expressed concern and that they want to know if the person recalls the DEA expressing that concern.,There are no anecdotes.,There is no quote.,"DEA expressed concern that this resulted in OxyContin being promoted to physicians who were not adequately trained in pain management. Uh, do you recall the DEA expressing that concern?"
The topic the person is talking about is the increase in prescriptions for OxyContin.,"The person's points are that the data may not be accurate, and that if it is accurate, it shows a significant increase in prescriptions for OxyContin.","The facts are that, according to IMS health data, the annual number of OxyContin prescriptions for non-cancer pain increased nearly tenfold from about 670,000 in 1997 to 6.2 million in 2002.",There are no anecdotes.,N/A,"Next two sentences produced promotion of OxyContin for the treatment of non-cancer pain contributed to a greater increase in prescriptions for non-cancer pain. Then for cancer pain from 1997 through 2002, according to IMS health data, the annual number of OxyContin prescriptions for non-cancer pain increased nearly tenfold from about 670,000 in 1997 to 6.2 million in 2002. Um, is that information accurate?"
The topic is unknown.,They want the person to go to a specific page.,N/A,N/A,N/A,If you'd go to page
The topic the person is talking about is Purdue's increase in sales representatives.,The person's points are that Purdue's increase in sales representatives led to an increase in the number of physicians to whom it was promoting OxyContin.,The facts are that Purdue's increase in sales representatives led to an increase in the number of physicians to whom it was promoting OxyContin.,There are no anecdotes.,There are no quotes.,"Uh, paragraph by more than doubling its total sales representatives, Purdue significantly increased the number of physicians to whom it was promoting OxyContin."
,The person summarizes the points made about how Purdue was marketing OxyContin.,The facts are that Purdue sales representatives had a list of physicians to call on and that they were expected to make a certain number of calls per week.,The person does not quote any anecdotes.,The person makes the claim that the information about how Purdue was marketing OxyContin is accurate.,"Uh, each Purdue sales representative had specific sales territory and is responsible for developing a list of about a hundred, five to 140 physicians to call on who already prescribe opioids or who or who are candidates for prescribing opioids. In 1996, the 300 plus Purdue sales representatives had a total physician call list of approximately 33,400 to 44,500 by 2000, the nearly 700 representatives had a total call list of approximately 70,500 to 94,000 physicians. Each Purdue sales representative is expected to make 35 physician calls per week, and typically calls on each physician every three to four weeks. Each hospital sales representatives is expected to make about 50 calls per week and typically calls on each facility every four weeks. Uh, was that to your knowledge, accurate information about how Purdue was, uh, marketing OxyContin through its sales force econ through its Salesforce?"
The topic they are talking about is how the total amount of bonuses that Purdue estimated were tied to OxyContin cells increased significantly from about 1 million in 1996 to 40 million in 2001.,They are talking about how the total amount of bonuses that Purdue estimated were tied to OxyContin cells increased significantly from about 1 million in 1996 to 40 million in 2001.,The facts are that the total amount of bonuses that Purdue estimated were tied to OxyContin cells increased significantly from about 1 million in 1996 to 40 million in 2001.,They do not support their point with anecdotes.,N/A,"All right. And if you'll go down to the middle of that next paragraph, the total amount of Bo the amount of total bonuses that Purdue estimated were tied to OxyContin cells increased significantly from about 1 million in 1996, when OxyContin was first marketed to about 40 million in 2001, do you recall, uh, do you have any reason to, um, disagree with the 40 million number for bonuses paid out to your marketing salesman? In 2001?"
The topic they are talking about is the amount of money Purdue spent on promotional efforts for Oxycontin.,They are summarizing the points.,The facts are that Purdue spent more on promotional efforts during Oxycontin's first six years on the market than it had spent on its older product.,There are no anecdotes.,There are no quotes.,"And then if you go to the next page, um, last paragraph, it says, according to Deas analysis of IMS health data, Purdue spent approximately six to 12 times more on promotional efforts during Oxycontin's first six years on the market than it had spent on its older product. MS. Contin during its first six years, or then had been spent by Janssen pharmaceutical or one of Oxycontin's drug, uh, competitors. Duragesic. Did you see"
The topic is unknown.,They do not provide any points.,N/A,N/A,N/A,Did. Is that
The topic is whether Purdue marketing was overly aggressive.,The person's points are that Purdue's marketing campaign was ambitious and that it is difficult to say whether it was too aggressive.,The facts are that Purdue's marketing campaign was ambitious and that it is difficult to say whether it was too aggressive.,There are no anecdotes.,There are no quotes.,Do you believe Purdue marketing was overly aggressive?
The topic is Purdue marketing.,The person's points are that they are unsure if Purdue marketing was appropriate and they would like to know the opinion of the person they are speaking to.,N/A,N/A,N/A,"Um, <affirmative> yeah. Do you believe Purdue marketing was appropriate?"
The topic is Oxycontin's wide availability.,They are reading from a document and summarizing what it says.,The facts are that Oxycontin's wide availability may have increased opportunities for illicit use.,N/A,N/A,"Um, it says here under on page 30 Oxycontin's wide availability may have increased opportunities for illicit use. Um,"
They are talking about a specific page.,They are looking for a specific page.,N/A,N/A,N/A,Page 30?
Unknown,They have not stated any points.,N/A,N/A,N/A,"Um, last paragraph."
The topic they are talking about is OxyContin.,They think that the large amount of OxyContin available in the marketplace has increased opportunities for abuse and diversion.,"The facts are that OxyContin became the top selling name, brand narcotic pain reliever in 2001.",They do not support their point with anecdotes.,N/A,"Thank you. The large amount of OxyContin available in the marketplace may have increased opportunities for abuse and diversion, both DEA and Purdue have stated that an increase in a drugs availability in the marketplace may be a factor that attracts interest by those who abuse and divert drugs. OxyContin. Uh, if you go on down, um, OxyContin became the top selling name, brand narcotic pain reliever in 2001. Um, is that accurate?"
The topic the person is talking about is the poster children of OxyContin.,The person's points are that they are not sure what happened to the poster children of OxyContin and they are curious about it.,There are no facts given.,There are no anecdotes given.,There are no quotes given.,"Yeah. So, um, let's mark that as exhibit 30 30. Have you ever seen an article called what happened to the poster children of OxyContin?"
Purdue Pharma,They argue that Purdue Pharma has not provided anything to the public.,N/A,N/A,N/A,Nobody has ever provided that to you at Purdue Pharma.
The topic is unknown.,They do not state any points.,N/A,N/A,N/A,"September 8th, 2012?"
The topic the person is talking about is whether Purdue OxyContin was successful.,"The person's points are that other companies were thinking about making their own version of OxyContin, which could mean that Purdue OxyContin was successful.",The facts are that other companies were thinking about making their own version of OxyContin.,There are no anecdotes.,N/A,Do you recall a time when Purdue OxyContin was considered so successful that other companies were thinking about whether they could make their own version of OxyContin?
The topic the person is talking about is OxyContin.,The person's points are that other companies were considering making their own version of OxyContin and that OxyContin was considered successful at the time.,The facts are that other companies were considering making their own version of OxyContin and that OxyContin was considered successful at the time.,There are no anecdotes.,There are no quotes.,Sure. Do you recall a period of time where OxyContin was considered so successful that other companies were considering making their own version of OxyContin?
They are talking about the email chain that was provided.,They think it is a good idea and are excited about it.,"The facts are that it is an email chain that was provided and it says subject press release or similar promotion author, Dr. Richard Sackler 8 23 96.",They do not support their point with anecdotes.,N/A,"So this is an email chain that was provided. Um, let's go ahead and mark that as 31. And, um, if you go to page two, it says subject press release or similar promotion author, Dr. Richard Sackler 8 23 96."
The topic is the amount of money that the average American family spends on gasoline.,"The person's points are that the average American family spends $1,200 a year on gasoline, and that this is a lot of money.","The facts are that the average American family spends $1,200 a year on gasoline.",There are no anecdotes.,There are no quotes.,"And it says, um,"
The topic is releasing information on OxyContin tablets.,The person's points are that the product has been successful and that releasing information would lead to more physicians prescribing it.,The facts are that the product has been successful and that releasing information would lead to more physicians prescribing it.,There are no anecdotes.,There are no quotes.,"I think it is no worthy to release information on OxyContin tablets, its use and success in the market and the tremendous reception it received in Vancouver. Uh, we've basically, uh, the newsworthy occasion is that this product has achieved our first year sales projection, four months early. And that by the end of the year, we should have from 130,000 to 150,000 per salesman of sales, the objectives of this release would be stimulate interest in the us community, in the medical community of the us to recognize the tremendous success of OxyContin tablets clinically, and the ratification commercially, we want many more physicians than have presently used it to become aware of its availability and importance in their practice. It would be hope that this would lead to greater use by those currently prescribing and broaden our prescribing base in the us and Canada."
The press release,Asking a question,N/A,N/A,N/A,"And, um, do you know whether that press release took place?"
The topic is a great idea.,They think it is a great idea and they are excited about it.,The facts are that it is a great idea and they are excited about it.,They do not support their point with anecdotes.,N/A,"And then above that, it looks like there's a response to your email from Robert reader."
They are talking about the best way to achieve all goals.,They think that a full flesh PR firm with a one to three year contract is the best way to achieve all goals.,The facts are that a full flesh PR firm with a one to three year contract is the best way to achieve all goals.,They do not support their point with anecdotes.,N/A,"Given the diverse, in both short and midterm goals, I would recommend a full flesh PR firm with a one to three year contract. That way this can be coordinated, actively to achieve all goals rather than a one shot flash. Is this a departure from traditional P slash P LP and that's Purdue Frederick slash Purdue Pharma LP strategy,"
The topic they are talking about is PR.,They support their points with facts and anecdotes.,"Yes, they support their point with facts.","Yes, they support their point with anecdotes.",They do not quote the anecdote.,"And you wrote back and said, I don't see this as a quote departure from policy. And then it looks like, and perhaps this is Friedman who says, my view is different. If you want to use PR to signal our market as to our development pipeline, I have no problem. I do not want to spend money on PR to increase sales. We do not need to have an agency in our pockets. I have learned my lessons. And then you write back on the page one and say, I agree about the agency. I want to signal the licensing in market for the product around the world, get an audience for our patent infringement suits so that we are feared as a tiger with claws, teeth, and balls, and build some excitement with prescribers. That OxyContin tablets is the way to go. And what was your concern there about, uh, licensing and patent infringement?"
The topic they are talking about is Howard UDel's trip to Kentucky.,They are trying to remember if Howard UDel made a trip to Kentucky to meet with attorney general Greg Stubo.,N/A,N/A,N/A,"Do you recall, um, Howard UDel making a trip down to Kentucky to meet with attorney general, Greg Stubo and other members of the,"
The topic is the President's staff.,The person's points are that he does not know many of his staff and does not want to get to know them because they are not his people.,The facts are that the person does not know many of his staff.,There are no anecdotes.,There is no quote.,Of his staff?
They are talking about the date of the letter.,They point out that the letter is dated before the plea agreement.,The facts are that the letter is dated before the plea agreement.,There are no anecdotes.,There is no quote.,"This is a letter dated May 17th, 2005. And that would be prior to the felony plea agreement that Purdue Frederick entered into. Correct."
"The topic is that none of the federal courts in Kentucky has found any misconduct on the part of Purdue, correct?","They point out that none of the federal courts in Kentucky has found any misconduct on the part of Purdue, correct?","The facts are that none of the federal courts in Kentucky has found any misconduct on the part of Purdue, correct?",They do not support their point with anecdotes.,N/A,"And on you'll turn to page six, this is appears to be a letter from Howard UAL dated May 17th, 2005 to Greg, the attorney general of Kentucky. And he points out that, um, none of <affirmative>, none of the federal courts in Kentucky has found any misconduct on the part of Purdue, correct?"
N/A,They have not stated any points.,N/A,N/A,N/A,I'm sorry. I'm on page five.
The topic is the third paragraph down.,They think it is a good idea and they support their points with facts.,The facts are that it is a good idea and it will help people.,They do not support their point with anecdotes.,N/A,The third paragraph down.
They are talking about the courts' findings on the matter of Purdue's misconduct.,They think that the courts have not found any misconduct on the part of Purdue.,The facts are that none of the courts have found any misconduct on the part of Purdue.,They do not support their point with anecdotes.,N/A,"No, it's, I'm reading middle of the paragraph significantly Howard, not one of these courts has found any misconduct on the part of Purdue."
The topic is a good idea.,They think it is a good idea and support their point with facts.,The facts are that it is a good idea and it will help people.,They do not support their point with anecdotes.,N/A,You see that right above the case sites.
The topic they are talking about is paragraph.,They think it is a good idea and support it.,The facts are that paragraph.,They do not support their point with anecdotes.,N/A,"Yes. Paragraph,"
The topic the person is talking about is Purdue's filing in cases and claims of wrongdoing.,"The person's points are that Purdue has filed an answer in all of these cases and claimed they had never done anything improper or wrong, and asks if that is true.",The facts are that Purdue has filed an answer in all of these cases and claimed they had never done anything improper or wrong.,N/A,N/A,Yeah. Purdue answered file an answer in all of these cases and claim they had never done anything improper or wrong. Isn't that true?
,,,,,"Are you aware prior to the,"
The topic is whether Purdue has done anything improper.,The person's points are that they are unsure if Purdue has done anything improper and that the company pled guilty to a felony.,The facts are that the company pled guilty to a felony.,There are no anecdotes.,There are no quotes.,"Are you aware of Purdue ever admitting to doing anything improper? Um, um, prior to the plea agreement where, um, the company pled guilty to a felony of misbranding a drug with the intent to defraud or mislead."
The topic is whether anyone at Purdue has admitted to anything improper.,The person's points are that they are unsure if anyone at Purdue has admitted to anything improper and they want to know if this is the case.,N/A,N/A,N/A,Are you aware of anyone at Purdue ever admitting they did anything improper prior to entering into the plea agreement where the company pled guilty to miss branding a drug with the intent to defraud or mislead?
The topic they are talking about is whether or not a defendant has committed an unlawful act.,They are questioning whether or not a defendant has committed an unlawful act.,"The facts are that a defendant has to prove that a practice of violation has occurred in order to file a suit, and that Purdue has not committed any unlawful act.",There are no anecdotes.,N/A,"And then if you go to page six, the middle of the second paragraph from the bottom, it says first, uh, any suit bought under the act requires proof that a defendant engaged in a practice of violation of KRS 360 7, 1 70, an insurmountable obstacle since Purdue has committed no unlawful act. Um, did I read that correctly?"
"The topic is Howard UDel's alleged unlawful act on May 17th, 2005.","They think that Howard UDel committed an unlawful act on May 17th, 2005.","The facts are that Howard UDel had communicated with Greg stumble that Purdue had commuted, committed.",They do not support their point with anecdotes.,N/A,"And were you aware that Howard UDel had communicated with Greg stumble that Purdue had commuted, committed? No. Unlawful act on May 17th, 2005."
"The topic is that Purdue Frederick existed from May 17th, 2005.",They support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,"Yeah. From May 17th, 2005, did Purdue Frederick exist?"
Companies,The person is asking if the companies were merged at some point,N/A,N/A,N/A,Do you know if the companies were merged at some point?
The topic they are talking about is the agreed statement of facts.,They want to make sure they have another copy of the agreed statement of facts.,The facts are that they want to make sure they have another copy of the agreed statement of facts.,There are no anecdotes.,There are no quotes.,Let's talk about the agreed statement of facts. Do we have another copy of this
The topic is marking the letter.,The person's points are that they have been told multiple times not to mark the letter and that it is a bad habit.,The facts are that the person has been told multiple times not to mark the letter.,There are no anecdotes.,There are no quotes.,"Mark the letter? Oh,"
The topic is the idea.,They think the idea is good and should be done.,N/A,N/A,N/A,Yeah. That's a good idea to
The topic they are talking about is handing out the letter.,They think that handing out the letter will be helpful.,The facts are that handing out the letter will be helpful.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Hand this out by the letter.
They are talking about the person in charge of preparing and approving the sales and marketing materials for Oxycontin.,They point out that the person in charge of preparing and approving the sales and marketing materials for Oxycontin was also in charge of preparing and approving the sales and marketing materials for a similar drug that was previously pulled from the market.,The facts are that the person in charge of preparing and approving the sales and marketing materials for Oxycontin was also in charge of preparing and approving the sales and marketing materials for a similar drug that was previously pulled from the market.,They do not support their point with anecdotes.,N/A,Who was in charge of preparing and approving the sales and marketing materials at the time of Oxycontin's release?
"The topic they are talking about is the song ""Release"" by Beyonc.",They think the song is good.,"The facts are that the song was written by Beyonc, Terius Nash, Shea Taylor, Ester Dean, and Cainon Lamb, and that it was produced by Hit-Boy, Beyonc, and Lamb.",They do not support their point with anecdotes.,N/A,Release
They are talking about the launch.,They point out that someone was in charge of the marketing department at the time of the launch.,The fact is that someone was in charge of the marketing department at the time of the launch.,They do not support their point with an anecdote.,N/A,"And at that time, at the time of the launch who was in charge of the marketing department"
The topic they are talking about is whether or not Michael Friedman was appointed CEO of Purdue.,They are asking if Michael Friedman was the person who was appointed CEO of Purdue.,N/A,N/A,N/A,"Okay. And Michael Friedman, was he the person who ultimately was appointed CEO of Purdue?"
They are talking about an individual's criminal record.,They want to know if the person in question pled guilty to a misdemeanor as part of a plea agreement.,They do not provide any facts.,They do not provide any anecdotes.,They do not quote any anecdote.,Is he one of the individuals who pled guilty to the misdemeanor at the time of the plea agreement?
The topic is Purdue's marketing of Ms. Cotton.,They are asking if the person recalls whether Purdue had received warning letters about its marketing of Ms. Cotton.,N/A,N/A,N/A,Do you recall whether Purdue had received warning letters about its marketing of Ms. Cotton?
The topic is that they cannot recall six warning letters coming in from Ms. Cotton.,They cannot recall six warning letters coming in from Ms. Cotton.,The facts are that they cannot recall six warning letters coming in from Ms. Cotton.,There are no anecdotes.,There are no quotes.,"You don't recall six warning letters coming in from Ms. Cotton? Uh,"
The topic they are talking about is Purdue's marketing of OxyContin.,They are saying that Purdue got warning letters for the way it marketed OxyContin.,The facts are that Purdue got warning letters for the way it marketed OxyContin.,They do not support their point with anecdotes.,N/A,"Do you recall Purdue getting warning letters with respect to the way it was marketing Ms. Uh, marketing OxyContin?"
Purdue University,The person is asking if Purdue University denied that it was doing anything wrong in marketing OxyContin.,N/A,N/A,N/A,"Do you know if Purdue, um, consistently denied it was doing anything wrong with respect to marketing OxyContin?"
The topic they are talking about is the stimulus package.,They think it is a good idea and they support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,All right. The
The topic is the person's guilt.,They think that the person is guilty and that they should have to face the consequences.,The facts are that the person is guilty and that they should have to face the consequences.,There are no anecdotes.,There are no quotes.,Were you involved in approving the agreed statement of facts or the guilty plea?
They are talking about the board adopting the agreed statement of facts.,They want to make sure that there is no confusion and that the board adopts the agreed statement of facts.,The facts are that the board voted to adopt the agreed statement of facts.,They do not support their point with anecdotes.,N/A,"And just so there's no confusion, the board, uh, and voted to adopt the agreed statement of facts. Um, is that correct?"
The topic is the accuracy of the agreed statement of facts.,They question the accuracy of the agreed statement of facts.,The facts are that they question the accuracy of the agreed statement of facts.,There are no anecdotes.,There is no quote.,"Uh, is the agreed statement of facts accurate?"
The topic is the drug OxyContin.,The points are that the drug is being misbranded and that it is harmful.,The facts are that the drug is being misbranded and that it is harmful.,There are no anecdotes.,There are no quotes.,"And in addition to the guilty plea of a felony for, or misbranding a drug with the intent to defraud on mislead, uh, and that drug is OxyContin, correct?"
The topic they are talking about is the criminal justice system.,They support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,"These three individuals, Howard UDel, Michael Friedman, and Paul Goldenheim also pled guilty to misdemeanors, correct?"
The topic they are talking about is Howard UDel.,They think that Howard UDel is a great executive vice president and chief legal officer.,The facts are that Howard UDel is a great executive vice president and chief legal officer.,They do not support their point with anecdotes.,They do not quote any anecdotes.,And Howard UDel was produced executive vice president and chief legal officer.
The topic the person is talking about is Michael Friedman.,The person's points are that Michael Friedman was a good president and CEO and that he did a lot of good for the company.,The facts are that Michael Friedman was the president and CEO of Purdue at the time of the guilty plea.,The anecdote is about how Michael Friedman did a lot of good for the company.,"The person quotes the anecdote by saying ""Michael Friedman was the president and CEO of Purdue at the time of the guilty plea.""",Michael Friedman was the president and CEO of Purdue at the time of the guilty plea.
They are talking about Paul Goldenheim.,They think that Paul Goldenheim did a great job as the executive vice president for worldwide research and development in chief scientific officer.,The facts are that Paul Goldenheim was the former executive vice president for worldwide research and development in chief scientific officer.,They do not support their point with anecdotes.,N/A,"Was. And Paul Goldenheim was the former executive vice president for worldwide research and development in chief scientific officer, correct?"
The topic is whether or not Dr. Goldenheim left Purdue voluntarily.,They are questioning whether or not Dr. Goldenheim left Purdue voluntarily.,The facts are that Dr. Goldenheim left Purdue in 2006.,They do not support their point with anecdotes.,N/A,"Uh, by 2006, Dr. Goldenheim had already left Purdue, correct? Yes. Did he leave voluntarily?"
The topic is why the person is leaving Purdue.,The person asks for the reason the other person is leaving Purdue. ,N/A,N/A,N/A,What reason did he provide you regarding why he was leaving Purdue?
The topic is the agreed statement of facts.,They support their points with facts.,They do not support their point with anecdotes.,,,"And have you seen this agreed statement of facts before,"
The topic is the document.,They are asking if the person provided comments on the document.,N/A,N/A,N/A,"Uh, did you provide comments on this document?"
The topic is the allegations in the document.,The person's points are that they were not surprised by the allegations and that the document does not contain new information.,The facts are that the person was not surprised by the allegations and that the document does not contain new information.,There are no anecdotes.,There are no quotes.,Were you surprised by any of the allegations in the document?
The topic is whether or not the person has read the entire document.,The person's points are that they have not read the entire document and they are questioning if the other person has read it.,The facts are that the person has not read the entire document.,There are no anecdotes.,There are no quotes.,"Okay. And when you say I didn't read the document, uh, as we sit here today, have you ever read the entire document?"
The topic the person is talking about is their position in the company at the time a document was signed.,The person's points are that they do not remember their position in the company at the time and that they want to know more about the topic.,The facts are that the person was employed by the company at the time the document was signed.,There are no anecdotes.,There are no quotes.,"Um, at the time this was signed in, uh, May 7th and eighth of 2007. What was your position in the company?"
The topic is unknown.,They are asking if the person had any other role at the time.,N/A,N/A,N/A,Did you have any other role at that time?
They are talking about the investigation of Purdue.,They point out that the CEO was notified of the investigation.,The facts are that the CEO was notified of the investigation.,There are no anecdotes.,N/A,"You ceased to be CEO in 2003. Is that correct? That's correct. When were you first notified that the, uh, us attorneys for the Western district of Virginia were investigating Purdue?"
The topic is not clear.,They are asking a question to gather information.,N/A,N/A,N/A,Was it before you left as CEO?
"The topic the person is talking about is the issues with addiction, dependency, tolerance buildup, abuse, and diversion prior to the CEO's departure.","The person's points are that there were issues with addiction, dependency, tolerance buildup, abuse, and diversion prior to the CEO's departure.","The facts are that there were issues with addiction, dependency, tolerance buildup, abuse, and diversion prior to the CEO's departure.",The person does not support their points with anecdotes.,N/A,"Do you recall there being issues about, uh, addiction, dependency, uh, tolerance buildup, uh, abuse and diversion, uh, prior to your leaving the CEO?"
The topic is addiction.,The person's points are that addiction is a problem and that there are issues with addiction.,The facts are that addiction is a problem and that there are issues with addiction.,The person does not support their point with anecdotes.,N/A,"Do you recall there being issues, uh, with addiction?"
The topic is abuse and diversion.,"The person's points are that they do not remember when they were first informed about possible abuse and diversion, and they would like to know more information about the topic.",The facts are that the person does not remember when they were first informed about possible abuse and diversion.,There are no anecdotes.,There are no quotes.,And when were you first informed about possible abuse and diversion?
The topic they are talking about is the problems with patients who were on OxyContin.,They are talking about how there have been problems with patients who were on OxyContin.,The facts are that there have been problems with patients who were on OxyContin.,They do not support their point with anecdotes.,N/A,"Okay. Let me see. Do you recall receiving a letter or being notified about a letter from a hospital in, um, Pikeville or hazard concerning, um, problems with patients who were on OxyContin?"
The topic they are talking about is the request for Purdue to identify the names of documents referenced in the agreed statement of facts.,They think it came to Purdue and they are wondering if the person saw the request for Purdue to identify the names of documents referenced in the agreed statement of facts.,The facts are that they have requested Purdue to identify the names of documents referenced in the agreed statement of facts.,They do not support their point with anecdotes.,N/A,"I don't believe so. I think it came to Purdue. And I'm wondering if you saw it's, let's go back to the plea agreement. We'll try to get through this. Um, um, okay. Um, are you aware that we've requested Purdue to identify the names of documents referenced in the agreed statement of facts?"
The topic is the agreed statement of facts.,They are asking if the other person is aware of the agreed statement of facts and if the individuals referenced have been identified.,N/A,N/A,N/A,"Um, are you aware, we've asked them to identify the individuals who are referenced in the agreed statement of facts?"
They are talking about the safety and effectiveness of OxyContin.,They are summarizing a point.,"The facts are that on December 28th, 2004, produced submitted an OxyContin NDA, the FDA, the NDA included clinical trials showing that OxyContin when dosed every 12 hours was as safe and as effective as immediate release oxycodone, dosed every 12 hours.",They do not support their point with anecdotes.,N/A,"Paragraph, if we can go to paragraph 13 of the agreed statement of paragraph 13 says that on December 28th, 2004, produced submitted an OxyContin NDA, the FDA, the NDA included clinical trials showing that OxyContin when dosed every 12 hours was as safe and as effective as immediate release oxycodone, dosed every 12 hours,"
They are talking about the hours.,They think it is good that the hours are every six hours.,The facts are that the hours are every six hours.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"Hours. I mean, sorry, every six hours. Yes."
time,"They are explaining the words ""then"", ""now"", and ""later"".",no,no,no,Then
The topic they are talking about is OxyContin.,They are summarizing the points made in paragraph 14.,"The facts are that OxyContin was not claimed to be safer or more effective than other pain medications, and that Purdue did not have any clinical studies demonstrating that OxyContin was less addictive, less subject to abuse and diversion, or less likely to cause tolerance and withdrawal than other pain medications.",They do not support their point with anecdotes.,N/A,"And then paragraph 14 says the NDA did not claim that OxyContin was safer or more effective than immediate release oxycodone or other pain medications. And Purdue did not have, and did not provide the FDA with any clinical studies demonstrating that OxyContin was less addictive, less subject to abuse and diversion, or less likely to cause tolerance and withdrawal than other pain medications. And is that paragraph correct?"
The topic they are talking about is medical officer reviews.,They support their points with facts.,They do not support their point with anecdotes.,,,"And then there are some medical officer reviews, correct?"
They are talking about OxyContin.,They think that OxyContin is not more effective than other opioids and that it is not safer.,The facts are that OxyContin is not more effective than other opioids and that it is not safer.,They do not support their point with anecdotes.,N/A,"Right. And, uh, and those also did not state that OxyContin was more effective than, or superior to safer had less opioid effects or caused fewer adverse events than any other marketed product."
The topic is information that salespeople give to physicians.,They want to know what type of information the physician usually asks the salesperson.,N/A,N/A,N/A,"And, and me back up a minute, do you know what PHY, when salespeople go call on physicians, what type of information the physician usually asks the salesperson?"
none,none,none,none,none,"You don't know whether, uh, they want to know if there's any studies, if there's any contraindications to the medicine, any problems reported, have you"
The topic the person is talking about is whether or not to switch to a new product.,"The person's points are that they are unsure of the benefits of the topic, and they want to know if it is reasonable to switch.",The facts are that the person is unsure of the benefits of the topic.,The anecdote is that the person wants to know if it is reasonable to switch.,"The quote is ""One of the things they might ask is why is it better than what I'm already using? Why should I switch? Is that reasonable.""","One of the things they might ask is why is it better than what I'm already using? Why should I switch? Is that reasonable,"
The topic the person is talking about is not stated.,The person's points are that they might ask for studies that show the topic is better.,The facts are that the person might ask for studies that show the topic is better.,The anecdote is that the person might ask for studies that show the topic is better.,"The person quotes the anecdote by saying, ""One of the things they might ask is, you know, you got any studies that show it's better is another thing that comes.""","One of the things they might ask is, you know, you got any studies that show it's better is another thing that comes"
The topic they are talking about is opioids.,They are summarizing points.,"The facts are that the medical officer review of the ISS included statements that the blood level data and clinical use suggest the opioid effects would be of OxyContin, immediate release oxycodone would be similar.",They do not support their point with anecdotes.,N/A,"Paragraph 16 says, um, the medical officer review, sir, review of the ISS included these statements, um, and the blood level data and clinical use suggest the opioid effects would be of OxyContin, immediate release oxycodone would be similar. Um, and to your knowledge, is, is that clinically correct?"
The topic they are talking about is the dosage reduction of a drug.,They are questioning the dosage reduction of a drug.,The facts are that withdrawal is possible in patients who have their dosage abruptly reduced or discontinued.,There are no anecdotes.,There are no quotes.,"Uh, under D it said withdrawal is possible in patients who have their dosage abruptly reduced or discontinued. Um, is that your understanding of the characteristic of a drug?"
The topic they are talking about is OxyContin.,They are summarizing the points made by the document.,"The facts are that OxyContin has been shown to be as good as current therapy, but has not been shown to have a significant advantage beyond reduction in frequency of dosing.",They do not support their point with anecdotes.,N/A,"And then it said care should be taken to limit competitive promotion. OxyContin has been shown to be as good as current therapy, but has not been shown to have a significant advantage beyond reduction in frequency of dosing. And, uh, is that your understanding of the characteristic of the drug?"
The topic is not stated.,The person's points are that they want to see studies or retrospective studies that support the statement.,The facts are that the person wants to see studies or retrospective studies that support the statement.,There are no anecdotes.,There are no quotes.,"Um, any studies, retrospective studies, anything of that nature that would support that statement?"
The topic is misbranding of OxyContin.,They are asking if making false claims about a drug is called misbranding the drug.,N/A,N/A,N/A,"So if you go on here under the heading misbranding of OxyContin, and, and when we talk about misbranding, that's just really making claims and statements that aren't true about a drug that's called misbranding the drug, is that correct?"
The topic is whether or not Purdue had information that physicians were concerned about the abuse potential for OxyContin.,"The person's points are that they are wondering if Purdue had information that physicians were concerned about the abuse potential for OxyContin, and if so, what that information was.",There are no facts given.,There are no anecdotes given.,There is no quote given.,"Um, yeah. Do you know if Purdue had information that physicians were concerned about the abuse potential for OxyContin?"
They are talking about the conduct at Purdue.,They are looking at the timeframe that the us attorney's office looked into the conduct at Purdue.,The facts are the timeframe that the us attorney's office looked into the conduct at Purdue.,They do not support their point with anecdotes.,N/A,"Let me refer you to paragraph 20. Yeah, it says here beginning on or about December 12th, 1995. And continuing on, or about June 30th, 2001. And that is the timeframe that the us attorney's office looked into, um, the conduct at Purdue, correct."
The topic is Purdue's OxyContin marketing practices.,"The person's points are that Purdue sales representatives were trained to market OxyContin as less addictive and less subject to abuse than other pain medications, even though Purdue's own study showed that a drug abuser could extract approximately 68% of the oxycodone from a single 10 milligram OxyContin tablet.","The facts are that Purdue sales representatives were trained to market OxyContin as less addictive and less subject to abuse than other pain medications, even though Purdue's own study showed that a drug abuser could extract approximately 68% of the oxycodone from a single 10 milligram OxyContin tablet.",The person does not support their points with anecdotes.,N/A,"Uh, right. Um, certain Purdue supervisors and employees with the intent to defraud or mislead, marketed, and promoted OxyContin as less addictive, less subject to abuse and diversion, and less likely to cause tolerance and withdrawal than other pain medications as follows under a, it says that you train Purdue sales representatives. Meaning when I say you mean Purdue, the company trained Purdue sales representatives and told some healthcare providers that it was more difficult to extract the oxycodone from an OxyContin tablet for the purpose of intravenous abuse. Although Purdue's own study showed that a drug abuser could extract approximately 68% of the oxycodone from a single 10 milligram milligram OxyContin tablet by crushing the tablet, stirring it in water and drawing the solution through cotton into a syringe. Were you aware that, uh, Purdue trained sales representatives to make that misrepresentation?"
The topic is a potential misrepresentation to physicians about OxyContin.,They are questioning if a misrepresentation would make physicians more likely to prescribe OxyContin.,N/A,N/A,N/A,"Uh, is that a misrepresentation that would, um, cause a physician to be more likely to use, uh, to write prescriptions for OxyContin or less likely to write prescriptions for OxyContin?"
The topic is Purdue sales representatives telling healthcare providers that OxyContin creates less chance for addiction.,The person's points are that Purdue sales representatives should not have told healthcare providers that OxyContin creates less chance for addiction and that this is misleading.,The facts are that Purdue sales representatives told healthcare providers that OxyContin creates less chance for addiction.,There are no anecdotes.,There are no quotes.,"And then number B says, told Purdue sales representatives, they could tell healthcare providers that OxyContin potentially creates less chance for addiction than immediate release opioids. Um, were you aware that Purdue told sales representatives, they could tell healthcare providers that there was less chance for addiction with OxyContin than with immediate release opioids?"
The topic is Purdue sales supervisors being taught to make misleading statements about OxyContin.,They are saying that Purdue sales supervisors were taught to make misleading statements about OxyContin having fewer peak and trough blood level effects than other opioids.,The facts are that Purdue sales supervisors were taught to make misleading statements about OxyContin having fewer peak and trough blood level effects than other opioids.,They do not support their point with anecdotes.,N/A,"And under C it says sponsored training that taught Purdue sales supervisors, that OxyContin had fewer peak and trough blood level effects than immediate release opioids resulting in less euphoria and less potential for abuse than short-acting opioids. Were you aware that they were teaching sales supervisors to make that, um, misleading? Um,"
The topic is OxyContin.,"The person's points are that healthcare providers were told that patients could stop therapy abruptly without experiencing withdrawal symptoms, and that patients who took OxyContin would not develop tolerance to the drug.","The facts are that healthcare providers were told that patients could stop therapy abruptly without experiencing withdrawal symptoms, and that patients who took OxyContin would not develop tolerance to the drug.",There are no anecdotes.,There are no quotes.,Under D it says told healthcare providers that patients could stop therapy abruptly without experiencing withdrawal symptoms. And that patients who took OxyContin would not develop tolerance to the drug.
The person is talking about the text they just read.,They are trying to understand what they just read.,N/A,N/A,N/A,"Oh, let me read it again. Under D Purdue told certain healthcare providers that patients could stop therapy abruptly without experiencing withdrawal symptoms. And that patients who took OxyContin would not develop tolerance to the drug. Were you aware that certain healthcare providers were being told that they could stop therapy abruptly without experiencing withdrawal symptoms? Uh, and that patients who took OxyContin would not develop tolerance to the drug?"
The topic is the statement.,They think the statement is false and provides no evidence to support their claim.,N/A,N/A,N/A,"Okay. And that statement is false, correct?"
The topic is not stated.,They are summarizing the points.,The facts are that there was a lot of back and forth on the topic.,They do not support their point with an anecdote.,N/A,"It. Well, there was actually a whole lot of back and forth on this"
The topic is the U.S. attorney's office.,They want to know if the U.S. attorney's office has reviewed the documents and if they are changing anything.,N/A,N/A,N/A,"And a lot of the things brought up the us attorney's office said, no, we're, we've reviewed the documents and we're not changing this stuff. Is that what happened?"
The topic is Purdue Pharma.,"The person's points are that Purdue Pharma made false statements to healthcare providers about OxyContin, and that these statements were made with the intent to defraud or mislead.",The facts are that Purdue Pharma made false statements to healthcare providers about OxyContin.,There are no anecdotes.,N/A,"Yes. Yes. Um, and because nobody at Purdue is able to say which employees were Purdue Frederick, and which employees were Purdue Pharma, as far as I've been able to ascertain in any of the depositions I've read so far, um, including one's taken in the past, but we'll cover that later. Um, U under E here, it says, um, that Purdue super certain Purdue supervisors and employees with the intent to defraud or mislead call told certain healthcare providers that OxyContin did not cause a buzz or euphoria caused less euphoria had less addiction, potential had less abuse. Potential was less likely to be diverted than immediate release opioids and could not be, and could be used to quote weed out addicts and drug seekers. And, uh, were you aware that those statements were being made to healthcare"
The topic is the miss branding of OxyContin use of graph graphical depictions by sales representatives.,They are summarizing the points made in the section.,"The facts are that data from Purdue clinical studies was used to create a graphical demonstration of the difference in the plasma levels at steady state, between patients who took OxyContin every 12 hours and patients who took immediate release OxyContin every six hours.",There are no anecdotes.,N/A,"And then the next section is miss branding of OxyContin use of graph graphical depictions by sales representatives. And it says data from Purdue clinical studies was used to create the following graphical demonstration of the difference in the plasma levels at steady state, between patients who took OxyContin every 12 hours and patients who took immediate release OxyContin every six hours. Um, and it says that on October 12th, 1995, Purdue requested comments from the FDA's division of drug marketing, advertising communication about its proposed launch marketing materials, which included the following graft and tech showing oxycodone plasma concentration provided by OxyContin on a logarithmic scale, along with a statement that OxyContin oxycodone blood plasma levels provided fewer peaks and valleys than immediate release OxyContin,"
The topic is oxycodone.,The person's points are that oxycodone is addictive and that it has a high potential for abuse.,The facts are that oxycodone is addictive and that it has a high potential for abuse.,There are no anecdotes.,There are no quotes.,"Oxycodone, I'm sorry on paragraph says on December 20th of 95 after"
The topic is not stated.,They have not stated any specific points.,N/A,N/A,N/A,"On December 20th, 95, after reviewing the proposed OxyContin launch materials, DD M a C what is DD M a C"
The topic is the presentation of blood levels in a graphic.,They think that the way the blood levels were presented was misleading and that both dosage forms should be presented in the graphic.,The facts are that the blood levels were presented in a way that was misleading.,There are no anecdotes.,There are no quotes.,"And, you know, to sort of cut through it. What they did is they said, if you wish to compare blood levels in this text, uh, we suggest that the blood levels for both dosage forms be presented in the graphic so that the reader can accurately interpret this claim. They felt it was misleading the way it was correct."
N/A,They do not make any points.,N/A,N/A,N/A,Okay.
"They are talking about how Purdue told D D M a that it had deleted the statement, fewer peaks and valleys than with immediate release oxycodone, and then took the statement out.","They are talking about how Purdue told D D M a that it had deleted the statement, fewer peaks and valleys than with immediate release oxycodone, and then took the statement out.","The facts are that Purdue told D D M a that it had deleted the statement, fewer peaks and valleys than with immediate release oxycodone, and then took the statement out.",They do not support their point with anecdotes.,N/A,"And then it says paragraph 24 on or about January 11th, 1996, Purdue told D D M a that it had quote, deleted the statement, fewer peaks and valleys than with immediate release oxycodone. And they took the statement out. Correct."
The topic the person is talking about is whether or not the person has looked at the data in the studies done prior to the launch.,The person's points are that they want to know if the person has looked at the data in the studies done prior to the launch.,The facts are that the person wants to know if the person has looked at the data in the studies done prior to the launch.,The person does not support their point with an anecdote.,The person does not quote an anecdote.,"Did, did you review any of the studies that were done? Um, I mean, actually get down and look at the data in the studies that were done prior to the launch."
The topic the person is talking about is unknown.,The person's points are that they have not seen the data of the studies and they want to know more about the topic.,N/A,N/A,N/A,"Forms. Okay. And as we sit here today, have you ever seen the data of the studies themselves?"
The topic of the conversation is unknown.,They are questioning the extent to which the speaker did their research before making a decision.,N/A,N/A,N/A,"Are, are you saying that your studies that you did before putting Purdue on the mark were extremely exhaustive?"
The topic they are talking about is the opioid.,They are saying that the company did not do any addiction studies before putting the drug on the market.,The facts are that the company did not do any addiction studies before putting the drug on the market.,They do not support their point with anecdotes.,N/A,"But when you took a controversial opioid and expanded it to non-malignant pain, uh, at pills that contain high dosages of opiate, you didn't do any addiction studies before putting in on the market, correct"
The topic is the class two narcotic.,The person's points are that the class two narcotic is not as strong as morphine and that the records show this.,The facts are that the class two narcotic is not as strong as morphine and that the records show this.,There are no anecdotes.,There are no quotes.,"A class two narcotic that your own records show, uh, there was a belief among physicians that it wasn't as strong as morphine, correct?"
The topic is whether physicians knew that fentanyl was more potent than morphine.,"The person's points are that some physicians were surprised by how much more potent fentanyl is than morphine, and that others may not have been.","The facts are that fentanyl is more potent than morphine, and that some physicians were surprised by this fact.",There are no anecdotes.,N/A,"So you think physicians, most physicians knew it was more potent than morphine."
The topic is what the prosecutor said.,They support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,"You just mark this as exhibit,"
They are talking about OxyContin.,They are talking about how OxyContin has been on the market for five years and it is a good product.,The facts are that OxyContin has been on the market for five years and it is a good product.,They do not support their point with anecdotes.,N/A,"Let me refer you to the first paragraph of this document dated January 26th, 2001. We're now five years after OxyContin has been on the market, correct."
The topic is hydrocodone.,They think that it will give physicians a great degree of comfort.,The facts are that physicians rank the drugs based on the position that they have created in their mind as a result of prescription.,They do not support their point with anecdotes.,N/A,"And it says up here, this is from mark Alfonso. Uh, the first paragraph says, I think it will, in the mind of the physicians, hydrocodone gives them a great degree of comfort. Physicians rank the drugs based on the position that they have created in their mind as a result of prescription"
The topic the person is talking about is Purdue Pharma's marketing strategies.,The person's points are that prescribing habit and promotion are Purdue Pharma's marketing strategies.,The facts are that Purdue Pharma's marketing strategies are prescribing habit and promotion.,There are no anecdotes.,There is no quote.,"Prescribing habit and promotion. Um, and promotion would be what marketing from Purdue Pharma?"
The topic is the meaning of the text.,The person's points are that they are confused about the meaning of the text and are asking for clarification.,N/A,N/A,N/A,"What, what do you think it means when it says"
The topic is the potency of different drugs.,The person's points are that morphine and hydromorphone are the most potent followed by oxycodone and then hydrocodone.,The facts are that morphine and hydromorphone are the most potent followed by oxycodone and then hydrocodone.,The person does not support their points with anecdotes.,N/A,Okay. It says for them morphine and hydromorphone are the most potent followed by oxycodone and then hydrocodone.
The topic they are talking about is Mark Alfonso's role at Purdue.,They are asking if the person was aware of Mark Alfonso's role at Purdue.,N/A,N/A,N/A,"Yeah. Were you aware that in January 25th, 2001, mark Alfonso, and what was his role at Purdue"
The topic is marketing.,They are summarizing the points.,The facts are that physicians did not feel like oxycodone was as potent as morphine.,They do not support their point with anecdotes.,N/A,Marketing. The head of marketing felt like physicians did not feel like oxycodone was as potent as morphine.
The topic is not stated.,They want to know the opinion of the person they are talking to.,N/A,N/A,N/A,"Well, let, let me ask you this"
It is unclear.,They do not make any points.,N/A,N/A,N/A,"By the no let's his word? Potent, not mine."
N/A,N/A,N/A,N/A,N/A,Word. I didn't change it. It's it's
The topic the person is talking about is the strength of a drug in comparison to morphine.,The person's points are that the documents are unclear and that physicians may be confused about the strength of the drug.,"The facts are that the documents use the word ""potent"" and that physicians think the drug is as strong as morphine.",There are no anecdotes.,N/A,"Right? When we first discussed the first group of documents, you said, no, they're just talking about effectiveness, not strength. The second group of documents where they said it's stronger than morphine, you said no, they just mean strong in a general sense. They don't mean potent here. They use the word potent. I mean, do you just not think physicians don't think it's as strong as morphine? Cause that's, that's what they keep saying. They don't want to clear up in the physician's mind that it's as strong as morphine."
,"The person's points are that everyone has experienced being on a date where they are suddenly not interested in the other person anymore, and that it is hard to pinpoint why.",The anecdote is about being on a date and not being interested in the other person anymore.,"The claims the person makes are that everyone has experienced being on a date where they are suddenly not interested in the other person anymore, and that it is hard to pinpoint why.","The premises the person relies on are that everyone has experienced being on a date where they are suddenly not interested in the other person anymore, and that it is hard to pinpoint why.","Well, we"
The topic is OxyContin.,They are summarizing a point made by someone else that OxyContin is as powerful as morphine and that this is a good thing.,The facts are that OxyContin is as powerful as morphine.,They do not support their point with anecdotes.,N/A,"So when he says here, remember that we tried to reposition OxyContin as powerful as morphine. And we could not finally, we decided not to mess with this perception since it was helping us in the non-cancer market. Did you see where he wrote that?"
The plea agreement,They want to go back and look at the plea agreement again.,N/A,N/A,N/A,"All right. Let's go back to the plea agreement. Oh,"
The topic they are talking about is that it is marked.,They think it is a good idea and are happy with it.,The facts are that it is marked.,They do not support their point with anecdotes.,They do not quote any anecdotes.,It's marked
The topic the person is talking about is training for district sales managers.,The person's points are that all of the district sales managers were trained and that this training occurred in December 1998.,The facts are that all of the district sales managers were trained and that this training occurred in December 1998.,There are no anecdotes.,There are no quotes.,"Paragraph 25 of the agreed statement of facts says on or about December, 1998, Purdue sponsored training for all its district sales managers. Um, now it wasn't some of 'em it's all of them, correct?"
The topic they are talking about is the retention of a pharmacist by Purdue.,They are asking if the person knows who the pharmacist was.,N/A,N/A,N/A,During this meeting a pharmacist retained by Purdue. Do you know who that pharmacist was?
The topic is Purdue's training methods.,"The person's points are that Purdue's training methods are false and misleading, and that the company has a history of deceptive practices.","The facts are that Purdue's training methods are false and misleading, and that the company has a history of deceptive practices.","The anecdotes are about Purdue's training methods being false and misleading, and about the company's history of deceptive practices.",The person does not quote the anecdote.,"Um, a Pharma pharmacist retained by Purdue to conduct a portion of the training used the following graphical demonstration parenthesis. Instead of the graphical demonstration of the actual clinical data described in paragraph 21 of this agreed statement of facts and falsely stated that OxyContin had significantly fewer peak and trough blood level effects than immediate release opioids resulting in less EU fear, euphoria, and less potential for abuse than short acting opioids. And they've got a graph that was used at the training for the"
The topic is the legal document.,They are summarizing the points in the document.,The facts are that Purdue Pharma sales representatives began in 1999.,They do not support their point with anecdotes.,N/A,"And it says on paragraph 26 beginning in or around 1999, some of Purdue new sales representatives, those would be Purdue Pharma sales representatives in 1999. Correct?"
The topic they are talking about is a job posting.,"They point out that the job posting is for new sales representatives, and they wonder if that means Purdue Pharma or Purdue.",N/A,N/A,N/A,Frederick. Yeah. But it says new sales representatives. So are we talking about Purdue Pharma or Purdue
,The person's points are that the lawyer is a weasel and that they have seen his deposition.,The anecdote is that the person has seen the lawyer's deposition.,The claims are that the lawyer is a weasel and that the person has seen his deposition.,The premises are that the person has seen the lawyer's deposition.,"Yeah. The guy that helped put the document together, the lawyer we took his deposition. Have you seen his deposition?"
It is not clear.,The person is summarizing what someone else said. They are not making any points themselves.,N/A,N/A,N/A,"Yeah. And he says, he doesn't know if they're Purdue Pharma or Purdue when he refers to this, I'm telling you"
The topic is unknown.,They are asking if the person is correct and if they don't know.,N/A,N/A,N/A,"Sure. And I'm asking him if it's correct. And he's saying you don't know, correct?"
The topic is Purdue's sales representatives drawing their own blood level graphs to falsely represent that OxyContin did not swing up and down between euphoria and pain.,"The person's points are that Purdue's sales representatives were drawing their own blood level graphs to falsely represent that OxyContin did not swing up and down between euphoria and pain, and that this resulted in less abuse potential.","The facts are that Purdue's sales representatives were drawing their own blood level graphs to falsely represent that OxyContin did not swing up and down between euphoria and pain, and that this resulted in less abuse potential.",There are no anecdotes.,There are no quotes.,"Okay. Um, it says some Purdue new sales representatives were permitted during training at Purdue headquarters to draw their own blood level graphs to falsely represent that OxyContin, unlike immediate release or short-acting opioids did not swing up and down between euphoria and pain and resulted in less abuse potential. And were you aware that the sales reps were doing that?"
The topic is the false statements made by Purdue reps about OxyContin.,"The person's points are that Purdue reps used graphical depictions to falsely state that OxyContin had less euphoric effect and less abuse potential than shorting opioids, and that this conduct was wrong.",The facts are that Purdue reps used graphical depictions to falsely state that OxyContin had less euphoric effect and less abuse potential than shorting opioids.,There are no anecdotes.,There are no quotes.,"And then it says during the period, 1999 through June 30th, 2001, Purdue reps used graphical depictions, similar to the one described in paragraph 25 of these grid statement and, uh, agreed statement of facts and falsely stated to some healthcare providers that OxyContin had less euphoric effect and less abuse potential than shorting opioid opioids. Were you aware that they had no engaged in that conduct?"
They are talking about the addictive nature of OxyContin.,They think that Purdue is deliberately misleading people about the addictive nature of OxyContin.,"The facts are that Purdue is claiming that there are no withdrawal or tolerance effects from using OxyContin, when in reality there are.",They do not support their point with anecdotes.,N/A,"And then to go on with the conduct, paragraph 28 says, uh, misbranding of OxyContin misleading use of article to claim, no withdrawal or tolerance and it proceeds to discuss, um, how Purdue,"
The topic the person is talking about is osteoarthritis.,The person's points are that they will try to shorten the story and that Purdue had an osteoarthritis study.,The facts are that the person will try to shorten the story and that Purdue had an osteoarthritis study.,There are no anecdotes.,There is no quote.,"Well, let's go ahead and read it. Um, uh, had an, I'll try to shorten this a little bit for Purdue had an osteoarthritis study. Um,"
The topic is not stated.,They are asking if the person is familiar with the topic.,N/A,N/A,N/A,Yeah. Are you familiar with that?
The topic they are talking about is the use of low doses of OxyContin by osteoarthritis patients.,They think it will save time.,"The facts are that certain Purdue supervisors and employees sent to the FDA, the results of a clinical study pertaining to the use of low doses of OxyContin by osteoarthritis patients.",They do not support their point with anecdotes.,N/A,"I'll tell you what it'll save time. I'll read it into the record. Okay. On or about January 16th, 1997, certain Purdue supervisors and employees sent to the FDA, the results of a clinical study pertaining to the use of low doses of OxyContin by osteoarthritis patients. Um, it's call it the osteoarthritis study and a final report that included in a section pertaining to respite periods. The statement parenthesis, no investigator reported withdrawal syndrome as an adverse experience during the respite periods in a section entitled adverse experiences by body system, during respite periods, the report's summary of the major results listed the most frequently reported adverse experiences in respite periods to be nervousness, insomnia, nausea, pain, anxiety, depression, and diarrhea followed by the statement 28 patients, 26% had symptoms recorded during one or more respite periods. Did I read that correctly?"
The topic they are talking about is Purdue's practices.,"They are summarizing points made in a document that says Purdue was aware that many physicians believed oxycodone was weaker than morphine, but they did not want to do anything to change that perception.",N/A,N/A,"""And then it says paragraph 29 on or about may 20 se uh, May, 1997, certain Purdue supervisors and employees stated that while they were well aware of the incorrect view held by many physicians that oxycodone was weaker than morphine. They did not want to do anything to make physicians think that oxycodone was stronger or equal to morphine or to take any steps in the form of an emotional materials, symposia, clinicals, publications, conventions, or communications with the field force that would affect the unique position that OxyContin had in many physicians' mind, uh, in quote.""","And then it says paragraph 29 on or about may 20 se uh, May, 1997, certain Purdue supervisors and employees stated that while they were well aware of the incorrect view held by many physicians that oxycodone was weaker than morphine. They did not want to do anything to make physicians think that oxycodone was stronger or equal to morphine or to take any steps in the form of an emotional materials, symposia, clinicals, publications, conventions, or communications with the field force that would affect the unique position that OxyContin had in many physicians' mind, uh, in quote. And did I read that correctly?"
The topic is the agreed statement of facts.,The person's points are that the agreed statement of facts is not clear and that it is not helpful.,The facts are that the agreed statement of facts is not clear and that it is not helpful.,N/A,N/A,And was that part of the agreed statement of facts
The topic is Purdue's possible negligence in warning patients about the risks of addiction and withdrawal associated with their products.,"The person's points are that Purdue knew about the risks of addiction and withdrawal associated with their products, and that they failed to warn patients and doctors.","The facts are that certain supervisors and employees of a United Kingdom company affiliated with Purdue provided certain Purdue supervisors and employees with an analysis of the osteoarthritis study together with another clinical study. This analysis included a list of eight patients in the osteoarthritis study and 11 patients in the other study who had symptoms recorded that may possibly have been related to opioid withdrawal, including one patient in the other study who required treatment for withdrawal symptoms syndrome.",N/A,N/A,"And then it goes on to say on or about February 12th, 1997, certain supervisors and employees of a United Kingdom company affiliated with Purdue provided certain Purdue supervisors and employees with an analysis of the osteoarthritis study together with another clinical study. This analysis included a list of eight patients in the osteoarthritis study and 11 patients in the other study who had symptoms recorded that may possibly have been related to opioid withdrawal, including one patient in the other study who required treatment for withdrawal symptoms syndrome. Did you ever review that study?"
The topic they are talking about is the development of physical dependence and withdrawal symptoms in patients who take OxyContin tablets.,They are summarizing the points made in the quote.,The facts are that some patients in clinical trials develop physical dependence and experience withdrawal symptoms as a result of abrupt discontinuation of OxyContin tablets.,There are no anecdotes given.,N/A,"Um, the discussion section of this analysis include the following quote. It's not surprising that some patients in the clinical trials develop some degree of physical dependence and consequently experience withdrawal symptoms as a result of abrupt discontinuation of OxyContin tablets, all patients who respected to have withdrawal symptoms have been reported, but this may have resulted in a falsely high incidence of the patients who participated in the osteoarthritis study in which patients entered respite periods without OxyContin tablets, many symptoms suspected to be due to opioid withdrawal may simply have resulted from the return of pain after withdrawal of OxyContin tablets, uh, patient 6 0 0 7 complained of nervousness patient 2 0 4 complained of insomnia and felt restless patient 2 22, 28 were restless in anxious. Since these are symptoms, which often accompany the return of significant pain. It may be wrong to label these as withdrawal symptoms. Nonetheless, the instance of withdrawal syndromes in patients three with OxyContin tablets is a concern and it is safer to over report than under report. This problem, this analysis conclusions included this statement as expected. Some patients did become physically dependent on OxyContin tablets, but this is not expected to be a clinical problem. So as long, so long as abrupt withdrawal of the drug"
The topic they are talking about is whether or not certain Purdue employees participated in the final draft of an article.,They are asking if the person was aware that certain Purdue employees participated in the final draft of an article.,N/A,N/A,N/A,"Were you aware that certain Purdue employees participating in the final draft of the article regarding the osteoarthritis study that was published in a medical journal on or about March 27th, 2000. Um, okay. Um, were you aware they participated in that publishing of that study?"
The topic they are talking about is the results of a study on the incidence of withdrawal syndrome and withdrawal symptoms experienced by patients taking OxyContin.,They are summarizing the points made in the article.,The facts they mention are that one patient was hospitalized for withdrawal symptoms and that a second patient experienced withdrawal symptoms after running out of study medication.,They do not mention any anecdotes.,N/A,"The results section of the article, uh, I'm reading from paragraph 31, right. Included the following three statements pertaining to the incidence of withdrawal syndrome and withdrawal symptoms experienced by study patients. One patient was hospitalized parenthesis for withdrawal symptoms. The patient who was hospitalized with withdrawal symptoms had completed the study on a previous day and had been, been receiving CR oxycodone 70 milligram symptoms resolved after three days. Um, <affirmative> um, a second patient received 60 milligrams CR oxycodone experienced withdrawal symptoms after running out study medication, the patient had not reported withdrawal symptoms during scheduled respite from doses of 30 or 40 withdrawal symptom was not reported as an adverse event for any patient during scheduled respite, adverse experiences reported by more than 10% of patients during scheduled respite were nervousness nine patients with insomnia, eight patients, um, purple paragraph 32 says the article included a comment section, uh, summarized, um, the three statements and the results and further suggested that patients taking low doses could have their OxyContin treatment abruptly discontinued without experiencing withdrawal if their condition so warranted. Were you aware they were making that claim?"
The topic they are talking about is the osteoarthritis study article.,They are asking if the person knows which supervisors and employees sent the full text of the osteoarthritis study article.,"The facts are that certain Purdue supervisors, employees sent the full text of this osteoarthritis study article.",They do not support their point with anecdotes.,N/A,"If you go over to paragraph 34, it says on or about June 26th, 2000 certain Purdue supervisors, employees sent the full text of this osteoarthritis study article. Do you know which supervisors and employees sent the full text of this article?"
The event,"The person is discussing whether or not a recent event was caused by the marketing group. They don't think so, and believe it was just a coincidence.",N/A,N/A,N/A,Do you know if it was the marketing group?
The topic they are talking about is Purdue's practices.,They are summarizing Purdue's own review of their accuracy of the withdrawal data in the osteoarthritis study.,The facts are that Purdue's own people reviewed the data and found it to be inaccurate.,There are no anecdotes.,N/A,"And it says, um, together with a marketing tip to produce entire Salesforce, the marketing tip stated that a reprint of the osteoarthritis study article was available for use in achieving sales success. The marketing tip also included as one of the articles, 12, 12 key points. There were two reports of withdrawal symptoms after patients abruptly stopped taking CR oxycodone at doses of 60 or 70 withdrawal syndrome was not reported as an adverse event during scheduled respite, indicating that CR oxycodone at doses below 60 milligrams can be discontinued without tapering the dose. If the patient conditions sow warrants, it says on or about February 13th, 2001, certain Purdue supervisors and employees received a review of the accuracy of the withdrawal data in the osteoarthritis study and stated, now this is Purdue's own people reviewing this data, correct."
The topic they are talking about is the data on the withdrawal symptoms experienced by patients in the osteoarthritis study.,They think that writing up the data would add to the negative press that Purdue is currently receiving and that it should be deferred.,"The facts are that 106 patients initially participated in the osteoarthritis study, 32 of them withdrew because of severe adverse events, and 38 patients remaining in the study at 12 months.",They do not support their point with anecdotes.,N/A,"Read it. And it says, quote, upon a review of all comments for the enrolled patients. It was noted that multiple had comments which directly stated or implied that an adverse experience was due to possible withdrawal symptoms. This was followed by a list of 11 study patients who reported adverse experience due to possible withdrawal symptoms. During these periods, 106 patients initially participated in the osteoarthritis study, 32 of them withdrew because of severe, I'm sorry, because of adverse events, not necessarily related to withdrawal and 38 patients remaining in the study at 12 months. Um, and then the next paragraph reads on or about March 28th, 2001. So this is a month and a half later a Purdue employee emailed a Purdue supervisor regarding the review of the withdrawal data described in paragraph 35 of the agreed statement of facts asking, do you think the withdrawal data from the osteoarthritis study is worth writing up parenthesis and abstract, or would this add to the current negative press that should be deferred? The supervisor responded? I would not write it up at this point and no abstract was prepared. Do you see that?"
The topic is whether Purdue was using the marketing material from the article improperly.,The person's points are that they object to the form of the question.,The facts are that Purdue was using the marketing material from the article improperly and not reporting the adverse effects.,There are no anecdotes.,There are no quotes.,"It. So am I correct that Purdue was using the marketing material from this article, um, improperly and not reporting the adverse effects, uh, and was allowing their sales force to use it. I object to the form of the question."
The topic is Purdue's marketing department using this article.,They think that Purdue's marketing department is using this article.,The facts are that Purdue's marketing department is using this article.,They do not support their point with anecdotes.,N/A,Sure. Was Purdue's marketing department using this article.
The topic is whether people were using the product inappropriately.,They are questioning whether people were using the product inappropriately.,N/A,N/A,N/A,"And were they using it, uh, inappropriately?"
The topic is whether or not to write up the withdrawal data from the arthritis study.,"The person's points are that the withdrawal data from the arthritis study is different than how the sales force is using it, and that they are not sure if they should write it up because it might add to the current negative press.",The facts are that the withdrawal data from the arthritis study is different than how the sales force is using it.,There are no anecdotes.,There is no quote.,"And when somebody pointed out that the withdrawal data from the arthritis study was actually different than how the sales force was using it and asked, should we write it up or is this going to add to the current negative press and should be deferred? The person supervisor said, I would not write it up at this point. Correct."
Unknown,"The person is asking if a study was ever written up, and if the doctors who were shown the study were ever told that the information in the study was incorrect.",No,No,No,"Do you know if it ever got written up? I don't know. Do you know if any of these doctors that were shown this were ever told that, uh, that it actually wasn't correct?"
The topic is whether or not somebody at Purdue made an effort to tell the doctors that the marketing things were not correct.,"The person's points are that they don't know if anybody made an effort to tell the doctors, and that the marketing things might not be correct.",There are no facts given.,There are no anecdotes given.,There is no quote given.,"Do you know if anybody at Purdue made an effort to go tell these doctors that all of these marketing things that had been brought up in the agreed statement of facts, um, uh, were not correct?"
The topic is Purdue employees making false marketing statements to doctors.,They are saying that Purdue employees made false marketing statements to doctors.,The facts are that Purdue employees made false marketing statements to doctors.,There are no anecdotes.,There are no quotes.,"Did you yourself ever tell anybody to go inform doctors that these marketing, um, statements that had been used by Purdue employees that were not accurate, um,"
They are talking about the accuracy of information.,They say that the facts were not accurate.,The facts are that the information was not accurate.,N/A,N/A,"Were, um, were in fact not accurate,"
The topic is Purdue Pharma.,"The person's points are that Purdue Pharma is responsible for the opioid crisis, and that the company's directors were aware of this.","The facts are that Purdue Pharma is responsible for the opioid crisis, and that the company's directors were aware of this.",There are no anecdotes.,There are no quotes.,"And as the director of Purdue Pharma, you were not made aware of any of this."
The topic is the CEO's awareness of illegal conduct at Purdue Pharma.,The person's points are that the CEO was aware of the illegal conduct and that it continued for a number of years.,The facts are that the CEO was aware of the illegal conduct and that it continued for a number of years.,There are no anecdotes.,There are no quotes.,"And at the time that this, uh, conduct went on from 96 to 2001, the time period investigated by at least this us attorney under this agreed statement of facts, you were in fact, the CEO of Purdue Pharma,"
The topic they are talking about is the CEO not writing up data.,They are summarizing points that the CEO made about an employee writing up data.,The facts are dates and what the employee was told to do.,They do not support their point with anecdotes.,N/A,"And so if this conduct occurred, um, on May 18th, 2000, June 22nd, 2000, February 13th, 2000. And on March 18th, 2001, this employee was told not to write up the withdrawal data because of negative press and that it should be deferred. You'd have been the CEO during this time period, correct?"
Robert Reader,Robert Reader's role at Purdue,Robert Reader was a professor at Purdue,Claims that Reader was a great professor,No,"Yeah. What, what was Robert reader's role at Purdue?"
The topic they are talking about is the distribution of the osteoarthritis study article by Purdue supervisors and employees.,"They are saying that Purdue supervisors and employees distributed copies of the reprint of the osteoarthritis study article to all of Purdue sales representatives for use in the promotion and marketing of OxyContin to healthcare providers, including the distribution of 10,615 copies to certain Purdue sales representatives between February 13th, 2001 and June 30th, 2001.","The facts are that Purdue supervisors and employees distributed copies of the reprint of the osteoarthritis study article to all of Purdue sales representatives for use in the promotion and marketing of OxyContin to healthcare providers, including the distribution of 10,615 copies to certain Purdue sales representatives between February 13th, 2001 and June 30th, 2001.",They do not support their point with anecdotes.,N/A,"Next paragraph says, uh, so between June 26th, 2000 and June 30th, 2001, certain Purdue supervisors and employees distributed copies of the reprint of the osteoarthritis study article to all of Purdue sales representatives for use in the promotion and marketing of OxyContin to healthcare providers, including the distribution of 10,615 copies to certain Purdue sales representatives between February 13th, 2001 and June 30th, 2001. Um, so it looks like on March 28th, the supervisor tells the employee don't write up the withdrawal data from the osteoarthritis study. Uh, it would add to the current, uh, negative press and should be deferred. And between February 13th, 2001 and June 30th, 2001, 10,615 copies of, uh, the osteoarthritis study were distributed to sales representatives. Correct."
The topic they are talking about is the purpose of submitting it to the sales representative.,They are questioning the purpose of submitting it to the sales representative.,N/A,N/A,N/A,"Um, was the purpose of submitting it to the sales representative so they could show it to the physicians that they called on."
They are talking about the number of sales reps at Purdue.,They point out that there are 800 sales reps at Purdue that produced the highest volume of sales reps during this period of time.,The facts are that there are 800 sales reps at Purdue that produced the highest volume of sales reps during this period of time.,They do not support their point with anecdotes.,N/A,"There's only, uh, 800 sales reps at Purdue that produced highest volume of sales reps during this period of time. Correct,"
They are talking about the number of copies that were printed.,"They think that 800 copies would have been sufficient, but 10,615 were printed.","The facts are that 800 copies would have been sufficient, but 10,615 were printed.",They do not support their point with anecdotes.,N/A,"So if you wanted to give a copy to each sales rep for their own use, you'd probably only need 800, but they printed off 10,615 copies, correct?"
topic is unknown,summarizes points,facts are that sales reps were showing these to doctors,no anecdotes,no quote,Is it reasonable to conclude that the sales reps were showing these to the doctors
The topic they are talking about is the osteoarthritis article.,"They are wondering if Purdue got any of the 10,000 16, 615 copies of the osteoarthritis article.",N/A,N/A,N/A,"Do you know if Purdue ever got any of this 10,000 16, 615 copies of the osteoarthritis article? Uh, back,"
The topic the person is talking about is unknown.,The person's points are that they are not sure if the thing is good and they do not know if it is worth the money.,The facts are that the person is unsure if the thing is good and does not know if it is worth the money.,The person does not support their point with anecdotes.,N/A,"Um,"
The topic is the statements made by the sales representatives about OxyContin.,"The person's points are that the statements made by the sales representatives are false and misleading, and that they are not accurate.","The facts are that the statements made by the sales representatives are false and misleading, and that they are not accurate.",There are no anecdotes.,There are no quotes.,"It says, um, on paragraph 38 during the period, June 26th, 2000 through June 30th, 2001, certain Purdue sales representatives distributed the reprint of the osteoarthritis article to some healthcare providers and falsely, or misleadingly stated that patients taking OxyContin doses below 60 milligrams per day can always be discontinued abruptly without withdrawal symptoms. And that patients on such doses would not develop tolerance. And that's not an accurate statement, is it?"
The topic is Purdue's OxyContin marketing practices.,"The person's points are that Purdue's OxyContin package insert approved by the FDA stated that delayed absorption as provided by OxyContin tablets is believed to reduce the abuse liability of the drug, and that certain Purdue supervisors, employees instructed Purdue sales representatives to use this statement to market and promote OxyContin, but that sales reps were falsely telling some healthcare providers that the reduced use liability statement meant that OxyContin did not cause a buzz or euphoria, cause less euphoria, had less addiction potential, was less likely to be diverted than immediate release opioids, and could be used to weed out addicts and drug seekers.","The facts are that the FDA approved OxyContin package insert stated that delayed absorption as provided by OxyContin tablets is believed to reduce the abuse liability of the drug, and that certain Purdue supervisors, employees instructed Purdue sales representatives to use this statement to market and promote OxyContin, but that sales reps were falsely telling some healthcare providers that the reduced use liability statement meant that OxyContin did not cause a buzz or euphoria, cause less euphoria, had less addiction potential, was less likely to be diverted than immediate release opioids, and could be used to weed out addicts and drug seekers.",There are no anecdotes.,N/A,"And then on, um, with regard to misbranding of OxyContin use of reduced abuse, liability claims in marketing, um, it says paragraph that's OxyContin package insert approved the FDA stated by the FDA stated delayed absorption as provided by OxyContin tablets is believed to reduce the abuse liability of the drug that's called the reduced abuse liability statement. Certain Purdue supervisors, employees instructed Purdue sales representatives to use this statement to market and promote OxyContin. Paragraph 40 says certain Purdue sales reps while promoting and marketing OxyContin, falsely told some healthcare providers that the reduced use liability statement meant that OxyContin did not cause a buzz or euphoria cause less euphoria had less addiction. Potential had less abuse. Potential was less likely to be diverted than immediate release opioids and could be used to weed out addicts and drug seekers. And, um, it says by March, 2000 various Purdue supervisors and employees in different parts of the company had received reports of OxyContin abuse and diversion occurring in different communities. And that on or about November 27th, 2000 certain Purdue supervisor and employees amended the reduced abuse liability statement to say that delayed absorption as provided by OxyContin tablets when used properly for the management of pain is believed to reduce the the	drug	and	instructed	produce	sales	reps	to	use	the	amended	statement	to	promote	and	market	OxyContin.	Uh,	do	you	know	why	that	statement	was	changed?"
The topic they are talking about is Purdue's response to the OxyContin crisis.,They are summarizing Purdue's response to the OxyContin crisis.,The facts are that Purdue changed their packet insert when they found out OxyContin was being abused.,There are no anecdotes.,N/A,"Well, when Purdue found out that OxyContin was being abused and diverted, uh <affirmative> they changed their packet, insert kind of cleverly, really, if you read it right. Uh, when used properly for the management of pain, do you know what they meant by that?"
The topic is the risks of abuse and addiction for OxyContin.,"The person's points are that the statements made by the sales representatives are not correct, and that OxyContin does have a risk for abuse and addiction.",The facts are that certain sales representatives made false statements about the risks of abuse and addiction for OxyContin.,There are no anecdotes.,N/A,"Okay. Next paragraph says from March, 2000 through June 30th, 2001, certain produced sales representatives while promoting and marketing OxyContin, falsely told some healthcare providers that they reduced abuse liability statement. And the amended statement meant that OxyContin did not cause a buzz or euphoria caused less euphoria had less addiction, potential had less abuse. Potential was less likely to be diverted than immediate release opioids and can be used to weed out a and drug seekers. And those statements are not correct."
The topic they are talking about is the introduction of misbranded OxyContin into interstate commerce.,They point out that Purdue manufactured and sold OxyContin in interstate commerce from various locations.,The facts are that Purdue manufactured and sold OxyContin in interstate commerce from various locations.,They do not support their point with anecdotes.,N/A,"Introduction of misbranded, uh, OxyContin into interstate commerce. And that is actually the, uh, the guilty plea. Pardon? Um, let's it's um, points out that, uh, Purdue manufactured and sold OxyContin in interstate commerce from various locations."
They are talking about the idea.,They think it is a good idea and are supportive of it.,The facts are that it is the next paragraph.,They do not support their point with anecdotes.,N/A,"That's the very next paragraph,"
The topic they are talking about is Purdue's sale of OxyContin.,They are pointing out that Purdue sold OxyContin all over the US.,The facts are that Purdue sold OxyContin all over the US.,They do not support their point with anecdotes.,N/A,And that's just pointing out that Purdue sold OxyContin all over the us. Correct.
no,does not state a position,no,no,no,"Yeah, you're right."
The topic is Purdue Pharma and OxyContin.,They are asking if Purdue Pharma sold OxyContin all over the US.,N/A,N/A,N/A,I'll withdraw the question. Okay. Did Purdue Pharma sell OxyContin all over the us
The topic is not stated.,They do not state any points.,N/A,N/A,N/A,"Um, 1996 to 2001."
The topic is Purdue's misrepresentations.,"The person's points are that Purdue was aware that physicians did not understand the complex processes of treating pain, and that this allowed Purdue to get away with making misrepresentations.",The facts are that Purdue was aware that physicians did not understand the complex processes of treating pain.,There are no anecdotes.,There are no quotes.,Now as part of the reason Purdue was able to get away with making these misrepresentations is because Purdue was aware that physicians did not understand the complex processes of treating pain.
The topic the person is talking about is whether Purdue owned focus groups showed that doctors didn't understand whether OxyContin was stronger than morphine.,"The person's points are that they are unsure if doctors understand the difference between OxyContin and morphine, and if Purdue owned the focus groups.",There are no facts given.,There are no anecdotes given.,There is no quote given.,"Um, did Purdue own focus groups show that doctors uh, didn't understand, um, whether OxyContin was stronger than morphine?"
The topic is pain treatment.,They want to know if doctors understand prescribing practices for pain treatment.,N/A,N/A,N/A,"What about the treatment of pain? Did you feel like doctors understood or physicians understood, uh, prescribing practices that should be utilized for the treatment of pain?"
They are talking about the need to spend money on educating physicians.,They think that the reason given for needing to spend so much money educating physicians is not valid.,N/A,N/A,N/A,"Um, in that the reason y'all were claiming that you needed to spend so much money educating physicians is cause they didn't understand pain prescribing."
The topic they are talking about is how to get a large sales force to use a marketing message.,They think that the only way to get a large sales force to use a marketing message is to instruct them explicitly and unmistakably to do so.,The facts are that the sales force needs to be instructed explicitly and unmistakably to use a marketing message.,They do not support their point with anecdotes.,N/A,"Um, would you agree that the only way to get a large sales force to use a marketing message is to instruct them explicitly and unmistakably to do so?"
The topic that the person is talking about is Mr. Shapiro's testimony regarding how a sales force can be instructed to use a marketing message.,"The person summarizes Mr. Shapiro's point by saying that he believes that in order for a sales force to use a marketing message, they need to be instructed to do so explicitly.",N/A,N/A,N/A,Mr. Shapiro has testified. I want you to assume he's testified that the only way to get a large sales force to use a marketing message is to instruct them explicitly and unmistakably to do so. Would you agree with that?
The topic is not clear.,They think it is a good idea and want you to agree with them.,N/A,N/A,N/A,"It to me. I'm I'm I want you to assume he's testified to that,"
N/A,They cannot summarize their points.,N/A,N/A,N/A,"In front of you. I don't have a transcript in front of me. I'm asking you from my own memory. Well, you"
The topic is evidence of improper training at Purdue.,"The person's points are that they are unsure if there is evidence of improper training at Purdue, and they want to know if the other person believes there is evidence.",There are no facts given.,There are no anecdotes given.,There are no quotes given.,"Um, do you believe there's evidence of improper training that has occurred at Purdue based on the agreed statement of facts?"
The topic is the use of improper statements to educate physicians about prescribing OxyContin.,The person's points are that the use of improper statements is wrong and that they want to know what percentage of the sales force is using them.,The facts are that the use of improper statements is wrong and that they want to know what percentage of the sales force is using them.,There are no anecdotes.,There are no quotes.,"Did you ever, um, do you know, as we sit here today, what percentage of your sales force was using this, these improper statements, uh, to educate physicians about prescribing OxyContin?"
The idea,They think that it was a bad idea and that it didn't work.,N/A,N/A,N/A,"Okay. Whether it was a hundred percent, 50%, 10%, you don't have any,"
The topic is whether anybody at Purdue tried to find out how many of their sales force had given physicians improper and incorrect information.,"The person's points are that they are curious if anybody at Purdue tried to find out how many of their sales force had given physicians improper and incorrect information, and if so, what the outcome was.",There are no facts given.,There are no anecdotes given.,There is no quote given.,Do you know if anybody at Purdue tried to find out how many of their sales force had given physicians improper and incorrect information?
The topic they are talking about is Purdue Pharma.,They question if anybody at Purdue Pharma attempted to go back and find out which reps specifically had made comments to physicians that were improper or misleading about the attributes of OxyContin.,The facts are that they question if anybody at Purdue Pharma attempted to go back and find out which reps specifically had made comments to physicians that were improper or misleading about the attributes of OxyContin.,They do not support their point with anecdotes.,N/A,"Yeah. And that's not really my question. My question is did anybody at Purdue Pharma attempt to go back and find out which reps specifically had made comments to physicians that were improper or misleading about the attributes, uh, of OxyContin"
The topic they are talking about is that making the statements could compromise patient care.,They think that making the statements could compromise patient care.,The facts are that making the statements could compromise patient care.,They do not support their point with anecdotes.,N/A,"Okay. Would you agree that giving, making the statements, uh, the improper statements that are referred to in the agreed statement of facts could compromise patient care?"
The topic they are talking about is the investigation.,They think that the investigation was not done properly.,The facts are that the person has not reviewed any of the call notes.,There are no anecdotes.,N/A,"And if I understand correctly, you have not reviewed any of the call notes that were pulled by Mr. Shapiro when he was doing his that's correct investigation."
The topic is the call notes system.,They are questioning whether or not a recommendation was made to change the call notes system.,N/A,N/A,N/A,Was there a recommendation made by somebody right about that same time that the call notes system be changed
The topic the person is talking about is an investigation.,The person's points are that they are reviewing the call notes and doing an investigation.,The facts are that the person is reviewing the call notes and doing an investigation.,There are no anecdotes.,There are no quotes.,About the same time he was doing his investigation and reviewing the call notes?
The topic they are talking about is call notes.,They think that call notes do not contain as much information as they used to.,The facts are that call notes used to contain more information in 2000.,They do not support their point with anecdotes.,N/A,"Yeah. And, uh, do the call notes, not contain as much information as they used to, uh, back in 2000"
They are talking about call notes and how less information in them may make auditing more difficult.,They question whether or not having less information in call notes makes auditing more difficult.,N/A,N/A,N/A,"If the call notes have less information in them, is it more difficult to audit them?"
The topic is how many they saw.,They saw three.,The facts are that they saw three.,They do not support their point with anecdotes.,N/A,How many did you see?
The topic is unknown.,The person's points are that they want to know who showed the other person the things they are talking about.,There are no facts given.,There are no anecdotes given.,There are no quotes given.,And who were those who showed those to you?
The topic is unclear.,They are asking if the person was shown call notes from representatives in Kentucky.,N/A,N/A,N/A,"Um, you were the call notes, you were shown call notes from Kentucky reps, or"
They are talking about the accuracy of the investigation.,They think that the investigation was not accurate.,The facts are that the investigation was not accurate.,They do not support their point with anecdotes.,N/A,Did you hire anybody or ask anybody to review Mr. She Shapiro's investigation for accuracy?
They are talking about the topic of doing their own investigation.,They think that they will find the same number of improper call notes.,The facts are that they think they will find the same number of improper call notes.,There are no anecdotes.,There are no quotes.,"And would you expect if we did our own investigation, we would have essentially about the same number of improper call notes that he found."
The topic they are talking about is the article.,They think the article is well-written and informative.,The facts are that the article is well-written and informative.,They do not support their point with anecdotes.,N/A,"At Purdue article second court, 2001,"
The topic they are talking about is an email.,They are summarizing points from an email.,The facts are from an email.,They do not support their points with anecdotes.,N/A,"No, I'm gonna pick up some more different, so let me show you, um, email, we've got a page two of this email. This is, um, from Jim Speed dated Tuesday, November 30th. Let's mark this as what exhibit dated November"
The topic the person is talking about is controlled release opioids.,"The person's points are that many salespeople have sold controlled release opioids as having less abuse potential, but the current situation has placed them in an awkward situation.","The facts are that many physicians now think OxyContin is obviously the street drug, and that people are finding ways to extract the oxycodone from the tablet and are using a cotton ball to filter the talk talk as they draw it up in a syringe for quote, mainlining and quote.",There are no anecdotes.,N/A,"During physician calls. This issue is a topic of hot discussion between me and the physician. While many salespeople have sold controlled release opioids as having less abuse potential. The current situation has placed us in an awkward situation. I feel like we have a credibility issue with our product. Many physicians now think OxyContin is obviously the street drug. All, uh, the drug addicts are seeking issues like purposely crushing the 40 milligram and 80 milligram tabs to quote get high, have been expressed. I have heard from physicians that pharmacists and pharmacists that on the streets, people are finding ways to extract the oxycodone from the tablet and are using a cotton ball to filter the talk talk as they draw it up in a syringe for quote, mainlining and quote. Um, were you aware that that was a concern in November of 1999?"
The topic the person is talking about is OxyContin being diverted or abused.,The person's points are that they first became aware of the issue and that it is a problem.,The facts are that OxyContin is being diverted or abused.,There are no anecdotes.,N/A,"When did you first become aware, uh, that OxyContin was being diverted or abused"
The topic they are talking about is Dr. J David Haddock.,They think that Dr. Haddock is a great doctor.,The facts are that Dr. Haddock is a great doctor.,They do not support their point with anecdotes.,They do not quote any anecdotes.,Who has Dr. J David haddock?
Purdue Pharma,The person is asking if the man worked for Purdue Pharma.,N/A,N/A,N/A,Did he work for Purdue Pharma?
The topic is the jobs of Rena Goldman and Wendell Fisher.,They are asking about the jobs of Rena Goldman and Wendell Fisher.,The facts are the jobs of Rena Goldman and Wendell Fisher.,They do not support their point with anecdotes.,N/A,"Um, and what about Rena Goldman and Wendell Fisher? What were their jobs?"
The topic they are talking about is Jim Speed.,They think Jim Speed is a great guy and a great addition to the team.,The facts are that Jim Speed is a great guy and a great addition to the team.,They do not support their point with anecdotes.,N/A,And what about Jim Speed?
The topic they are talking about is Wendell Fisher.,They are asking if Wendell Fisher was a regional manager.,N/A,N/A,N/A,"Is it true that Wendell, uh, Fisher Fisher was a regional manager with oversights for the districts and territories located in Kentucky?"
The topic is whether OxyContin produces a buzz or euphoria.,"The person's points are that they have heard OxyContin produces a buzz or euphoria, and they want to know if it is true.",There are no facts given.,There are no anecdotes given.,There is no quote given.,"Um, is it true that OxyContin, uh, does produce a buzz or euphoria? Just like, uh, the controlled release, just like the immediate release"
The topic they are talking about is using it in pain patients.,They think it is helpful and that it works well.,The facts are that it is helpful and that it works well.,They do not support their point with anecdotes.,N/A,When used in pain patients?
The person is talking about drugs and their effects.,"The person's points are that they are unsure if the speed of the drug's effects has anything to do with how it makes the user feel, and they would like to know if there is a correlation.",N/A,N/A,N/A,Whether you feel a buzz or euphoria does that have to do with how quickly the drug works?
The topic is OxyContin.,They are asking if the peaks and valleys in the marketing materials refers to somebody experiences a euphoria from taking OxyContin.,N/A,N/A,N/A,"And, um, with respect to peaks and valleys, um, do the peaks and valleys that are referred to in all the marketing materials or a number of the marketing materials, um, does that have to do with whether somebody, uh, experiences a euphoria from taking OxyContin,"
The topic is Purdue's marketing of OxyContin.,They think that Purdue's marketing of OxyContin is misleading and that the drug is more addictive than Purdue claims. 4. They support their point with facts.,"The facts are that Purdue knew that OxyContin was more addictive than they claimed, but they marketed it as having less abuse potential.",They also claim that Purdue downplayed the risks of addiction and encouraged doctors to prescribe the drug for more pain than necessary.,"Purdue knew that OxyContin was more addictive than they claimed, but they marketed it as having less abuse potential.",When did you first become aware that Purdue had marketed and promoted OxyContin as having less abuse potential?
The topic they are talking about is dependency on OxyContin.,They are asking if someone who has never had an opioid before and is put on a 20 milligram dose of OxyContin twice a day would develop dependency and how long it would take.,The facts are that they are asking if someone who has never had an opioid before and is put on a 20 milligram dose of OxyContin twice a day would develop dependency and how long it would take.,They do not support their point with anecdotes.,N/A,"Let me, let me ask you about, uh, patients who, um, have not had a prior incidence of addiction or abuse, but just, uh, someone who's put on OxyContin, uh, and has never had, uh, an opioid in the past. Do you know if they're put on a 20 milligram dose of OxyContin twice a day, how long they would have to take it before developing dependency?"
The topic the person is talking about is opioids.,The person's points are that they want to know if Purdue ever conducted any studies to determine how long a non-malignant pain patient who's never had an opioid before would have to be on the drug before they developed dependency or addiction.,The facts are that the person wants to know if Purdue ever conducted any studies to determine how long a non-malignant pain patient who's never had an opioid before would have to be on the drug before they developed dependency or addiction.,The person does not support their points with anecdotes.,N/A,Yes. Do you know if Purdue ever conducted any studies to determine how long a non-malignant pain patient who's never had an opioid before would have to be on the drug before they developed dependency or addiction?
The fairness of a potential study.,They are suggesting that a study could be done to determine if something is fair.,N/A,N/A,N/A,"Uh, is it fair to say that if Purdue wanted to do, uh, a study to make that determination, uh, that could be done"
The topic is whether or not a retrospective study could be done.,"The person's points are that a retrospective study could be done, but it is not clear if it would be beneficial.","The facts are that a retrospective study could be done, but it is not clear if it would be beneficial.",There are no anecdotes.,There are no quotes.,Could you do a retrospective study or could you have done a retrospective study if you had wanted to look at patients?
Robert Reader's role,The person is asking about Robert Reader's role,N/A,No,N/A,And what was Robert reader's role?
The topic is OxyContin.,They are asking if the person agrees or disagrees with a statement.,N/A,N/A,N/A,"And I want you to assume he's testified that Purdue lacked any evidence that OxyContin had a lower abuse potential. Uh, if that's true, if he testified to that, assuming he testified to that, would you agree with that statement or disagree?"
The topic they are talking about is OxyContin.,They think that the evidence proves that OxyContin has a lower abuse potential.,The facts are that OxyContin has a lower abuse potential.,They do not support their point with anecdotes.,N/A,"Yeah. That he testified Purdue, like any evidence that OxyContin had a lower abuse potential."
N/A,They do not state any points.,N/A,N/A,N/A,All right.
The topic is support for a topic.,The person's points are that the topic is good and that they support it.,The facts are that the topic is good and that they support it.,The anecdote is that the person supports the topic.,"Yes, the person supports the topic.",Yes.
Purdue Pharma,They want to know if Purdue Pharma has done a study since then.,N/A,N/A,N/A,"Has, has Purdue Pharma done a study since then"
The deposition of Curtis Wright in the Poston case.,They have not seen the deposition and are curious about it.,N/A,N/A,N/A,Have you ever seen the deposition of Curtis Wright in the Poston case
The topic is unclear.,They make no points.,N/A,N/A,N/A,Poston P O S T O N?
The topic is the abuse potential of OxyContin.,They are questioning whether or not studies were done on the abuse potential of OxyContin before it was released.,N/A,N/A,N/A,"Did you ever discuss with Curtis Wright, whether, um, studies could have been done on the abuse potential of OxyContin prior to the release of OxyContin?"
They are talking about the release of OxyContin.,They think it is good that the studies were performed and that they were able to be released prior to the release of OxyContin.,The facts are that the studies were performed and that they were able to be released prior to the release of OxyContin.,They do not support their point with anecdotes.,N/A,"If he testified those studies were possible and could have been performed prior to the release of OxyContin, would it surprise you?"
N/A,They don't have any points.,N/A,N/A,N/A,I'm not sure what you're talking about.
The topic they are talking about is the contents of the email.,They are summarizing an email.,The facts are in the email.,They do not support their point with anecdotes.,N/A,"Um, this, uh, let hand you this email, sorry about this way there, this is an email here to be Richard Sackler on 8 27 97 to Craig, a McMan in Utah. Um, that's a doctor, is that right?"
no,cannot summarize points,no,no,no,"If you'll go to the, why don't we mark, this did already"
They are talking about the product OxyContin.,They are summarizing the points in the literature.,The facts are that the product has a rapid onset and lasts for 12 hours.,There are no anecdotes.,N/A,"If you go to the bottom, um, of the, of the second paragraph you, you write to him, um, I am drawing your attention to our newest product, OxyContin tablets, controlled release, oxycodone HCI, and have included some literature most important to your practice. Time of onset of OxyContin is as rapid as immediate release oxycodone, but duration is a full 12 hours and the patient reaches full blood levels in just two doses one day. Uh, was it your belief that the time of onset of OxyContin was as rapid as immediate release oxycodone?"
The topic is the person.,They want to know more about the person.,N/A,N/A,N/A,And who is he?
The topic the person is talking about is the email.,The person's points are that the email is from 1996 and that the person it was sent to works for Purdue Pharma.,The facts are that the email is from 1996 and that the person it was sent to works for Purdue Pharma.,There are no anecdotes.,There are no quotes.,"Let me give you a copy of this. And this is, um, if we can mark this as exhibit 37, this is an email dated May 15th, 1996. Looks like it was received by P Goldenheim MD. And, uh, he does work for Purdue Pharma, correct?"
It is unclear what topic they are talking about.,They do not mention any points.,N/A,N/A,N/A,"And it looks like, uh, you were also included by fax Dr. Richard Richard"
The topic they are talking about is the potential abuse and addiction of OxyContin.,They want more information and clarification on the potential abuse and addiction of OxyContin.,The facts are that OxyContin has a rapid onset of action.,They do not support their point with anecdotes.,N/A,"Says. And if you go to the third page, it says professor dare did not see any major problems regarding registration of OxyContin in Switzerland. Some specific points need to be clarified parenthesis, monitored release approval. As for DHC, prince may be a possibility in prince. He considers the following subjects as important and would need further investigations. And the first paragraph says information about the abuse addiction potential versus other opioids because of the rapid onset of action of OxyContin. Did I read that correctly? You did. Did, uh, do you know if you, uh, obtained approval to sell OxyContin in Switzerland?"
They are talking about OxyContin.,They point out that OxyContin is a rapid onset opioid.,The facts are that OxyContin is a rapid onset opioid.,There are no anecdotes.,There are no quotes.,"And did you provide him with, uh, the information about the abuse addiction potential versus other opioids? Uh, because of the rapid onset act of action of OxyContin that he requested?"
The topic the person is talking about is the rapid onset of action of OxyContin.,The person's points are that they are unsure why the person was concerned about the rapid onset of action of OxyContin and that they think it might be because of abuse and addiction.,The facts are that the person was concerned about the rapid onset of action of OxyContin and that they think it might be because of abuse and addiction.,There are no anecdotes.,There are no quotes.,"Do you know why he was concerned about the rapid onset of action of OxyContin? Um, with respect to abuse and addiction?"
The topic the person is talking about is peaks and valleys present in the plasma blood levels.,The person's points are that they want to know if the person has looked at the information to see if there are peaks and valleys present in the plasma blood levels.,The facts are that the person wants to know if there are peaks and valleys present in the plasma blood levels.,The person does not support their point with an anecdote.,N/A,"Um, with respect to the claims about peaks and valleys, did you ever review the information to see what peaks and valleys were present in the plasma blood levels with respect to"
N/A,They have not stated any points.,N/A,N/A,N/A,No. Did you ever review
The topic is peaks and valleys.,They are questioning the other person's claim that there are different types of peaks and valleys.,N/A,N/A,N/A,"That's okay. I said with respect to, um, peaks and valleys, uh, the claim that there are peak valleys are different. Did you ever review the literature? Uh, regarding that"
The topic is the level of peaks and troughs.,They are asking a question to gain more information.,N/A,N/A,N/A,Do you know if the level of peaks and troughs are similar or different?
The topic the person is talking about is controlled release drugs and addiction.,"The person's points are that controlled release drugs maintain a higher level throughout the day, and they are unsure if this would cause addiction.",The facts are that controlled release drugs maintain a higher level throughout the day.,The person does not support their points with anecdotes.,N/A,"Do you know whether the controlled release, because it maintained a higher level and didn't have as much trough, um, during the day would be more likely to cause addiction or less likely to cause addiction?"
The topic the person is talking about is addiction.,The person's points are that somebody who has a controlled release and maintains a higher level during the day is less likely to become addicted.,The facts are that somebody who has a controlled release and maintains a higher level during the day is less likely to become addicted.,The person does not support their point with anecdotes.,N/A,"Of. My, my question is if somebody has a controlled release and maintains a higher level, uh, uh, during the day with respect to valleys, uh, they don't have as many valleys. Does that cause is that more likely to make them become addicted or less likely? Do you know?"
The person is talking about the potential use of the drug for breakthrough pain.,The person's points are that the drug could be used for breakthrough pain and that it is correct that it could be used that way.,The facts are that the drug could be used for breakthrough pain and that it is correct that it could be used that way.,There are no anecdotes given.,There is no quote given.,"And if they use it as made and presented, they would also, uh, be taking drugs for breakthrough pain, potentially. Correct."
They are talking about a rescue prescription.,They think it is a good idea because the studies show that it lasts from eight to 12 hours.,The facts are that the studies show it lasts from eight to 12 hours.,They do not support their point with anecdotes.,N/A,"Right? If they, if, you know, the, the studies show that it lasts from eight to 12 hours, um, and if it lasts eight or nine hours in a patient and doesn't last till 12, uh, he may need an additional prescription rescue, uh, prescription for that also correct."
The topic is whether patients who were given controlled release oxycodone and then had to take another one because it didn't last 12 hours were more likely to develop addiction or less likely to develop addiction.,"The person's points are that they don't know if there was a study done on this topic, and if so, what the results were.",There are no facts given.,There are no anecdotes given.,There is no quote given.,"Do do you know, uh, was, was there any study done to determine whether patients who were given, uh, controlled release oxycodone an then had to take another one because it didn't last 12 hours, we're more likely to develop addiction, uh, or less likely to develop addiction."
N/A,They do not state any points.,N/A,N/A,N/A,"Can we go off the record one second? Sure. Yeah, we are off the record"
The topic is sifting through documents.,The person's points are that the documents should be sifted through and that the GAO report is an exception.,The facts are that the documents are kept in the ordinary course of business at Purdue.,There are no anecdotes.,There are no quotes.,"Um, <affirmative> um, what I'd like to do is have you sift through these documents and with the exception of the GAO report, are all of these documents that are kept in the ordinary course of business at Purdue?"
The topic is whether the documents were generated in the ordinary course of business at Purdue.,"The person's points are that they are not sure if the documents were generated in the ordinary course of business at Purdue, and they want to know if that is the case.",N/A,N/A,N/A,Are these all documents that were generated in the ordinary course of business at Purdue
The topic is Purdue Pharma and Monday Pharma.,The person's points are that they are unsure about Purdue Pharma and Monday Pharma.,N/A,N/A,N/A,"Purdue Pharma, um, and Monday Pharma,"
The topic is business records.,They think that business records are important and should be kept.,The facts are that business records are important for businesses.,They do not support their point with anecdotes.,N/A,Then are all of these business records.
N/A,The person is asking if the other person can answer the question.,N/A,N/A,N/A,I'm not sure it is. Can you answer the question?
The topic they are talking about is addiction and dependency rates of OxyContin users.,They are asking if anything was done to determine how many people would become addicted or dependent if they took OxyContin for a certain period of time.,The facts are that they are asking if anything was done to determine how many people would become addicted or dependent if they took OxyContin for a certain period of time.,They do not support their point with anecdotes.,N/A,"Um, I asked you about the OxyContin 20 milligrams prescription to your knowledge, was anything done to determine, um, how many people put on 40 milligram, 80 milligram or 160 milligram prescriptions would become addicted or dependent if they took it for a certain period of time?"
The topic they are talking about is that Purdue's OxyContin marketing and promoting in Kentucky caused the prescription drug addiction problems now plaguing the Commonwealth.,They think that Purdue's OxyContin marketing and promoting in Kentucky caused the prescription drug addiction problems now plaguing the Commonwealth.,The facts are that Purdue's OxyContin marketing and promoting in Kentucky caused the prescription drug addiction problems now plaguing the Commonwealth.,They do not support their point with anecdotes.,N/A,"Sitting here today. Um, after all, you've come to learn as a witness. Do you believe Purdue conduct in marketing and promoting OxyContin in Kentucky caused any of the prescription drug addiction problems now plaguing the Commonwealth?"
The topic they are talking about is the production of opioids.,They are summarizing what has been learned and asking if it is believed that the production of opioids has led to an excessive amount in Kentucky.,The facts are that there has been an increase in opioids in Kentucky.,They do not support their point with anecdotes.,N/A,Sitting here today after all you've come to learn is witnessed. Do you believe that produced con in Kentucky has led to an excessive or unnecessary amount of opioids being located throughout the Commonwealth of Kentucky?
The topic is whether or not increased conduct has led to an increase in addiction in Kentucky.,The person's points are that they are unsure if there is a correlation between the two and that more research needs to be done.,The facts are that there is not enough evidence to determine if there is a correlation between the two.,There are no anecdotes.,N/A,Do you believe that any of produced conduct has led to an increase in people being addicted in the Commonwealth of Kentucky?
The topic is whether education information presented by a drug company to physicians needs to be fair and balanced.,"The person's points are that drug companies should present both the positive and negative aspects of their drugs, and that physicians need to be able to make informed decisions.","The facts are that drug companies should present both the positive and negative aspects of their drugs, and that physicians need to be able to make informed decisions.",There are no anecdotes.,There are no quotes.,Do you agree that education information presented by a drug company to physicians needs to be fair and balanced?
The topic the person is talking about is whether or not a company has a responsibility to educate a physician about a drug if the physician does not understand the drug.,"The person's points are that a company has a responsibility to educate a physician about a drug if the physician does not understand the drug, but they are unsure if this is always the case.",The facts are that a company has a responsibility to educate a physician about a drug if the physician does not understand the drug.,There are no anecdotes given.,There is no quote given.,And do you agree if a company learns a physician does not understand a drug that is being sold by the company that they have a responsibility to educate them properly about the drug?
The topic is whether Purdue has an obligation to provide physicians with truthful information.,The person's points are that they are unsure of whether Purdue has an obligation to provide physicians with truthful information and they would like to know more about the topic.,N/A,N/A,N/A,Do you think Purdue has an obligation to provide physicians with truthful information?
The topic is whether Purdue provided any of the physicians in Kentucky with information that was not truthful.,"The person's points are that they are not sure if Purdue provided any of the physicians in Kentucky with information that was not truthful, and they would like to know more about the situation.",N/A,N/A,N/A,Do you believe Purdue provided any of the physicians in Kentucky with information that was not truthful?
The topic is whether or not the sales reps in Kentucky engaged in the conduct described in the felony plea agreement.,"The person's points are that they are unsure if the sales reps in Kentucky engaged in the conduct described in the felony plea agreement, and they want more information on the matter.",N/A,N/A,N/A,"Okay. And is that because you don't believe any of the sales reps engaged in the, in the, uh, conduct that is any of the sales reps in Kentucky engaged in the conduct that is described in the felony plea agreement?"
Checking.,The person's points are that the other person never checked and that the person is accused.,N/A.,N/A.,N/A.,"And you never checked, did you,"
The topic is whether or not to look at the call notes from sales people in Kentucky.,The person's points are that looking at the call notes would be a waste of time and that the information referenced in the plea agreement is probably the same.,The facts are that looking at the call notes would be a waste of time and that the information referenced in the plea agreement is probably the same.,There are no anecdotes.,There are no quotes.,Could you have looked at the call notes from your sales people in Kentucky to see what they were telling physicians and whether it was the same information referenced in the felony plea agreement?
The topic is not stated.,The person's points are that they are unsure of why the other person has that belief and they want to know more about it.,There are no facts given.,There are no anecdotes given.,There is no quote given.,And why do you have that belief?
The topic they are talking about is drug abuse.,They think that people who abuse drugs should be able to get help from doctors without stigma.,The facts are that people who abuse drugs often don't seek help because of the stigma.,They do not support their point with anecdotes.,N/A,"And when the call notes say, I told the doctor about less abuse, or I told the doctor, the drug had less euphoria or emphasized that that would be improper, correct?"
The topic is whether the people hired to give a presentation and defend Purdue in the us attorney's office in the Western district of Virginia gave accurate and truthful information to the us attorneys.,They think that the people hired to give a presentation and defend Purdue in the us attorney's office in the Western district of Virginia did not give accurate and truthful information to the us attorneys.,The facts are that the people hired to give a presentation and defend Purdue in the us attorney's office in the Western district of Virginia did not give accurate and truthful information to the us attorneys.,They do not support their point with anecdotes.,N/A,"Did it ever occur to you to check and see whether the, the people you hired and paid 50 million for, to do a presentation and defend Purdue in the us attorney's office in the Western district of Virginia gave accurate and truthful information to the us attorneys regarding the call notes?"
,They support their point with facts.,The claims they make are that Dylan was able to find out how the call note searches went.,The premises they rely on are that Dylan was able to find out how the call note searches went.,The topic they are talking about is call note searches.,"When Dylan, I call notes, sir, when doing a call note search, did you ever find out how they went about it?"
They are talking about the people who were hired.,They think that the people who were hired did not do a good job.,The facts are that the people who were hired did not do a good job.,They do not support their point with anecdotes.,N/A,"When, when the people you hired did their call note search. Did you ever find out how they went about it"
The topic is the results.,They want to know if the results were ever provided.,N/A,N/A,N/A,Was a breakdown of the results ever provided to you
The topic is not clear.,They are asking a question about the topic.,N/A,N/A,N/A,"When you say in a way, how was it provided? Well,"
It is unclear what topic the person is talking about.,They think that they should be able to go into the matter if the judge says no.,N/A,N/A,N/A,"Well, certify the question and we'll talk to the judge about it. I think I'm entitled to go into it if a judge says no, then, then of course we can't. That's"
The topic is unknown.,They are asking if the person knows who Mark Dubrick is.,N/A,N/A,N/A,"So here's, um, um, a call on a mark Dubrick um, in Lexington, Kentucky from a K period boils. Do you know who that is?"
The topic they are talking about is whether it is appropriate to convince a doctor to tell patients that they won't get buzz as they will with short acting.,They are questioning whether it is appropriate to convince a doctor to tell patients that they won't get buzz as they will with short acting.,N/A,N/A,N/A,"Okay. Under a notes memo, it says, got to convince him to counsel patients that they won't get buzz as they will with short acting. Now, with that be an appropriate thing to do. Counsel, the doctor that the patients, uh, tell the doctor, convince the doctor to counsel patients, that they won't get buzz as they will with short acting."
They are talking about the copy.,They think it is a good copy.,The facts are that it is a good copy.,They do not support their point with anecdotes.,They do not quote any anecdotes.,That's this is the only copy.
The topic they are talking about is OxyContin.,"They are questioning whether it would be inappropriate to convince a doctor's patients that they would get less of a ""buzz"" from OxyContin than from another medication.",N/A,N/A,N/A,"Question? Yes. Would it be inappropriate to counsel the doctor to convince the doctor, to counsel his patients, that they would get less buzz with OxyContin versus?"
The topic they are talking about is the statement agreed upon by the facts in the felony.,They are asking whether telling patients they won't get a buzz was one of the things prohibited by the statement.,N/A,N/A,N/A,"Um, do you know whether telling patients they won't, uh, telling doctors, patients won't get a buzz, uh, was one of the things prohibited by the, um, in the statement, agreed statement of facts in the felony, please."
The topic is not stated.,They do not state any points.,N/A,N/A,N/A,Uh here's one
The topic is not clear.,They want to ask a question about the topic.,N/A,N/A,N/A,"No. I'm just gonna ask him about these here is one. Um,"
The topic is losing their only copy.,They don't want to lose their only copy.,They don't want to lose their only copy.,They don't want to lose their only copy.,"""Well, this is my only copy. That's why I don't want, um,""","Well, this is my only copy. That's why I don't want, um,"
The topic is getting out of there.,They want to get out of there.,The facts are that they want to get out of there.,They do not support their point with anecdotes.,N/A,"Copy. If you wanna mark it later, you can, but I'm gonna ask him my questions right now so I can get outta here. I,"
The topic the person is talking about is whether or not they have to mark something.,"The person's points are that they do not have to mark something if they do not want to, and that Ellen Ballard is a sales rep in Louisville, Kentucky.","The facts are that the person does not have to mark something if they do not want to, and that Ellen Ballard is a sales rep in Louisville, Kentucky.",There are no anecdotes.,There are no quotes.,"Of questions. You can object. I don't have to mark it if I don't want here's Ellen Ballard in Louisville, Kentucky sales rep, mark Kern. Do you know who that is?"
The topic is Oxy.,They are summarizing a point.,The fact is that patients get less euphoria with Oxy.,They do not support their point with an anecdote.,N/A,"And in here it says, talked of less euphoria and more Conval with Oxy. Would it be inappropriate to tell patients they get less euphoria with Oxy?"
The topic is the statement of facts.,"The person's points are that the statement of facts does not say that doctors have to promise less euphoria, and that if doctors mention or infer that it causes less euphoria, it is improper.","The facts are that the statement of facts does not say that doctors have to promise less euphoria, and that if doctors mention or infer that it causes less euphoria, it is improper.",There are no anecdotes.,There are no quotes.,"An agreed statement of facts. Doesn't say you have to promise less euphoria. It says if you mention to a doctor or infer that it causes less euphoria, that's improper. Correct?"
The topic they are talking about is whether it is improper to do in 1998 and 2007.,They think that it is improper to do in 1998 and 2007.,The facts are that it is improper in 1998 and 2007.,They do not support their point with anecdotes.,They do not quote any anecdote.,"What difference does that make, if it's improper in 2007, wouldn't it be improper in 1998?"
The topic is the improper conduct.,They are questioning the time period of the improper conduct.,The facts are the time period of the improper conduct.,They do not support their point with anecdotes.,N/A,"Well, the, the improper conduct that the agreed statement of facts, uh, the time period was 1996 to 2001, correct? Yes. And if this is 1998, it's within that time period, correct?"
The topic is what was said in 1998.,The person's points are that what was said in 1998 was twisted logic and that it would cause problems in 2007.,The facts are that the agreed statement of facts is in 2007.,There are no anecdotes.,There are no quotes.,"Okay. Um, so by what kind of twisted logic are you saying that saying this in 1998, wouldn't be improperly cause the, because the agreed statement of facts is in 2007,"
The topic is unknown.,They do not make any points.,N/A,N/A,N/A,"If you can answer, go ahead."
The topic they are talking about is the use of Oxycontin.,They are asking for the reasons behind the other person's beliefs.,N/A,N/A,N/A,"Well, let me ask you this. Tell me all the basis you have for believing that, saying this in 1998, talk of less euphoria. Um, with Oxy, he, uh, would somehow not be a problem because the agreed statement was in 2007."
"They are talking about the statement ""Oxy gives flat blood levels. So less buzzed than Lortab.""","They are questioning if the statement ""Oxy gives flat blood levels. So less buzzed than Lortab."" is prohibited by the agreed statement of facts.","The facts are that the statement ""Oxy gives flat blood levels. So less buzzed than Lortab."" is prohibited by the agreed statement of facts.",They do not support their point with anecdotes.,N/A,"Let me ask you about this document. James Donley is the doctor at the Trover clinic in Madisonville, Kentucky, who was called on by Holly will. And the notes memo says quick, reminded him that Oxy gives flat blood levels. So less buzzed than Lortab. Is that the type of statement that's prohibited by the agreed statement of facts?"
The topic is unknown.,They are asking if the person has ever spoken to her.,N/A,N/A,N/A,Have you ever spoken to her?
The topic the person is talking about is the idea of giving effective pain relief.,The person's points are that the idea should be discussed with Dr. David Parks and that it gives effective pain relief.,The facts are that the idea gives effective pain relief.,There are no anecdotes.,There are no quotes.,"Okay. Uh, this is Dr. David Parks in bowling green, Kentucky, who was called on by Philip Gross love the idea of giving effective pain relief, but not euphoria to get rid of druggie. If it was discussed with him that it gives effective pain relief, but not euphoria. And he loved the idea. Would that be inappropriate comments to make"
It is unclear what topic they are talking about.,They have not stated any clear points.,N/A,N/A,N/A,"Okay. Um, if the re"
The topic they are talking about is Oxycontin.,They think that it is improper for the Purdue sales rep to call a doctor and explain to him that Oxy has less potential for abuse due to its sustained release.,The facts are that Purdue pled guilty to a felony.,There are no anecdotes.,There are no quotes.,"If the, if the, um, Purdue sales rep calls on a doctor in Kentucky and explains to him that Oxy has less potential for abuse due to its sustained release, would that be improper? And the type of statement that was agreed was improper in the agreed statement of facts when Purdue pled guilty to a felony."
The topic is a hypothetical statement from Purdue about OxyContin.,They are asking if a hypothetical statement from Purdue about OxyContin would be inappropriate.,N/A,N/A,N/A,"Sure. If Purdue called, I want you to assume a hypothetical, if Purdue called on a doctor and said that, uh, OxyContin has less potential for abuse due to its sustained release, would that be the type of statement that would be inappropriate?"
The topic is appropriate statements for representatives to tell doctors.,They want to know what would be considered an inappropriate statement for a representative to tell a doctor.,N/A,N/A,N/A,"No, I'm just a, trying to get an idea of what statements you consider inappropriate versus appropriate. Would that be an inappropriate statement for a rep to tell a doctor"
The topic they are talking about is whether something was appropriate or not.,They are questioning whether it was appropriate or not.,N/A,N/A,N/A,Okay. Would it have been inappropriate from 1996 to 2001?
The topic they are talking about is the agreed statement of facts.,"They think that by looking at the agreed statement of facts, it would be easy to see if any improper comments were made between 1996 and 2001.",The facts are that the agreed statement of facts outlines the comments that were made between 1996 and 2001.,They do not support their point with anecdotes.,N/A,It'd be pretty easy to tell if we looked at the agreed statement of facts because they outlined the comments they felt were improper between 1996 and 2001. Correct?
The topic is call notes.,"The person's points are that representatives are required to do call notes and instructed to do them within minutes of the call, which is correct.",The facts are that representatives are required to do call notes and instructed to do them within minutes of the call.,There are no anecdotes.,There are no quotes.,"And these call notes, you all actually required your, your representatives or salespeople to do call notes and instructed them to do 'em within minutes of completion of the call, correct?"
They are talking about the topic of information accuracy.,They say that information is more accurate when it's recorded immediately after the sales call.,The facts are that information is more accurate when it's recorded immediately after the sales call.,They don't support their point with anecdotes.,N/A,And that's because the information recorded is generally more accurate when it's recorded immediately after the sales call while the events of the call are fresh in the representative's minds. Correct?
The topic is how to determine which sales reps need to be disciplined.,The person's points are that sales reps need to be disciplined and that it is difficult to determine which ones need to be disciplined.,The facts are that sales reps need to be disciplined.,The person does not support their points with anecdotes.,N/A,"When you disciplined people, how did you make a determination? Which ones needed to be disciplined? Um, sales reps needed to be disciplined."
The topic the person is talking about is whether or not the people who made the determination to discipline relied on the call notes.,The person's points are that they are unsure if the people who made the determination to discipline relied on the call notes and they would like to know.,There are no facts given.,There are no anecdotes given.,There are no quotes given.,Okay. Do you know if the people who did make that determination relied on the call notes in determining whether discipline should take place?
The topic is whether or not the reps in Kentucky were disciplined for having inappropriate call notes.,"The person's points are that they are unsure if the reps were disciplined and if they were, what the consequences were.",N/A,N/A,N/A,"Do you know if the reps in Kentucky were disciplined for having, uh, inappropriate call notes, uh, reflected, uh, uh, their conversations with physicians?"
The topic the person is talking about is whether or not a sales rep making a comment to a doctor about lack of buzz being drug seeking would be inappropriate.,"The person's points are that if a sales rep went to a doctor and said discuss lack of buzz, and this won't be drug seeking, it could be seen as inappropriate.",There are no facts given to support the point.,There are no anecdotes given to support the point.,There is no quote given from the anecdote.,"If <affirmative>, if a sales rep went to a doctor and said, discuss lack of buzz, and this won't be drug seeking. Uh, would that be an inappropriate comment to make?"
"The topic is whether or not it is appropriate for a sales representative to make a comment about getting a ""buzz"" from OxyContin.","They think that a sales representative should not make comments about getting a ""buzz"" from OxyContin.","The fact is that if a sales representative made such a comment, it would be inappropriate.",They do not support their point with an anecdote.,N/A,"A, if a sales rep went to a physician and said you don't get a buzz with OxyContin, would that be an inappropriate comment? Yes. If a sales rep went to a physician, I have to,"
The topic they are talking about is asking questions.,They think it is fair and that they should be able to ask their question.,The facts are that they have notes or documents.,They do not support their point with anecdotes.,N/A,"Think it's fair. No, I'm asking him what types of questions a sales rep says and whether I've got notes or documents or I've got 'em in my head. Doesn't matter. I get to ask my question. You can follow up if"
The topic is whether it would be inappropriate for a salesman to discuss the potential benefits of oxycodone without mentioning the potential for abuse.,"The person's points are that discussing the potential benefits of oxycodone without mentioning the potential for abuse could be seen as inappropriate, but they are not sure.",There are no facts given.,There is one anecdote given.,"No, the anecdote is not quoted.","From. Yeah. If a salesman went in and discussed abuse, potential and benefits of oxycodone or OxyContin, I'm sorry. Uh, and it not giving a euphoria, would that be inappropriate?"
The topic they are talking about is OxyContin.,They are questioning whether it would be inappropriate for a sales representative to tell a doctor that there is less euphoria with OxyContin.,N/A,N/A,N/A,"If he tells him that there's less euphoria with OxyContin or he or she sales rep says there's less euphoria with OxyContin, OxyContin, would that be inappropriate,"
N/A,They don't mention any points.,N/A,N/A,N/A,Either of those?
The topic they are talking about is unclear.,They are asking if it would have been inappropriate during a specific time period.,N/A,N/A,N/A,Okay. Would it have been inappropriate in between 1996 and 2006?
The topic is the misbranding of OxyContin.,They want to go back and talk about what will help them understand the situation better.,The facts are that there were several things brought up that were inappropriate.,They do not support their point with anecdotes.,N/A,"Okay. Let me, let me go back and talk about what, um, maybe this will, will help us here. Uh, under misbranding of OxyContin, there were several things that were brought up that were, um, were in, uh, inappropriate. And it says with the intent to defraud or mislead, are you reading, I'm reading from page five of the agreed statement of facts let's"
"The topic they are talking about is that Purdue supervisors and employees between December 12th, 1995 defrauded or misled people.","They are saying that Purdue supervisors and employees between December 12th, 1995 defrauded or misled people.","The facts are that Purdue supervisors and employees between December 12th, 1995 defrauded or misled people.",There are no anecdotes.,There are no quotes.,"Page five, uh, paragraph 20 with the intent to defraud or mislead, or I'm sorry, let's back up. Purdue supervisors and employees between December 12th, 1995."
The topic they are talking about is the OxyContin scandal.,They are summarizing the points of the document.,"The facts are that certain Purdue supervisors and employees with the intent to defraud or mislead, marketed, and promoted OxyContin as less addictive, less subject to abuse and diversion, less likely to cause tolerance and withdrawal than other pain medications.",There are no anecdotes.,N/A,"All right. Well, I'll just read it in its entirety then. Okay. Beginning on or about December 12th, 1995. And continuing on, or about June 30th, 2001, certain Purdue supervisors and employees with the intent to defraud or mislead, marketed, and promoted OxyContin as less addictive, less subject to abuse and diversion, less likely to cause tolerance and withdrawal than other pain medications. Did I read that correctly?"
The topic they are talking about is the plea agreement.,They point out that the agreement was based on a review of the call notes.,The facts are that the agreement was based on a review of the call notes.,There are no anecdotes.,There are no quotes.,And it was a review of the call notes by the us attorney's office that formed the basis of this plea agreement. Correct?
The topic is Purdue Pharma.,They think that Purdue Pharma should have been more transparent about their documents and they question why they pled guilty to a felony.,The facts are that Purdue Pharma pled guilty to a felony.,There are no anecdotes.,There are no quotes.,"Did you ever review any of the, uh, documents filed by the us attorney's office in the case? Were Purdue pled guilty to the felony?"
The topic is whatever is being read from the document.,They are summarizing the points.,The facts are that it says here.,They are not supporting their point with anecdotes.,N/A,"All right. And it, it says here"
The person is talking about the effects of OxyContin.,"The person's points are that OxyContin did not cause a buzz or euphoria, and that would be improper.",The facts are that OxyContin did not cause a buzz or euphoria.,The person does not support their point with anecdotes.,N/A,"Um, under number subparagraph E it says told certain healthcare providers that OxyContin did not cause a buzz or euphoria. And that would be improper, correct?"
The topic is buprenorphine.,"The person's points are that buprenorphine is less addictive than opioids, has less potential for abuse, and is less likely to be diverted than immediate release opioids.","The facts are that buprenorphine is less addictive than opioids, has less potential for abuse, and is less likely to be diverted than immediate release opioids.",There are no anecdotes.,There are no quotes.,"Caused less euphoria had less addiction, potential had less abuse. Potential was less likely to be diverted than immediate release op opioids and could be used to weed out addicts and drug seekers"
The topic they are talking about is the osteoarthritis study.,They point out that the osteoarthritis study was helpful.,The facts are that the osteoarthritis study was helpful.,They do not support their point with anecdotes.,N/A,"And one of the things that it points out in here, um, when we went on was the osteoarthritis study. Do you remember us talking about that?"
The topic is the comments made by the sales rep.,The person believes that the comments made by the sales rep were improper and inappropriate because they could be seen as encouraging addiction.,N/A,N/A,N/A,"Here's Carol Neil Heisel sales rep. This is William Ys, Dr. Florence, Kentucky, and the notes memo says brought osteoarthritis studies that show non addiction discussed how he could use Oxy to deter addictive behavior, less pills, less potential for abuse. Would you agree that those comments would be improper and inappropriate"
The topic they are talking about is the idea.,They think it is a good idea and they support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,And
The topic they are talking about is Purdue states that.,They are summarizing the points.,The facts are that Purdue states that.,There are no anecdotes.,There are no quotes.,"I was not going to mark it. No. And it says here Purdue states that,"
The topic is restitution.,They argue that the defendant should have to pay for the repairs because they caused the damage.,The facts are that the defendant caused the damage and should have to pay for the repairs.,There are no anecdotes.,There are no quotes.,I'm reading from the reply of the United States to defendant's response to blue cross blue shield of Tennessee and other private third party repairs request for restitution.
The topic is the information in a document.,They want to ask for clarification on the information.,N/A,N/A,N/A,I just want to ask you about some of the information in here.
The topic is not stated.,The person's points are that it would be convenient but they don't trust the technology.,There are no facts given to support the points.,The anecdote is about not trusting the technology.,"""What if it doesn't work the way it's supposed to?""",I
The topic they are talking about is the percentage of sales notes that were improper.,They are looking at the third paragraph which states that less than 0.2% of sales notes were improper.,The facts are that less than 0.2% of sales notes were improper.,There are no anecdotes.,N/A,"Is. I, I thought I did. It's a reply of the United States, the defendant's response to blue cross blue shield. Um, it's, uh, I'm looking at the third paragraph. Purdue states an analysis of the notes that Purdue sales representatives kept from their visit to physicians revealed that less than 0.2% contain any evidence of statements that were arguably improper. And, um, were you aware that, that they had claimed that two tens of 1% of the sales notes were arguably improper,"
The topic is OxyContin.,The person's points are that OxyContin is addictive and that the company lied to doctors about its addiction potential.,The facts are that OxyContin is addictive and that the company lied to doctors about its addiction potential.,There are no anecdotes.,There are no quotes.,"<affirmative>, but the us attorney says this bear statistical reference does not provide a complete picture of the magnitude of the unlawful activity described in the information and the agreed statement of facts. These very, in fact, these very same notes show the pervasive nature of the false and misleading statements. For example, according to the notes in at least 41 states, physicians were informed that addicts would not like OxyContin or that OxyContin could be used to weed out drug seekers because addicts would not like it. And at least 49 states physicians were informed that OxyContin produces no buzz or euphoria. And in 50 states, physicians were informed that OxyContin had less abuse potential than other opioids. Would all of those comments be improper?"
The topic is Purdue Pharma.,They think that Purdue Pharma should be investigated because they think that the company is corrupt.,The facts are that Purdue Pharma was aware of the investigation and changed their call note system.,They do not support their point with anecdotes.,N/A,"Yes. And it says, in addition, once Purdue learned of the investigation, it conducted training that cautioned sales representatives to avoid, including references to the false and misleading statements in their call notes. Eventually Purdue changed the call note system altogether to preclude such references by allowing sales representatives, to choose only from pre-selected menu items that not surprisingly omitted, the false and misleading statements that the employees had previously, that, that the employees previously had previously spontaneously recorded in the notes. Were you aware of that?"
The topic is awareness.,They think it is good that he was aware of the activity.,The facts are that he was aware of the activity.,They do not support their point with anecdotes.,N/A,"Of it. I'm asked. He was aware of that activity,"
The topic is Purdue.,The person's points are that Purdue was aware of the investigation and that they conducted training to avoid making false and misleading statements.,The facts are that Purdue was aware of the investigation and that they conducted training to avoid making false and misleading statements.,There are no anecdotes.,There are no quotes.,"That, uh, once Purdue learned of the investigation, it conducted training that cautioned sales representatives to avoid, including references to the false and misleading statements in their call notes that's number. Were you aware they did that?"
The topic is the call note system.,"The person's points are that the call note system is false and misleading, and that Purdue changed the system to allow sales representatives to choose from a pre-selected menu of items that did not include the false and misleading statement.","The facts are that the call note system is false and misleading, and that Purdue changed the system to allow sales representatives to choose from a pre-selected menu of items that did not include the false and misleading statement.",There are no anecdotes.,There are no quotes.,"And it says eventually Purdue changed the call note system altogether to preclude such references by allowing sales representatives, to choose from a pre-selected menu items that not surprisingly omitted the false and misleading statement that the employees had previously spontaneously recorded in their notes. Were you aware that that had occurred?"
The topic they are talking about is the misbranding of OxyContin.,They think that the statements are false and that OxyContin is being misbranded.,The facts are that the statements are false and that OxyContin is being misbranded.,N/A,N/A,"The statements referenced, um, in the statement of facts under misbranding of OxyContin,"
The topic is unclear.,They do not state any clear points.,N/A,N/A,N/A,"Okay. Uh, the statements, I'm sorry."
The topic is documenting the statement of facts.,They want to know if documenting the statement of facts is necessary.,N/A,N/A,N/A,"Document or not? No, I'm, I'm asking you about the degree statement of facts now."
The topic is the statement under misbranding of OxyContin.,The person's points are that they are not sure about the statement and that they want more information.,N/A,N/A,N/A,"The statement under misbranding of OxyContin, uh,"
They are talking about the idea.,They think it is a good idea and support their points with facts.,The facts are that it is a good idea.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"Page five. You've read, uh, paragraph 20 in its entirety, correct?"
The topic is statements that were improper and if they constituted a guilty plea.,They want to know if the statements were improper and if they constituted a guilty plea.,N/A,N/A,N/A,"Yeah. Are those the statements that, uh, were improper and constituted the, um, guilty plea?"
The topic is support for a topic.,The person's points are that the topic is good and that they support it.,The facts are that the topic is good and that they support it.,The anecdote is that the person supports the topic.,"Yes, the person supports the topic.",Yes.
They are talking about the statements made by the produce sales force.,They are asking if the statements in paragraph 20 are the ones that were made with the intent to defraud.,The facts are in paragraph 20.,They do not support their point with anecdotes.,N/A,"Yeah. The statements outlined in paragraph 20, are those the improper, uh, and misleading statements that were made with intent to defraud, um, by produce sales force. Um, does that set them forth?"
no,cannot summarize points,no,no,no,"What? I don't mean. I just mean other paragraph 20. Okay. Would that constitute, um, um,"
Inappropriate examples,Cannot summarize points,No,No,No,"Of examples of inappropriate, um, and that's"
The topic is misleading statements.,The person's points are that misleading statements are bad because they are not truthful and can be confusing.,The facts are that misleading statements are not truthful and can be confusing.,There are no anecdotes.,There are no quotes.,Misleading statements
The topic is good.,The person's points are that the topic is good and that they support it.,The facts are that the topic is good and that they support it.,The anecdote is that the person supports the topic.,"Yes, the person supports the topic.",Yes.
The topic is unclear.,They want the question read back to them.,N/A,N/A,N/A,Can you read my question back?
The topic they are talking about is OxyContin.,They are questioning whether or not it would be appropriate for a sales representative to tell a doctor that using OxyContin would provide smoother blood levels.,N/A,N/A,N/A,"If, uh, a sales rep told a doctor that using OxyContin would provide smoother blood levels, would that be an appropriate statement?"
The topic they are talking about is their deposition.,They summarize their points by saying that they reviewed information to prepare for their deposition today.,The facts are that they reviewed information to prepare for their deposition today.,They do not support their point with an anecdote.,They do not quote an anecdote.,All right. What information did you review to prepare for your deposition today?
The topic they are talking about is the usefulness of the documents.,They think that the documents are helpful and provide a lot of information.,The facts are that the documents are helpful and provide a lot of information.,They do not support their point with anecdotes.,N/A,Which documents?
The topic they are talking about is whether or not to review additional documents.,They think that the documents are helpful and that reviewing them is a good idea.,The facts are that the documents are helpful and that reviewing them is a good idea.,They do not support their point with anecdotes.,N/A,"Um, yes. Any other documents that you reviewed"
The topic is reviewing call notes.,They are summarizing points.,The facts are that the person reviewed six less than eight call notes.,There are no anecdotes.,N/A,"You did say you reviewed six less than eight call notes, is that right? Yes. And that was the first time you'd seen call notes. Yes."
"The topic the person is talking about is whether or not Purdue Pharma LP, Purdue Pharma, Inc., The Purdue Frederick Company, Purdue Pharmaceuticals LP, and PF Laboratories, Inc. have the same directors.",The person's points are that they are unsure if the entities have the same directors and they would like to know.,N/A,N/A,N/A,"Yes. Purdue Pharma LP, Purdue Pharma, Inc. The Purdue Frederick company, Purdue Pharmaceuticals LP, PF Laboratories, Inc. Do you know if they have the same directors or are there different directors for those entities?"
The topic is the current state of the medical profession.,The person's points are that they are a doctor and they feel neutral about the profession.,The facts are that the person is a doctor.,There are no anecdotes.,There are no quotes.,"Um, do you currently practice medicine?"
The topic the person is talking about is practicing medicine.,The person's points are that they do not have time to practice medicine.,The facts are that the person does not have time to practice medicine.,The person does not support their point with an anecdote.,The person does not quote an anecdote.,Don't. When is the last time that you practice medicine
The topic they are talking about is the person's involvement with Purdue Pharma LP.,They point out that the person was the president of Purdue Pharma LP from 1999 to 2002.,The facts are that the person was the president of Purdue Pharma LP from 1999 to 2002.,They do not support their point with anecdotes.,They do not quote any anecdotes.,"Uh, from 1999 to 2002. You were the president of Purdue Pharma LP"
The topic the person is talking about is OxyContin.,The person's points are that they were the president of Purdue Frederick and they were involved with OxyContin.,The facts are that the person was the president of Purdue Frederick and they were involved with OxyContin.,There are no anecdotes.,There is no quote.,"Were you also at some point, uh, the president of Purdue Frederick?"
They are talking about office titles at Purdue Frederick.,They make the point that Purdue Frederick did not have any office titles.,The facts are that Purdue Frederick did not have any office titles.,They do not support their point with anecdotes.,N/A,"No. Did you have any, uh, office, uh, title at Purdue Frederick?"
what topic are they talking about?,can you summarize their points?,"if they support their point with facts, what are the facts?","if they support their point with anecdotes, what are the anecdotes?",can you quote the anecdote?,What was that
The topic is giving up the title.,They think that it was a bad idea to give up the title.,The facts are that the person gave up the title.,They do not support their point with anecdotes.,N/A,And do you know when you relinquished that title?
The topic the person is talking about is different types of corporations.,The person's points are that there are different types of corporations and that Purdue Frederick and Purdue Pharma are for-profit corporations.,The facts are that there are different types of corporations and that Purdue Frederick and Purdue Pharma are for-profit corporations.,There are no anecdotes.,There are no quotes.,"Um, there are different types of corporations. There are not for profit corporations. Uh, and there are for-profit corporations. Would I be correct that Purdue Frederick and Purdue Pharma are for-profit corporations. There"
The topic is whether Purdue Frederick or Purdue Pharma are for profit.,They are questioning whether Purdue Frederick or Purdue Pharma are for profit.,N/A,N/A,N/A,"All right. Um, that's a good distinction. Uh, would I be correct that Purdue Frederick or Purdue Pharma are for profit? Not, not for profit."
N/A,They have no points to summarize.,N/A,N/A,N/A,Go off the record a minute.
The topic is the document.,The person's points are that the document is from Richard Sackler and they are not sure if it is relevant.,N/A,N/A,N/A,"All, yeah. All right, let's go back through, um, I'm gonna hand you a document that is, um, at the top. Let's mark this as exhibit 38 38. It's from Richard Sackler. Did you recognize that?"
The topic is email.,They cannot summarize their points.,N/A,N/A,N/A,All right. Was this an email that you sent to Michael Friedman?
The topic they are talking about is addiction.,They are questioning why certain individuals have been chosen to give a presentation on addiction.,N/A,N/A,N/A,"And it says here under importance, uh, down below importance, low, but down below it says, why don't you guys plan a presentation about addiction that could be given first by R or BK now, who are those individuals,"
"The topic is whether addiction is a convenient way to ""just say no.""","The person's points are that addiction may be a convenient way to ""just say no"" and that CR products are less prone to addiction, potential abuse or diversion than IR products.","The facts are that CR products are less prone to addiction, potential abuse or diversion than IR products.",There are no anecdotes.,There are no quotes.,"And, uh, and eventually by our senior managed healthcare people next paragraph, I think that Paul has a good point, but we should consider that quote addiction in quote, maybe a convenient way to quote, just say no. And when this objection is obliterated, they will fall back on the question of cost, unless we can give a convincing presentation that CR products that's controlled release products is that yes, are less prone to addiction, potential abuse or diversion than IR products that immediate release."
It is unclear what topic they are talking about.,They do not state any specific points.,N/A,N/A,N/A,"<affirmative> I think that this can be done, but I defer to BK and rrr and other experts."
They are talking about the topic of controlled release products.,They are trying to show that controlled release products are less prone to addiction abuse or diversion.,The facts are that controlled release products are less prone to addiction abuse or diversion.,They do not support their point with anecdotes.,N/A,"And what were you trying to accomplish there by trying to show that, uh, <affirmative> that, um, controlled release products are less prone to addiction abuse or diversion than immediate release products?"
The topic is controlled release products versus immediate release products.,"The person's points are that they are not aware of any presentation showing that controlled release products are less prone to addiction, potential abuse or diversion than immediate release products, and they don't know if such a presentation exists.","The facts are that the person is not aware of any presentation showing that controlled release products are less prone to addiction, potential abuse or diversion than immediate release products.",There are no anecdotes.,There are no quotes.,"Are you aware of any presentation showing that, um, controlled release products are less prone to addiction, potential abuse or diversion than immediate release products no. Was ever done?"
The topic is that the person is for it.,They support their points with facts.,They do not support their point with anecdotes.,N/A,N/A,"All right. And then the another email I'm gonna hand you that one. Thank you, mark. This as exhibit 39. And this is dated, um, looks like at the bottom analgesic plans, Dr. Richard Sackler at Norwalk. Uh, and is this an email that you sent?"
The topic is John Stewart.,They are confused about who John Stewart is and why he sent an email.,N/A,N/A,N/A,"And if you go back to page three, uh, the email that proceeded, it was from John Stewart. Yes. Who is John Stewart?"
The topic is the opioid crisis.,They are saying that Purdue Pharma is responsible for the opioid crisis.,The facts are that Purdue Pharma is an affiliate of a company that makes opioids.,They do not support their point with anecdotes.,N/A,And is that a Purdue Pharma affiliate?
The topic is the Sackler family owning PF Canada.,They think the Sackler family is good for PF Canada.,The facts are that the Sackler family owns PF Canada.,They do not support their point with anecdotes.,N/A,"Does, does the Sackler family own PF Canada? Yes."
They are talking about how to produce greater sales.,They are summarizing the points made by another person.,N/A,N/A,N/A,"He says, um, under the first paragraph, in my opinion, the action that will produce the greatest sales gains are the acquisition of IMS practice, quartile data, and the resulting improvement in targeting of our sales and marketing activities. Um, what does that mean"
They are talking about Oxy PRN.,They are asking a question.,N/A,N/A,N/A,"Okay. And if you look at your response to him, um, on 9 27 96, you say your most important question to me was, have physicians been reluctant to use Oxy PRN? What does Oxy PRN mean?"
They are talking about the OxyContin controlled release.,They think that the sales performance and growth is because of the rapid rate of onset.,The facts are that the OxyContin controlled release does not have a significant clinical statistical difference with rate of onset when compared to oxycodone immediate release.,They do not support their point with anecdotes.,N/A,"In place of IR forms of oxycodone and that's immediate release oxycodone. Correct. Right. Uh, I've not asked this question, but judging from the very strong sales performance and continuing growth, I would guess that this has not been a problem. I think that we're this the case, it would be because of the very rapid rate of onset parenthesis, as fast as IR oxycodone, that is 45 minutes versus 41 minutes for the IR form, not even close to a significant clinical or statistical difference. And was it your understanding when you wrote this, that OxyContin controlled release did not have a significant clinical statistical difference with rate of onset when compared to oxycodone immediate release?"
They are talking about the drug OxyContin.,They are summarizing the points.,The facts are that the drug is patented and that it is effective.,They do not mention any anecdotes.,N/A,"And it says here, the fast rise character now, quote, parenthesis. Now a patent in the us, in parenthesis of the drug combined with familiarity and a marketing program that emphasized that IR was the old was, I think that's supposed to be way yes. And OxyContin tablets are the new way to treat moderate to severe pain has resulted in our success. Did I read that correctly?"
They are talking about OxyContin.,They are saying that OxyContin has a fast rise as far as when relief occurs.,The facts are that OxyContin has a fast rise as far as when relief occurs.,They do not support their point with anecdotes.,N/A,"And when it says the fast rise character you're referring to OxyContin having a fast rise as par as far as when relief occurs, correct?"
"They are talking about the schema that marketing has worked R four, three of the four.","They are talking about the schema that marketing has worked R four, three of the four.",N/A,N/A,N/A,"Um, and then down below that, if you go to about the fourth paragraph, the overall schema that marketing here has worked R four, three of the four, I think that's out of three of the four should probably be, but it's written yes. The overall schema that marketing here has worked R four, three of the four is Oxy one IR old way, OxyContin tablet, new way emphasizing the B I D was Q4 H versus"
The topic the person is talking about is Q4 V I D versus Q4 H.,The person's points are that the Q4 V I D and Q4 H are similar in onset and that there are other benefits that are emphasized such as range of doses and small tablet size.,The facts are that Q4 V I D and Q4 H are similar in onset and that there are other benefits that are emphasized such as range of doses and small tablet size.,The person does not support their points with anecdotes.,N/A,"Q4, V I D versus Q4 H and underscoring. The similarity of onset. Other differential benefits are emphasized such as range of doses, the very small tablets, etcetera. And then Oxy two. Uh, your second point with ING, Oxy is in cancer and severe nonmalignant pain. The one to start with and the one to stay with here, we are going directly after the MSC and Duragesic business. What is MSC"
They are talking about the product Duragesic.,They think it is a good product.,The facts are that it is a good product.,They do not support their point with anecdotes.,N/A,And Duragesic who made Duragesic
The topic is the strategy.,"The person's points are that the strategy has outperformed expectations, market research and fondest dreams.","The facts are that the strategy has outperformed expectations, market research and fondest dreams.",There are no anecdotes.,There are no quotes.,"And you say, clearly this is highlighted or capitalized. Clearly this strategy has outperformed our expectations, market research and fondest dreams."
The topic is reading.,They think it is important to read things correctly.,The fact is that they read something correctly.,They do not support their point with an anecdote.,They do not quote an anecdote.,I read that correctly.
The topic is unknown.,They have not stated any points.,N/A,N/A,N/A,"Um, alright. And then the last one I want to ask you about"
They are talking about the company's success.,They point out that the company outperformed their expectations in terms of market share and earnings.,The facts are that the company outperformed their expectations in terms of market share and earnings.,They do not support their point with anecdotes.,N/A,"When you say it outperformed your fondest dreams, you're talking in terms of market share and what it was earning, is that correct?"
N/A,They don't have any points.,N/A,N/A,N/A,And then
The topic they are talking about is the sales bulletins.,They are asking if the person read the sales bulletins.,N/A,N/A,N/A,"One more email to ask you about who was, oh, I'm sorry. Let's mark this as number 40. Um, did you read the sales bulletins, uh, when you were the, um, are they, um, when these were sent to you?"
Russ Gaia,N/A,N/A,N/A,N/A,"Uh, who is Russ Gaia."
The topic is the prescription sales force.,They think that the prescription sales force is a good thing.,The facts are that the prescription sales force went out to everybody.,They do not support their point with anecdotes.,N/A,"And this is January 25th, 1999 prescription sales force. Does that mean it went out to everybody?"
They are talking about the distribution of OxyContin.,They are asking a question.,N/A,N/A,N/A,Would it have gone to everyone selling OxyContin?
The topic they are talking about is a new idea to help with sales volume and growth.,They think it is a good idea because it will help with sales volume and growth.,"The facts are that it is effective with the first quarter, 1999, and that it will help with sales volume and growth.",They do not support their point with anecdotes.,N/A,"Yes. And, um, the first paragraph says effective with the first quarter, 1999, Ms. Cotton sales volume and growth."
They are talking about the announcement at the national meeting.,They think it is good that it was announced at the national meeting.,The facts are that it was announced at the national meeting.,They do not support their point with anecdotes.,N/A,As was announced at the national meeting. Right.
The topic is a change in how Ms. Cotton's sales volume and growth will be calculated.,"The person's points are that the change will take effect in the first quarter of 1999, and that Ms. Cotton's sales volume and growth will be calculated at 50 cents.","The facts are that the change will take effect in the first quarter of 1999, and that Ms. Cotton's sales volume and growth will be calculated at 50 cents.",There are no anecdotes.,There are no quotes.,"Effective with the first quarter, 1999, Ms. Cotton sales volume and growth, as well as quota will be calculated at 50 cents."
The topic is not stated.,The person's points are that the topic is good and beneficial.,The facts are that the topic is good and beneficial.,N/A,N/A,The first paragraph.
The topic the person is talking about is their own indecisiveness.,The person's points are that they are undecided and that they want to make a decision.,N/A,N/A,N/A,"Me give you this one and we'll make it the exhibit. Uh,"
The topic is sales volume and growth.,The person's points are that they do not understand what the topic is and they need clarification.,N/A,N/A,N/A,"Uh, so let's read the first paragraph as was announced at the national sales meeting effective with the first quarter, 1999, Ms. Cotton sales, volume, and growth, as well as quota will be calculated at 50 cents for every $1. What does that mean?"
They are talking about OxyContin sales.,They think that OxyContin sales will be calculated at $1 and 15 cents for every $1.,The facts are that OxyContin sales will be calculated at $1 and 15 cents for every $1.,They do not support their point with anecdotes.,N/A,"Uh that's all right. I'm gonna read it with you here. Oh, okay. Next sentence says, so then OxyContin sales, volume and growth, as well as quota will be calculated at $1 and 15 cents for every $1."
The topic they are talking about is the fourth quarter 1998 bonus payout.,They are summarizing points.,"The facts are that the fourth quarter 1998 bonus payout will be another record payout, and that they are driving more business towards OxyContin.",They do not support their point with anecdotes.,N/A,"And then the next paragraph says early estimates indicate that the fourth quarter 1998 bonus payout will be another record payout. Remember this record payout came at a time when we were utilizing a factor of 55 cents for every Ms. Cotton dollar and a dollar 15 for every OxyContin dollar, as we continue to drive more business toward OxyContin, each of you will benefit significantly from the factoring of a $1 and 15 cent for every $1 of OxyContin. And again, is that referring to D uh, incentivizing MS. Contin cells and incentivizing OxyContin cells?"
The topic is whether or not the sales force was instructed to sell OxyContin.,The person's points are that the sales force may have been instructed to sell OxyContin and that this is concerning.,The fact is that the sales force was instructed to sell OxyContin.,There are no anecdotes.,There are no quotes.,"And then it says, as pointed out your priority is to sell, sell, sell, um, and that's in bold OxyContin, right? Well, and is that what the sales force was instructed to do?"
The topic they are talking about is OxyContin.,They are summarizing the points of the document.,N/A,N/A,N/A,"It also says in the last paragraph remain focused on positioning OxyContin as the opioid to start with and stay with in chronic malignant and non-malignant pain states. In addition, continue to aggressively position OxyContin for use in osteoarthritis, low back pain, post neuropathic neurology, and post-surgical applications where appropriate finally continue to highlight the advantages of OxyContin, especially for use in the elderly. If you have any questions regarding the bonus calculations for the first quarter of 99, please contact your district manager"
The topic is addiction.,"The person's points are that they do not know how many patients became addicted, and they are curious about the number.",The facts are that the person does not know how many patients became addicted.,There are no anecdotes.,There are no quotes.,"Um, have you made any, uh, effort or as we sit here today, do you know how many patients who took OxyContin in Kentucky became dependent or addicted?"
The topic the person is talking about is whether an excessive number of patients who took OxyContin in Kentucky became addicted or dependent.,"The person's points are that they are not sure if an excessive number of patients who took OxyContin in Kentucky became addicted or dependent, and they want to know if other people believe this as well.",N/A,N/A,N/A,"Do you believe that, um, an inappropriate number of patients or an excessive number of patients who took OxyContin in Kentucky became, uh, addicted or dependent?"
The topic they are talking about is OxyContin.,They want to know if Purdue has made any effort to find out how many people who were started on OxyContin became dependent and moved on to heroin.,N/A,N/A,N/A,"Do you know, uh, or has Purdue made any effort to ascertain ascertained? Um, how many people who were started on OxyContin wound up becoming dependent and moving on to heroin at some point?"
N/A,N/A,N/A,N/A,N/A,I think it's all questions I have Dr. Sackler. Thank you very much.
